Antibodies targeting DLL3 and antibody-drug conjugates and uses thereof
Patent Information
- Application Number
- CA3329161
- Authority / Receiving Office
- CA · CA
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2024-12-06
- Filing Date
- 2025-04-28
- Publication Date
- 2025-11-06
AI Technical Summary
Existing DLL3 antibody-drug conjugates (ADCs) face challenges with low clinical dosing dosage, high toxicity, and average efficacy, limiting their effectiveness in treating DLL3-expressing tumors.
Development of anti-DLL3 antibodies and ADCs with high binding affinity, fast endocytosis efficiency, and stable linker-payload, achieving DAR values up to 8, which specifically target DLL3 on tumor cells and enhance bystander killing effects.
The new ADCs demonstrate high antitumor efficacy, low toxicity, improved stability, and uniform product quality, effectively inhibiting tumor growth and overcoming chemotherapy resistance.
Abstract
Description
Antibodies targeting DLL3 and antibody-drug conjugates and uses thereofTechnical Field
[0001] The present invention relates to antibodies or antigen-binding fragments thereof that specifically bind to DLL3, as well as antibody-drug conjugates (ADCs) that target DLL3 and compositions containing the same. The invention also relates to therapeutic and diagnostic uses of these antibodies or ADCs.Background
[0002] Therapies using cytotoxic agents are important therapies for treating cancer, but cytotoxic agents with low selectivity often kill normal cells, causing severe toxic side effects. Biomacromolecule drugs, such as antibodies or antibody fragments, although highly targeting, have limited therapeutic effects on solid tumors, thereby limiting their applications. The antibody-drug conjugate (ADC) is a conjugate of an antibody and a small molecule drug, combines the targeting effect of the antibody with the high activity of the small molecule drug (such as a cytotoxic agent) , and has the advantages of high therapeutic effect, high safety, and the like.
[0003] DLL3 (i.e., delta-like ligand 3 or delta-like protein 3) is a type I single transmembrane protein and is one of the Notch ligands, comprising one DSL domain, six epidermal growth factor-like domains and one transmembrane domain. Normally, DLL3 is expressed limitedly in normal tissues, localized to the Golgi apparatus, and not expressed on the cell membrane surface, whereas in some cells of neuroendocrine tumor types (including SCLC and LCNEC) , such as small cell lung cancer, DLL3 (70%-80%) is abnormally high, and abnormally expressed DLL3 is not only localized to the Golgi apparatus, but also detected on the cell membrane surface.
[0004] Thus, DLL3 is a promising target for neuroendocrine tumor therapy. Therapeutic agents directed to DLL3 have been developed in recent years for the treatment of DLL3 expressing tumors or cancers.
[0005] For DLL3, an antibody toxin conjugate (ADC) can be developed that is formed by conjugating an antibody and a toxin together. However, DLL3-ADC (Rova-T) developed based on this strategy faces huge challenges in clinic, probably because the Rova-T drug selects PBD with stronger activity as toxin payload, the clinical dosing dosage is low, the toxicity is high, and the efficacy is average.
[0006] Accordingly, there remains a need to develop new DLL3 antibody molecules and ADC molecules comprising the same, preferably with advantages such as high efficacy, high safety (including low side effects) , and / or high product uniformity.Summary of the invention
[0007] One aspect of the present invention relates to a binding molecule that specifically binds to DLL3, such as an anti-DLL3 antibody or antigen-binding fragment thereof, or an immunoconjugate constructed based thereon, such as an antibody-drug conjugate (ADC) .
[0008] One aspect of the present invention relates to an anti-DLL3 antibody or antigen-binding fragment thereof.
[0009] In some embodiments, the anti-DLL3 antibody or antigen-binding fragment thereof of the present invention specifically binds to DLL3 (e.g., human DLL3 or monkey DLL3) . In some embodiments, the anti-DLL3 antibodies or antigen-binding fragments thereof of the present invention binds to DLL3 (e.g., human DLL3) with a binding affinity of KD value of less than or equal to about 10nM, 9nM, 8nM, 7nM, 6nM, 5nM, 4nM, 3nM, 2nM, 1nM, 0.9nM, 0.8nM, 0.7nM, or 0.6nM, or between said values. In some embodiments, the anti-DLL3 antibodies or antigen-binding fragments thereof of the present invention binds to DLL3 (e.g., human DLL3) with a binding affinity of KD value greater than or equal to about 0.5nM. In some embodiments, the affinity is determined by bio-layer interferometry technique (BLI) .
[0010] In some embodiments, the anti-DLL3 antibodies or antigen-binding fragments thereof of the present invention are capable of effectively binding to DLL3 while not binding to DLL1 and DLL4. In some embodiments, the antibodies or antigen-binding fragments thereof of the present invention bind DLL3 expressed on cell surface.
[0011] In some embodiments, the anti-DLL3 antibodies or antigen-binding fragments thereof of the present invention have a faster endocytosis efficiency, e.g., about 50%endocytosis at 30 minutes, on DLL3 positive cells, e.g., DLL3 positive tumor cells.
[0012] The invention provides an immunoconjugate comprising an antibody that targets DLL3 (e.g., an antibody or antigen-binding fragment thereof of the present invention that specifically binds to DLL3) and an additional payload. In some aspects, the immunoconjugate is an antibody-drug conjugate.
[0013] Therefore, the invention provides an antibody targeting DLL3 and an antibody-drug conjugate (ADC) targeting DLL3. The antibodies of the present invention have advantages such as higher endocytosis efficiency and / or higher affinity.
[0014] In an aspect, the present invention provides an antibody-drug conjugate of formula (I) : Ab- (L-D) p (I)
[0015] or a pharmaceutically acceptable salt or solvate thereof,
[0016] wherein:
[0017] Ab is an antibody or fragment thereof that binds to DLL3 (e.g., human DLL3) ;
[0018] L is a linker;
[0019] D is a drug, preferably an anti-tumor compound; and
[0020] p is an integer selected from 1 to 16, for example 4 to 10,
[0021] preferably, Ab is an antibody or antigen-binding fragment thereof that binds to DLL3 as defined herein.
[0022] In another aspect, the present invention provides a pharmaceutical composition comprising the antibody or antigen-binding fragment thereof, the immunoconjugate or antibody-drug conjugate or the pharmaceutically acceptable salt or solvate thereof as described above, and optionally one or more other therapeutic agents, for example chemotherapeutic agents, angiogenesis inhibitors, cytokines, cytotoxic agents, other antibodies, small molecule drugs, or immune modulators, as well as optionally pharmaceutically acceptable excipients.
[0023] In another aspect, the present invention provides a pharmaceutical combination comprising the antibody or antigen-binding fragment thereof, the immunoconjugate or antibody-drug conjugate or the pharmaceutically acceptable salt or solvate thereof as described above, and one or more other therapeutic agents, for example chemotherapeutic agents, angiogenesis inhibitors, cytokines, cytotoxic agents, other antibodies, small molecule drugs, or immune modulators.
[0024] In another aspect, the present invention provides a method of preventing or treating a tumor in a subject, comprising administering to the subject an effective amount of the antibody or antigen-binding fragment thereof, the immunoconjugate or antibody-drug conjugate or the pharmaceutically acceptable salt or solvate thereof as described above, or the pharmaceutical composition as described above, or the pharmaceutical combination as described above.
[0025] The antibody-drug conjugate of the present invention has the following advantages, the antibody-drug conjugate:
[0026] (1) binds to target cells expressing human DLL3 with high affinity;
[0027] (2) can enter cells through endocytosis to kill target cells; the ADC of the present invention has high endocytosis efficiency;
[0028] (3) has remarkable bystander killing effect;
[0029] (4) has high antitumor effect, stronger killing effect on tumor cells and stronger inhibiting effect on the growth of tumors, particularly tumors with high expression of DLL3; still have strong efficacy against tumors treated with chemotherapy;
[0030] (5) has DAR values up to 8, the product is more uniform;
[0031] (6) has low toxicity;
[0032] (7) has good stability, and the linker-payload used by the present invention has high stability;
[0033] (8) has good draggability including improved PK profile.
[0034] Description of the drawings:
[0035] Fig. 1 shows the experimental results of the endocytosis of the antibodies to be tested on SHP-77 cells.
[0036] Fig. 2 shows the experimental results of the binding of the antibodies to be tested to cells overexpressing hDLL3, hDLL1, hDLL4.
[0037] Fig. 3 shows a schematic representation of the endocytosis rate assay.
[0038] Fig. 4 shows the results of the endocytosis rate of 23A1 mAb on SHP-77 cells.
[0039] Fig. 5 shows the results of the endocytosis rate of 23A1 mAb on DMS53 cells overexpressing hDLL3.
[0040] Fig. 6 shows the results of comparative experiments of 23A1-ADC and naked antibody binding to DMS53-DLL3 cells.
[0041] Fig. 7 shows DLL3 expression on small cell lung cancer and H460 cells.
[0042] Fig. 8A shows the results of in vitro killing of 23A1-ADC on DMS53-DLL3 cells.
[0043] Fig. 8B shows the results of in vitro killing of 23A1-ADC on H82 cells.
[0044] Fig. 8C shows the results of in vitro killing of 23A1-ADC on DMS79 cells.
[0045] Fig. 8D shows the results of in vitro killing of 23A1-ADC on SHP-77 cells.
[0046] Fig. 8E shows the results of in vitro killing of 23A1-ADC on DMS53 cells.
[0047] Fig. 8F shows the results of in vitro killing of 23A1-ADC on H460 cells.
[0048] Fig. 9 shows the killing effect of some DLL3-ADCs on DMS53 cells overexpressing hDLL3.
[0049] Fig. 10A shows the results of in vitro killing of ADCs obtained by conjugating 23A1 with different toxins on DMS53-DLL3 cells.
[0050] Fig. 10B shows the results of in vitro killing of ADCs obtained by conjugating 23A1 with different toxins on H82 cells.
[0051] Fig. 10C shows the results of in vitro killing of ADCs obtained by conjugating 23A1 with different toxins on DMS79 cells.
[0052] Fig. 10D shows the results of in vitro killing of ADCs obtained by conjugating 23A1 with different toxins on SHP-77 cells.
[0053] Fig. 10E shows the results of in vitro killing of ADCs obtained by conjugating 23A1 with different toxins on DMS53 cells.
[0054] Fig. 10F shows the results of in vitro killing of ADCs obtained by conjugating 23A1 with different toxins on H460 cells.
[0055] Fig. 11 shows the 23A1-ADC bystander kill results.
[0056] Fig. 12A shows tumor inhibition by 23A1-ADC in H82 mouse transplantation tumor model.
[0057] Fig. 12B shows the change in mouse body weight in the 23A1-ADC treated H82 mouse transplantation tumor model.
[0058] Fig. 13A shows tumor inhibition by 23A1-ADC in SHP-77 mouse transplantation tumor model.
[0059] Fig. 13B shows the change in mouse body weight in the 23A1-ADC treated SHP-77 mouse transplantation tumor model.
[0060] Fig. 14A shows tumor inhibition by 23A1-ADC in DMS79 mouse transplantation tumor model.
[0061] Fig. 14B shows the change in mouse body weight in the 23A1-ADC treated DMS79 mouse transplantation tumor model.
[0062] Fig. 15A shows the anti-tumor effect of 23A1-ADC compared to that of chemotherapeutic agents on SHP-77 mouse transplantation tumor model.
[0063] Fig. 15B shows the change in mouse body weight in SHP-77 mouse transplantation tumor model (23A1-ADC vs. chemotherapeutic agents) .
[0064] Fig. 16 shows the anti-tumor effect of 23A1-ADC in SHP-77 mouse transplantation tumor model after chemotherapy resistance.
[0065] Fig. 17 shows the preparation route (A) and structure (B) of the D3-107 / CD3-C1 bispecific antibody.
[0066] Fig. 18 shows the binding of the D3-107 / CD3-C1 bispecific antibody to a cell line overexpressing DLL3 as well as to T cells.
[0067] Fig. 19 shows the killing activity of the D3-107 / CD3-C1 bispecific antibody against tumor cells in vitro.
[0068] Fig. 20 shows tumor inhibition in the H82 mouse transplantation tumor model for 23A1-ADC, D3-107 / CD3-C1, and the combination therapy.
[0069] Fig. 21 shows the PK study of 23A1-ADC molecules in mice.
[0070] Fig. 22A shows the tumor inhibition effect of DLL3-ADC, 5mg / kg in SHP-77 mouse transplantation tumor model.
[0071] Fig. 22B shows the tumor inhibition effect of DLL3-ADC, 1mg / kg in SHP-77 mouse transplantation tumor model.
[0072] Fig. 22C shows the change in mouse body weight in the DLL3-ADC treated SHP-77 mouse transplantation tumor model.
[0073] Fig. 23A shows tumor inhibition by DLL3-ADC in DMS79 mouse transplantation tumor model.
[0074] Fig. 23B shows the change in mouse body weight in the DLL3-ADC treated DMS79 mouse transplantation tumor model.Detailed Description
[0075] I. Definition
[0076] Before the invention is described in detail below, it should be understood that the invention is not limited to the particular methodology, protocols, and reagents described herein, as these may vary. It should also be understood that the terminology used herein is for the purpose of describing particular embodiments only, and is not intended to limit the scope of the present invention, which will be limited only by the appended claims. Unless otherwise defined, all technical and scientific terms used herein have the same meaning as commonly understood by those of ordinary skill in the art to which the invention belongs.
[0077] For the purpose of explaining this specification, the following definitions will be used, and wherever appropriate, terms used in the singular may also include the plural and vice versa. It is understood that the terminology used herein is for the purpose of describing particular embodiments only and is not intended to be limiting.
[0078] The term "about" when used in combination with a numerical value is intended to encompass numerical values within a range having a lower limit that is 5%, 4%, 3%, 2%, or 1%less than the specified numerical value and an upper limit that is 5%, 4%, 3%, 2%, or 1%greater than the specified numerical value.
[0079] As used herein, the term "and / or" means any one of the options or two or more of the options.
[0080] The term "comprise" or "include" as used herein means including the elements, integers or steps described, but does not exclude any other elements, integers or steps. The term also covers the situation consisting of the elements, integers or steps mentioned herein when the term "comprises" or "include" is used, unless otherwise specified. For example, it is also intended to cover the antibody variable region composed of the specific sequence when referring to the antibody variable region "comprises" a specific sequence.
[0081] When referring to "first" and "second" herein, it is merely to distinguish the two domains or the two chains but do not indicate the positions of the two domains in any way.
[0082] The term "DLL3" as used herein refers to a type I transmembrane protein belonging to the family of Notch ligands. In some embodiments, DLL3 is human DLL3. Human DLL3 includes, for example, having the amino acid sequence as shown in UniProtKB / Swiss-Prot: Q9NYJ7. In some embodiments, DLL3 is monkey DLL3, e.g., rhesus DLL3. Rhesus monkey DLL3 comprises, for example, the amino acid sequence as shown in Uniprot numbering F6TFV4.
[0083] As used herein, an "antibody that binds DLL3" or an "anti-DLL3 antibody" or an "antibody that specifically binds to DLL3" refers to such an antibody that is capable of binding to DLL3 with appropriate affinity.
[0084] General information on the amino acid sequences or nucleotide sequences of human immunoglobulin light and heavy chains is given in Kabat, E. A. et al, Sequences of Proteins of Immunological Interest, 5th edition, Public Health Service, National Institutes of Health, Bethesda, MD (1991) .
[0085] With respect to polypeptide sequences, "conservative alterations" include substitutions, deletions, or additions to the polypeptide sequence that do not substantially alter the desired functional activity of the polypeptide sequence. For example, conservative substitutions often result in the substitution of an amino acid for a chemically similar amino acid. Conservative substitution tables providing functionally similar amino acids are well known in the art. The following list 8 groups of amino acids that can be conservatively substituted for each other: 1) alanine (a) , glycine (G) ; 2) aspartic acid (D) , glutamic acid (E) ; 3) asparagine (N) , glutamine (Q) ; 4) arginine (R) , lysine (K) ; 5) isoleucine (I) , leucine (L) , methionine (M) , valine (V) ; 6) phenylalanine (F) , tyrosine (Y) , tryptophan (W) ; 7) serine (S) , threonine (T) ; and 8) cysteine (C) , methionine (M) . In some embodiments, the term "conservative sequence changes" is used to refer to amino acid modifications that do not significantly affect or alter the desired antigen-binding characteristics of the antibody molecules or binding protein molecules of the present invention containing the amino acid sequence. For example, conservatively modified variants will retain at least 80%, 85%, 90%, 95%, 98%, 99%or more, e.g., 100-110%or more, binding affinity for the antigen of interest relative to the parent antibody or binding protein.
[0086] The term "vector" as used herein refers to a nucleic acid molecule capable of propagating another nucleic acid to which it is linked. The term includes vectors which self-replicating nucleic acid structures as well as vectors which are incorporated into the genome of a host cell into which they have been introduced. Some vectors are capable of directing the expression of a nucleic acid to which they are operably linked. Such vectors are referred to herein as "expression vectors" .
[0087] When referring to an "Ab is derived from an antibody" it is meant that the binding domain constituting the Ab is or is derived from a binding domain of the antibody that specifically binds to antigen, e.g., a fragment of the Ab that specifically binds to antigen, e.g., Fab, is or is derived from a corresponding fragment of the antibody, e.g., Fab, or a heavy chain variable region and / or a light chain variable region of the antigen binding region of the Ab is or is derived from a heavy chain variable region and / or a light chain variable region of the antibody, or 1, 2, 3, 4, 5, or 6 CDRs of said antigen binding region are CDRs of the antibody.
[0088] The terms "whole antibody" or "full-length antibody" are used interchangeably herein to refer to an antibody molecule having the structure of a native immunoglobulin molecule. In the case of a conventional four-chain IgG antibody, the full-length antibody comprises two heavy chains (H) and two light chains (L) interconnected by disulfide bonds. In the case of a heavy chain antibody having only heavy chains but lacking light chains, the full-length antibody comprises two heavy chains (H) interconnected by disulfide bonds. For conventional four-chain IgG antibodies, the full-length antibody heavy chain typically consists of a heavy chain variable region (abbreviated herein as VH) and a heavy chain constant region, wherein the heavy chain constant region comprises at least 3 domains CH1, CH2, and CH3. The full-length antibody light chain consists of a light chain variable region (abbreviated herein as VL) and a light chain constant region, wherein the light chain constant region consists of one domain CL. Each heavy chain variable region VH and each light chain variable region is composed of three CDRs and 4 FRs, arranged from amino-terminus to carboxy-terminus in the following order: FR1, CDR1, FR2, CDR2, FR3, CDR3, FR4. The term "antibody fragment" includes a portion of an intact antibody. In a preferred embodiment, the antibody fragment is an antigen-binding fragment.
[0089] The term "antigen-binding fragment" of an antibody is a molecule distinct from a full-length antibody that comprises a portion of the full-length antibody, but is capable of binding to an antigen of the full-length antibody or competes for binding to an antigen with the full-length antibody (i.e., the full-length antibody from which the antigen-binding fragment is derived) . Antigen-binding fragments may be prepared by recombinant DNA techniques, or by enzymatic or chemical cleavage of intact antibodies. Antigen binding fragments include, but are not limited to, Fab, Fab', F (ab') 2, Fv, single chain Fv, diabodies, single domain antibodies (sdAbs) , nanobodies. For example, Fab fragments can be obtained by papain digestion of full-length antibodies. In addition, digestion of the complete antibody by pepsin below the disulfide bond in the hinge region produces F (ab') 2, which is a dimer of Fab'a nd is a bivalent antibody fragment. The F (ab') 2 may be reduced under neutral conditions by disrupting the disulfide bond in the hinge region, thereby converting the F (ab') 2 dimer into a Fab 'monomer. The Fab'monomer is essentially a Fab fragment with a hinge region. The Fv fragment consists of the VL and VH domains of a single arm of an antibody. The two domains of the Fv fragment, VL and VH, may be encoded by separate genes, but can also be produced as a single protein chain using a recombinant method, using a synthetic connector peptide to connect the two domains, and in the single protein chain the VL region and the VH region are paired to form a single-chain Fv (scFv) .
[0090] "Fab fragment" or "Fab" are used interchangeably herein to refer to an immunoglobulin fragment consisting of two polypeptide chains, comprising an immunoglobulin heavy chain variable domain VH, a heavy chain constant domain CH1, a light chain variable domain VL, and a light chain constant domain CL, wherein one polypeptide chain comprises, from N-terminus to C-terminus, VH and one constant region selected from CH1 and CL, and the other polypeptide chain comprises, from N-terminus to C-terminus, VL and another constant region selected from CL and CH1, wherein the VH and VL domains pair to form an antigen-binding site or an antigen-binding region. Herein, the Fab polypeptide chain comprising the heavy chain constant region CH1 is also referred to as the "Fab heavy chain" ; accordingly, the Fab polypeptide chain comprising the light chain constant region CL is also referred to as "Fab light chain" .
[0091] “Complementarity determining region” or “CDR region” or “CDR” is a region in an antibody variable domain that is highly variable in sequence and forms a structurally defined loop (“hypervariable loop” ) and / or comprises antigen-contacting residues ( “antigen contact sites” ) . CDRs are primarily responsible for binding to antigenic epitopes. The CDRs of the heavy and light chains are generally referred to as CDR1, CDR2, and CDR3, and are numbered sequentially from the N-terminus. The CDRs located in the heavy chain variable domain of the antibody are referred to as HCDR1, HCDR2, and HCDR3, whereas the CDRs located in the light chain variable domain of the antibody are referred to as LCDR1, LCDR2 and LCDR3. In a given amino acid sequence of a light chain variable region or a heavy chain variable region, the exact amino acid sequence boundaries of each of the CDR may be determined using any one or a combination of many well-known antibody CDR assignment schemes including, for example, Chothia based on the three-dimensional structure of antibodies and the topology of CDR loops (Chothia et al., (1989) Nature, 342: 877-883; Al-Lazikani et al., “Standard conformations for the canonical structures of immunoglobulins” , Journal of Molecular Biology, 273: 927-948 (1997) ) , Kabat based on antibody sequence variability (Kabat et al., Sequences of Proteins of Immunological Interest, 4th Ed., U.S. Department of Health and Human Services, National Institutes of Health (1987) ) , AbM (University of Bath) , Contact (University College London) , International ImMunoGeneTics database (IMGT) (www. imgt. cines. fr or https: / / www. imgt. org) and North CDR definition based on the affinity propagation clustering using a large number of crystal structures. Unless otherwise stated, the term “CDR” or “CDR sequence” used herein encompasses CDR sequences determined by any one of the schemes described above. CDRs can also be determined based on having the same Kabat numbering positions as a reference CDR sequence (e.g., any of the exemplary CDRs of the present invention) .
[0092] In some embodiments, the CDRs of the heavy chain variable region of an antibody of the invention are determined according to Kabat or Chothia, or a combination of Kabat and Chothia (hereinafter referred to "Kabat &Chothia" , corresponding to H26-H32 under the Kabat numbering system) . In some embodiments, the CDRs of the light chain variable region of the antibodies of the invention are determined according to Kabat.
[0093] In an embodiment, HCDR1 in the anti-DLL3 antibodies of the invention is defined according to Kabat &Chothia schemes, HCDR2, HCDR3 are defined according to Kabat scheme, and LCDRs are defined according to Kabat scheme, respectively.
[0094] The calculation of sequence identity between sequences was performed as follows.
[0095] To determine the percent identity of two amino acid sequences or two nucleic acid sequences, the sequences are aligned for optimal comparison purposes (e.g., gaps can be introduced in one or both of the first and second amino acid sequences or nucleic acid sequences for optimal alignment or non-homologous sequences can be discarded for comparison purposes) . In a preferred embodiment, the length of the aligned reference sequences is at least 30%, preferably at least 40%, more preferably at least 50%, 60%and even more preferably at least 70%, 80%, 90%, 100%of the length of the reference sequence for comparison purposes. The amino acid residues or nucleotides at corresponding amino acid positions or nucleotide positions are then compared. When a position in the first sequence is occupied by the same amino acid residue or nucleotide as the corresponding position in the second sequence, then the molecules are identical at that position.
[0096] As used herein, the term “anti” , “binding” , or “specific binding” means that the binding effect is selective for targets or antigens and may be distinguished from unwanted or non-specific interactions. The ability of a binding site to bind to a particular target or an antigen may be determined by flow cytometry, enzyme-linked immunosorbent assay (ELISA) , or conventional binding assays known in the art, such as radioimmunoassay (RIA) , bio-layer interferometry, MSD assay, or surface plasmon resonance (SPR) .
[0097] “Affinity” or “binding affinity” refers to the inherent binding affinity that reflects the interaction between members of a binding pair. The affinity of molecule X for its partner Y may be generally represented by the dissociation constant (KD) , which is a ratio of the dissociation rate constant (Kdis) to the association rate constant (Kon) . Affinity can be measured by common methods known in the art. One specific method for measuring affinity is the ForteBio kinetic binding assay described herein.
[0098] The term "host cell" refers to a cell into which an exogenous polynucleotide has been introduced, including progeny of such a cell. Host cells include "transformants" and "transformed cells, " which include the primary transformed cell and progeny derived therefrom.
[0099] As used herein, "antibody-drug conjugate (ADC) " refers to a structure obtained by linking an antibody to a (small molecule) drug.
[0100] The term "linker" refers to a structural fragment that links a drug (e.g., a small molecule drug) to an antibody moiety. It should be understood that the linker, prior to attachment to the antibody or antigen-binding fragment thereof, has a functional group that can form a bond with a functional group of the antibody or antigen-binding fragment thereof.
[0101] The term "linker-payload" refers to a compound formed by linking a payload, such as a drug (e.g., a small molecule drug) , to a linker.
[0102] The term "site-specific conjugation" as used herein refers to conjugation of a drug specifically to a specific site of an antibody via a linker.
[0103] As used herein, the term "alkyl" refers to a fully saturated branched or unbranched hydrocarbon group. The alkyl group preferably contains 1 to 16 carbon atoms, for example 1 to 12 carbon atoms, 1 to 10 carbon atoms, 1 to 6 carbon atoms or 1 to 4 carbon atoms. Representative examples of alkyl groups include, but are not limited to, methyl, ethyl, n-propyl, isopropyl, n-butyl, sec-butyl, isobutyl, tert-butyl, n-pentyl, isopentyl, neopentyl, n-hexyl, 3-methylhexyl, 2, 2-dimethylpentyl, 2, 3-dimethylpentyl, n-heptyl, n-octyl, n-nonyl, n-decyl, and the like.
[0104] The term "alkylene" refers to an alkyl group as defined above, but which is divalent, i.e., has two single bonds linked to two other groups. Non-limiting examples of alkylene groups include -CH2-, -CH2CH2-, -CH2CH2CH2-, -CH2CH2CH2CH2-, -CH (-CH2CH3) -or -CH2CH (-CH3) -.
[0105] The term "alkenyl" refers to a straight or branched chain hydrocarbon group containing 2 to 16 carbon atoms and containing at least one double bond and no triple bond. The alkenyl group preferably contains 2 to 12 carbon atoms, 2 to 10 carbon atoms, 2 to 8 carbon atoms, 2 to 6 carbon atoms, or 2 to 4 carbon atoms. Representative examples of alkenyl groups include, but are not limited to, ethenyl, propenyl, butenyl, pentenyl, hexenyl, and the like.
[0106] The term "alkynyl" refers to a straight or branched hydrocarbon group containing 2 to 16 carbon atoms and comprising at least one triple bond. Alkynyl groups preferably contain 2 to 12 carbon atoms, 2 to 10 carbon atoms, 2 to 8 carbon atoms, 2 to 6 carbon atoms, or 2 to 4 carbon atoms. Representative examples of alkynyl groups include, but are not limited to, ethynyl, propynyl, butynyl, pentynyl, hexynyl, and the like.
[0107] The term "halogen" or "halo" refers to fluoro (-F) , chloro (-Cl) , bromo (-Br) , and iodo (-I) .
[0108] The term "haloalkyl" refers to an alkyl group as defined herein, substituted with one or more halo groups as defined herein. The haloalkyl group may preferably be a monohaloalkyl group, a dihaloalkyl group or a polyhaloalkyl group (including a perhaloalkyl group) . The monohaloalkyl group may contain one iodo, bromo, chloro or fluoro in the alkyl group. The dihaloalkyl and polyhaloalkyl groups may contain two or more of the same halogen atoms in the alkyl group or a combination of different halo groups. Preferably, the polyhaloalkyl contains up to 12, 10 or 8 or 6 or 4 or 3 or 2 halo groups. Non-limiting examples of haloalkyl groups include fluoromethyl, difluoromethyl, trifluoromethyl, chloromethyl, dichloromethyl, trichloromethyl, pentafluoroethyl, heptafluoropropyl, difluorochloromethyl, dichlorofluoromethyl, difluoroethyl, difluoropropyl, dichloroethyl, and dichloropropyl. Perhaloalkyl refers to alkyl groups in which all hydrogen atoms are replaced by halogen atoms.
[0109] The term "haloalkenyl" refers to an alkenyl group as defined herein, substituted with one or more halo groups as defined herein. The term "haloalkynyl" refers to an alkynyl group as defined herein, which is substituted with one or more halo groups as defined herein. The meaning of "halo" as defined for "haloalkyl" is applicable to "haloalkenyl" and "haloalkynyl" .
[0110] The term "polyol group" refers to an alkyl group as defined above containing multiple (e.g., 2 to 10, e.g., 3, 4, 5, 6, 7 or 8) hydroxyls, optionally containing one or more (e.g., 2, 3 or 4) other groups (e.g., amino, carbonyl) . Non-limiting examples of "polyol groups" include, for example, wherein, the chiral center without specified stereoconfiguration may be R or S configuration, preferably
[0111] The term "amino acid" refers to both naturally occurring and synthetic amino acids. The amino acids may be either L or D isomers, preferably amino acids (L-amino acids) with naturally occurring configuration. The conventional amino acids referred to herein are written following a conventional approach. See, for example, Immunology-ASynthesis (2nd Edition, E. S. Golub and D. R. Gren, eds., Sinauer Associates, Sunderland, Mass. (1991) ) which is incorporated herein by reference. In addition, in the present disclosure, the amino acids are generally represented by the single and three letter abbreviations commonly known in the art. For example, the amino acids may be selected from phenylalanine (Phe; F) , tyrosine (Tyr; Y) , leucine (Leu; L) , glycine (Gly; G) , alanine (Ala; A) , valine (Val; V) , lysine (Lys; K) , citrulline (Cit) , serine (Ser; S) , glutamic acid (Glu; E) , aspartic acid (Asp; D), asparagine (Asn) , isoleucine (Ile) , arginine (Arg) , proline (Pro) and glutamine (Gln) .
[0112] The term "pentose" , also known as five-carbon saccharide, refers to a monosaccharide containing five carbon atoms. The pentose includes D-type and / or L-type pentose. Examples of pentose include, but are not limited to, xylose, arabinose, ribose, and deoxyribose.
[0113] The term "hexose" , also known as six-carbon saccharide, refers to a monosaccharide containing six carbon atoms. The hexose includes D-type and / or L-type hexose. Examples of hexose include, but are not limited to, glucose, galactose, mannose and fructose.
[0114] The term "penturonic acid" refers to a compound formed by the oxidation of the primary hydroxyl of pentose as defined above to carboxyl group. Examples of penturonic acid include, but are not limited to, xyluronic acid, arabinuronic acid.
[0115] The term "hexuronic acid" refers to a compound formed by the oxidation of the primary hydroxyl of hexose as defined above to carboxyl group. Examples of hexuronic acid include, but are not limited to, glucuronic acid, galacturonic acid, and mannuronic acid.
[0116] The term "disaccharide" refers to a disaccharide formed by two molecules of monosaccharides (pentose and / or hexose as defined above) via a glycosidic bond. Examples of disaccharides include, but are not limited to, sucrose, lactose, and maltose.
[0117] The term “trisaccharides” refers to a trisaccharide formed by three molecules of monosaccharides (pentose and / or hexose as defined above) via a glycosidic bond.
[0118] The term "glycosidic bond" refers to, in an acetal derivative formed by dehydration condensation of a hydroxyl located on a hemiacetal of the sugar structure with an additional hydroxyl-containing compounds (such as alcohols, phenols or other sugars) , wherein the chemical bond that connects the sugar to the additional hydroxyl-containing compounds is the glycosidic bond.
[0119] It will be understood that the pentose, hexose, penturonic acid, hexuronic acid, disaccharide, and trisaccharide, when mentioned as a group within the structure, refers to a group formed by the loss of one hydrogen from the hydroxyl (for example, hydroxyl at 1, 2, 3, 4, 5 or 6 position, preferably at 1 position) of the corresponding sugar or uronic acid. It can also be called as pentosyl, hexosyl, etc. Preferably, saccharides or uronic acids are covalently linked to other structures or moieties via a glycosidic bond.
[0120] The term "optional" or "optionally" means that the subsequently described event or condition occurs or does not occur, and that the description includes instances where said event or condition occurs and instances where it does not occur. For example, when a group or structure is "optionally substituted" , the group or structure may or may not be substituted.
[0121] The term "pharmaceutically acceptable salt" refers to a salt that retains the biological effects and properties of the ADC conjugates of the present invention, and which is not biologically or otherwise undesirable. The ADC conjugates of the present invention may exist in the form of their pharmaceutically acceptable salt, including acid addition salts and base addition salts. In the present invention, pharmaceutically acceptable non-toxic acid addition salts refer to salts formed by the ADC conjugates of the present invention with organic or inorganic acids including, but not limited to, hydrochloric acid, sulfuric acid, hydrobromic acid, hydroiodic acid, phosphoric acid, nitric acid, perchloric acid, acetic acid, oxalic acid, maleic acid, fumaric acid, tartaric acid, benzenesulfonic acid, methanesulfonic acid, salicylic acid, succinic acid, citric acid, lactic acid, propionic acid, benzoic acid, p-toluenesulfonic acid, malic acid, and the like. Pharmaceutically acceptable non-toxic base addition salts mean salts formed by the ADC conjugates of the present invention with organic or inorganic bases, including but not limited to alkali metal salts, such as lithium, sodium or potassium salts; alkaline earth metal salts, such as calcium or magnesium salts; organic base salts, for example ammonium salts, formed with organic bases containing N groups.
[0122] The term "solvate" refers to an associated complex formed by one or more solvent molecules with an ADC antibody-drug conjugate of the present invention. Solvents that form solvates include, but are not limited to, water, methanol, ethanol, isopropanol, ethyl acetate, tetrahydrofuran, N, N-dimethylformamide, dimethylsulfoxide, and the like.
[0123] "Pharmaceutically acceptable" and "pharmaceutically useful" are used interchangeably herein, unless it conflicts with the context.
[0124] The term "drug to antibody ratio" or "DAR" refers to, in an ADC molecule, the ratio of drug moiety (D) conjugated to the Ab moiety as described herein to the Ab moiety. In some embodiments described herein, the DAR may be determined by p in formula I. For example, DAR may be an integer of 1 to 16, e.g. an integer of 2 to 16, 4 to 16, 5 to 12, 6 to 10, 2 to 8, 3 to 8, 2 to 6, 4 to 6, 6 to 10, e.g. 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12. DAR may also be calculated as the average DAR of a population of molecules in a product, i.e., the overall ratio of drug moiety (D) conjugated to the Ab moiety described herein to the Ab moiety as measured by detection methods (e.g., by conventional methods such as mass spectrometry, ELISA assays, electrophoresis, and / or HPLC) in a product, such DAR being referred to herein as average DAR or measured DAR, the average DAR may be an integer or a decimal. In some embodiments, the average DAR of the conjugate of the present invention is 1 to 16, e.g., 2 to 16, 4 to 16, 5 to 12, 6 to 10, 2 to 8, 3 to 8, 2 to 6, 4 to 6, 6 to 10, e.g., 1.0 to 8.0, 2.0 to 6.0, e.g., 0.5, 0.6, 0.7, 0.8, 0.9, 1, 1.1, 1.2, 1.3, 1.4, 1.5, 1.6, 1.7, 1.8, 1.9, 2, 2.1, 2.2, 2.3, 2.4, 2.5, 2.6, 2.7, 2.8, 2.9, 3, 3.1, 3.2, 3.3, 3.4, 3.5, 3.6, 3.7, 3.8, 3.9, 4, 4.1, 4.2, 4.3, 4.4, 4.5, 4.6, 4.7, 4.8, 4.9, 5.0, 5.1, 5.2, 5.3, 5.4, 5.5, 5.6, 5.7, 5.8, 5.9, 6.0, 6.1, 6.2, 6.3, 6.4, 6.5, 6.6, 6.7, 6.8, 6.9, 7.0, 7.1, 7.2, 7.3, 7.4, 7.5, 7.6, 7.7, 7.8, 7.9, 8, 8.1, 8.2, 8.3, 8.4, 8.5, 8.6, 8.7, 8.8, 8.9, 9.0, 9.1, 9.2, 9.3, 9.4, 9.5, 9.6, 9.7, 9.8, 9.9 or 10.0, and a ranges with two of these values as endpoints. It should be understood that, in the case that an average DAR is referred to, the ADCs according to the present invention refer to a population of ADC molecules or a mixture of ADC molecules comprising ADC molecules with the same and / or different DARs.
[0125] The term "therapeutic agent" as described herein comprises any substance effective in preventing or treating tumors (such as cancer) , including chemotherapeutic agents, cytokines, angiogenesis inhibitors, cytotoxic agents, other antibodies, small molecule drugs or immune modulators (such as an immunosuppressant) .
[0126] The term "cytotoxic agent" used in the invention refers to a substance that inhibits or prevents the cell function and / or causes cell death or destruction.
[0127] "Chemotherapeutic agents" include chemical compounds useful in treatment of cancer or immune system disease.
[0128] The term "drug" refers to an organic compound capable of modulating a biological process, in particular altering or preventing a pathological process.
[0129] The term "prodrug" refers to a chemically modified active or inactive compound that, is converted into an active drug upon administered to a subject and subjected a physiological effect in vivo (e.g., hydrolysis, metabolism, etc. ) . Techniques for preparing and using prodrugs are well known to those skilled in the art.
[0130] The term "small molecule drugs" refers to organic compounds with low molecular weight that can regulate biological processes, especially alter or prevent pathological processes. "Small molecule" is defined as a molecule with molecular weight less than 10kD, generally less than 2kD and preferably less than 1kD, more preferably less than 500D. Small molecules include but are not limited to inorganic molecules, organic molecules, organic molecules containing inorganic components, molecules containing radioactive atoms, synthetic molecules, peptide mimics and antibody mimics. As a therapeutic agent, small molecules can penetrate cells more easily than large molecules, and are less susceptible to degradation and less prone to trigger immune response.
[0131] "Anti-tumor compounds" are pharmaceutically active compounds that have an effect on tumors, including but not limited to cytotoxic agents or chemotherapeutic agents, especially small molecule cytotoxic agents or chemotherapeutic agents, such as camptothecins e.g., those disclosed in WO 2021 / 173773, WO2022180581, CN 102574866, exatecans (topoisomerase I inhibitor, Exatecan) , Dxd (a novel topoisomerase I inhibitor, a derivative of Exatecan) , auristatins, e.g., monomethyl auristatin E (MMAE) , maytansinoids, e.g., small molecule microtubule inhibitor, DM1. It should be understood that the anti-tumor compounds may be substituted with isotopes including, but not limited to, deuterium, tritium, and the like. For example, following substitution with deuterium, the carbon-deuterium bonds replace carbon-hydrogen bonds, since the former are more stable than the latter, the substitution can directly affect the certain properties of drugs such as absorption, distribution, metabolism, excretion, etc. thereby improving the efficacy, safety, and tolerability of the drugs. Thus, the "anti-tumor compound" of the present application may encompass compounds substituted with deuterium.
[0132] "Substituted with deuterium" is meant that a hydrogen in the molecule is replaced with a deuterium, for example one or more hydrogens, for example 1 to 10 (e.g. 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10) hydrogen (s) is / are replaced with deuterium (s) .
[0133] “Camptothecins” refers to a compound having a camptothecin core structure (for example a fused five-cycle structure of camptothecin or a fused four-cycle structure therein) and anti-tumor activity. “Camptothecins” is a term conventionally used in medicinal chemistry. A person skilled in the art can easily determine whether a structure is camptothecins according to the structure of the compound.
[0134] “Auristatins” refers to a compound having an auristatin core structure and anti-tumor activity.
[0135] “Maytansinoids” refers to a compound having a maytansinoid core structure and anti-tumor activity.
[0136] The term “immunomodulatory agent” used herein refers to a natural or synthetic agent or drug that suppresses or modulates (e.g., activates) an immune response. The immune response may be a humoral response or a cellular response. The immunomodulatory agent includes an immunosuppressant. In some embodiments, the immunomodulatory agent of the present invention includes an immune checkpoint inhibitor or an immune checkpoint agonist.
[0137] The term “effective amount” refers to an amount or dosage of the antibody, fragment, composition, or combination of the present invention which generates expected effects in a patient in need of treatment or prevention after being administered to the patient in a single or multiple doses. A "therapeutically effective amount" and a "prophylactically effective amount" may be included, depending on the desired effect.
[0138] “Therapeutically effective amount” refers to an amount effective to achieve a desired therapeutic result at a necessary dose for a necessary period of time. The therapeutically effective amount is also such an amount that any toxic or detrimental effect of the antibody, fragment thereof, composition, or combination is inferior to the therapeutically beneficial effect. The “therapeutically effective amount” preferably inhibits a measurable parameter (e.g., tumor volume) by at least about 30%, even more preferably by at least about 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, or even 100%relative to an untreated subject.
[0139] “Prophylactically effective amount” refers to an amount effective to achieve a desired prophylactic result at a necessary dose for a necessary period of time. Generally, since a prophylactic dose is administered in a subject before or at an earlier stage of a disease, a prophylactically effective amount will be less than a therapeutically effective amount.
[0140] The terms "host cell, " "host cell line, " and "host cell culture" are used interchangeably and refer to a cell into which an exogenous nucleic acid is introduced, including the progeny of such a cell.
[0141] The term "label" as used herein refers to a compound or composition that is directly or indirectly conjugated or fused to an agent (such as a polynucleotide probe or antibody) and facilitates detection of the agent to which it is conjugated or fused. The label may be detectable by itself (e.g., a radioisotope label or a fluorescent label) or, in the case of an enzymatic label, may catalyze chemical alteration of a substrate compound or composition which is detectable. The term is intended to encompass direct labeling of a probe or antibody by coupling (i.e., physically linking) a detectable substance to the probe or antibody as well as indirect labeling of the probe or antibody by reaction with another reagent that is directly labeled.
[0142] An "individual" or "subject" includes a mammal. Mammals include, but are not limited to, domestic animals (e.g., cattle, sheep, cats, dogs, and horses) , primates (e.g., human and non-human primates such as monkeys) , rabbits, and rodents (e.g., mice and rats) . In some embodiments, the individual or subject is a human.
[0143] An "isolated" antibody or other molecule (e.g., an ADC molecule) is one that has been separated from its natural environment or components of the environment in which it is expressed. In some embodiments, the antibody or ADC molecule is purified to greater than 95%or 99%purity as determined by, for example, electrophoresis (e.g., SDS-PAGE, isoelectric focusing (IEF) , capillary electrophoresis) or chromatography (e.g., ion exchange or reverse phase HPLC) .
[0144] The term "anti-tumor effect" refers to a biological effect that can be showed by a variety of means, including, but not limited to, for example, a reduction in tumor volume, a reduction in tumor cell number, a reduction in tumor cell proliferation, or a reduction in tumor cell survival.
[0145] The terms "cancer" and "cancerous" refer to or describe the physiological condition in mammals that is typically characterized by unregulated cell growth. The cancer may be in an early, intermediate or advanced stage or metastatic cancer. DLL3-positive cancers suitable for treatment by the molecules of the present invention include, but are not limited to, lung cancer such as small cell lung cancer, including metastatic forms of those cancers.
[0146] The term “tumor” refers to all neoplastic cell growth and proliferation, whether malignant or benign, and as well as pre-cancerous and cancerous cells and tissues. "Tumor" encompasses both solid and hematological tumors and metastatic lesions terms “cancer” , “carcinoma” , and “tumor” are not mutually exclusive when referred to herein.
[0147] The term "pharmaceutically acceptable excipient" refers to a diluent, an adjuvant (e.g., Freund's adjuvant (complete and incomplete) ) , a vehicle, a carrier, a stabilizer or the like with which the active substance is administered.
[0148] The term "pharmaceutical composition" refers to a composition that is present in a form that allows for the biological activity of the active ingredients contained therein to be effective, and that does not contain additional ingredients that have unacceptable toxicity to the subject to which the composition is administered.
[0149] The term "pharmaceutical combination" refers to a non-fixed combination or a fixed combination, including but not limited to a kit, a pharmaceutical composition. The term "non-fixed combination" means that the active ingredients (e.g., (i) the antibody or the immunoconjugate thereof, e.g., an ADC molecule thereof of the present invention, and (ii) another therapeutic agent) are administered, either simultaneously or sequentially (without specific time limitation or at identical or different time intervals) , to a patient as separate entities, wherein such administration provides two or more prophylactically or therapeutically effective active agents in the patient. In some embodiments, the antibody or the immunoconjugate thereof, e.g., an ADC molecule thereof of the present invention and the other therapeutic agents used in the pharmaceutical combination are administered at a level that does not exceed their level when used alone. The term “fixed combination” means that two or more active agents are administered to a patient simultaneously in the form of a single entity. The dose and / or time intervals of two or more active agents are preferably selected such that the combined use of each components can result in a therapeutic effect on the disease or disorder which is greater than that achieved by the use of either component alone. The ingredients may each take a separate formulation form and such separate formulation forms may be the same or different.
[0150] The term “combination therapy” refers to the administration of two or more therapeutic agents or modalities (e.g., a radiotherapy or a surgery) to treat the diseases as described herein. Such administration includes co-administration of these therapeutic agents in a substantially simultaneous manner, for example, in a single capsule with a fixed proportion of active ingredients. Alternatively, such administration includes co-administration of each of the active ingredients in a variety of or separate containers (such as tablets, capsules, powder and liquid) . The powder and / or liquid can be reconstituted or diluted to a desired dose before administration. In addition, this administration also includes the use of each type of therapeutic agent at approximately the same time or at different times in a sequential manner. In any case, the therapeutic regimen will provide a beneficial effect of the pharmaceutical combination in the treatment of the diseases or conditions described herein.
[0151] As used herein, "treatment" (or "treat" or "treating" ) refers to easing, interrupting, arresting, alleviating, stopping, reducing, or reversing the progression or severity of an existing symptom, disorder, condition, or disease.
[0152] As used herein, "prevention" (or "prevent" or "preventing" ) includes inhibition of the onset or progression of a disease or disorder or a symptom of a particular disease or disorder. In some embodiments, subjects with a family history of cancer are candidates for a prophylactic regimen. Generally, in the context of cancer, the term "prevention" refers to the administration of a drug prior to the onset of signs or symptoms of the cancer, particularly in a subject at risk for the cancer.
[0153] The term "vector" as used herein refers to a nucleic acid molecule capable of propagating another nucleic acid to which it is linked. The term includes vectors which are self-replicating nucleic acid structures as well as vectors which are incorporated into the genome of a host cell into which they have been introduced. Some vectors are capable of directing the expression of a nucleic acid to which they are operably linked. Such vectors are referred to herein as "expression vectors" .
[0154] "Subject / patient / individual sample" refers to a collection of cells or fluids obtained from a patient or subject. The source of the tissue or cell samples can be solid tissues, e.g., from fresh, frozen and / or preserved organ or tissue samples or biopsy samples or puncture samples; blood or any blood component; body fluids such as cerebrospinal fluids, amniotic fluids, peritoneal fluids (ascites) , or interstitial fluids; cells from a subject at any time during pregnancy or development. Tissue samples may comprise compounds which are naturally not mixed with tissues, such as preservatives, anticoagulants, buffers, fixatives, nutrients, antibiotics, and the like.
[0155] II. Anti-DLL3 antibodies, encoding nucleic acids and preparation thereof
[0156] II-1. Anti-DLL3 antibodies or antigen-binding fragments thereof
[0157] In some embodiments, the anti-DLL3 antibody or antigen-binding fragment thereof of the present invention comprises 3 complementarity determining regions (HCDRs) from the heavy chain variable region, HCDR1, HCDR2 and HCDR3. In some embodiments, the anti-DLL3 antibody or antigen-binding fragment thereof of the present invention comprises 3 complementarity determining regions from the light chain variable region (LCDRs) : LCDR1, LCDR2 and LCDR3. In some embodiments, the anti-DLL3 antibody or antigen-binding fragment thereof of the present invention comprises 3 complementarity determining regions (HCDRs) from the heavy chain variable region and 3 complementarity determining regions (LCDRs) from the light chain variable region.
[0158] In some aspects, the anti-DLL3 antibody or antigen-binding fragment thereof of the present invention comprises a heavy chain variable region (VH) . In some aspects, the anti-DLL3 antibody or antigen-binding fragment thereof of the present invention comprises a light chain variable region (VL) . In some aspects, the anti-DLL3 antibody or antigen-binding fragment thereof of the present invention comprises a heavy chain variable region (VH) and a light chain variable region (VL) . In some embodiments, the heavy chain variable region comprises 3 complementarity determining regions from a heavy chain variable region (HCDRs) : HCDR1, HCDR2 and HCDR3. In some embodiments, the light chain variable region comprises 3 complementarity determining regions (LCDRs) from light chain variable region, LCDR1, LCDR2, and LCDR3.
[0159] The HCDR1, HCDR2, HCDR3, LCDR1, LCDR2, LCDR3, VH, VL of the anti-DLL3 antibody or antigen-binding fragment thereof of the present invention are defined herein.
[0160] In some embodiments, the heavy chain variable region VH of the anti-DLL3 antibodies of the present invention
[0161] (i) comprises or consists of an amino acid sequence having at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%or 99%identity to the amino acid sequence of SEQ ID NO: 2, 45, 55 or 65, or
[0162] (ii) comprises or consists of an amino acid sequence of SEQ ID NO: 2, 45, 55 or 65; or
[0163] (iii) comprises or consists of an amino acid sequence comprising one or more (preferably not more than 10, more preferably not more than 5, 4, 3, 2, 1) amino acid changes (preferably amino acid substitutions, more preferably amino acid conservative substitutions) compared to the amino acid sequence of SEQ ID NO: 2, 45, 55 or 65, preferably said amino acid change (s) does not occur in the CDR regions.
[0164] In some embodiments, the light chain variable region VL of the anti-DLL3 antibodies of the present invention
[0165] (i) comprises or consists of an amino acid sequence having at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%or 99%identity to the amino acid sequence of SEQ ID NO: 8, 50, 60 or 69; or
[0166] (ii) comprises or consists of the amino acid sequence of SEQ ID NO: 8, 50, 60 or 69; or
[0167] (iii) comprises or consists of an amino acid sequence comprising one or more (preferably not more than 10, more preferably not more than 5, 4, 3, 2, 1) amino acid changes (preferably amino acid substitutions, more preferably amino acid conservative substitutions) compared to the amino acid sequence of SEQ ID NO: 8, 50, 60 or 69, preferably said amino acid change (s) does not occur in the CDR regions.
[0168] In some embodiments, the 3 complementarity determining regions (HCDRs) : HCDR1, HCDR2, and HCDR3 from the heavy chain variable region of the anti-DLL3 antibody or antigen-binding fragment thereof of the present invention are
[0169] (i) three complementarity determining regions HCDR1, HCDR2 and HCDR3 contained in the VH set forth in SEQ ID NO: 2, 45, 55 or 65, or
[0170] (ii) sequences which contain at least one and no more than 5, 4, 3, 2 or 1 amino acid change (preferably amino acid substitution, preferably conservative substitution) in total on the three HCDR regions compared to the sequences of (i) ,
[0171] for example, the HCDR1, HCDR2, HCDR3 are determined according to any CDR definition scheme, e.g., as determined by Kabat, Chothia, Contact, AbM, IMGT, or a combination thereof respectively;
[0172] for example, the HCDR1 is defined according to the Kabat &Chothia schemes, and the HCDR2 and HCDR3 are defined according to the Kabat scheme, respectively.
[0173] In some embodiments, the 3 complementarity determining regions (LCDRs) : LCDR1, LCDR2, and LCDR3 from the light chain variable region of the anti-DLL3 antibody or antigen-binding fragment thereof of the present invention are
[0174] (i) three complementarity determining regions LCDR1, LCDR2 and LCDR3 contained in VL set forth in SEQ ID NO: 8, 50, 60 or 69, or
[0175] (ii) sequences which contain at least one and no more than 5, 4, 3, 2 or 1 amino acid change (preferably an amino acid substitution, preferably a conservative substitution) in total on the three LCDR regions compared to the sequences of (i) ;
[0176] for example, the LCDR1, LCDR2, LCDR3 are determined according to any CDR definition scheme, e.g., as defined by Kabat, Chothia, Contact, AbM, IMGT, or a combination thereof, respectively;
[0177] for example, the LCDR1, 2 and 3 are determined according to Kabat scheme, respectively.
[0178] In some embodiments, the HCDR1 described herein comprises or consists of the amino acid sequence set forth in SEQ ID NO: 4, 47 or 57, or an amino acid sequence having 1, 2 or 3 amino acid changes (preferably amino acid substitutions, preferably conservative substitutions) compared thereto.
[0179] In some embodiments, the HCDR2 described herein comprises or consists of the amino acid sequence set forth in SEQ ID NO: 5, 48, 58 or 67, or an amino acid sequence having 1, 2 or 3 amino acid changes (preferably amino acid substitutions, preferably conservative substitutions) compared thereto.
[0180] In some embodiments, the HCDR3 described herein comprises or consists of the amino acid sequence set forth in SEQ ID NO: 6, 49, 59 or 68, or an amino acid sequence having 1, 2 or 3 amino acid changes (preferably amino acid substitutions, preferably conservative substitutions) compared thereto.
[0181] In some embodiments, the LCDR1 described herein comprises or consists of the amino acid sequence set forth in SEQ ID NO: 10, 52 or 62, or an amino acid sequence having 1, 2 or 3 amino acid changes (preferably amino acid substitutions, preferably conservative substitutions) compared thereto.
[0182] In some embodiments, the LCDR2 described herein comprises or consists of the amino acid sequence set forth in SEQ ID NO: 11, 53, 63 or 71, or an amino acid sequence having 1, 2 or 3 amino acid changes (preferably amino acid substitutions, preferably conservative substitutions) compared thereto.
[0183] In some embodiments, the LCDR3 described herein comprises or consists of the amino acid sequence set forth in SEQ ID NO: 12, 54, 64 or 72, or an amino acid sequence having 1, 2 or 3 amino acid changes (preferably amino acid substitutions, preferably conservative substitutions) compared thereto.
[0184] In some embodiments, in the anti-DLL3 antibodies of the present invention,
[0185] (i) . HCDR1 comprises or consists of the amino acid sequence set forth in SEQ ID NO: 4; HCDR2 comprises or consists of the amino acid sequence set forth in SEQ ID NO: 5; HCDR3 comprises or consists of the amino acid sequence set forth in SEQ ID NO: 6; LCDR1 comprises or consists of the amino acid sequence set forth in SEQ ID NO: 10; LCDR2 comprises or consists of the amino acid sequence set forth in SEQ ID NO: 11; and / or LCDR3 comprises or consists of the amino acid sequence set forth in SEQ ID NO: 12;
[0186] (ii) . HCDR1 comprises or consists of the amino acid sequence set forth in SEQ ID NO: 47; HCDR2 comprises or consists of the amino acid sequence set forth in SEQ ID NO: 48; HCDR3 comprises or consists of the amino acid sequence set forth in SEQ ID NO: 49; LCDR1 comprises or consists of the amino acid sequence set forth in SEQ ID NO: 52; LCDR2 comprises or consists of the amino acid sequence set forth in SEQ ID NO: 53; and / or LCDR3 comprises or consists of the amino acid sequence set forth in SEQ ID NO: 54;
[0187] (iii) . HCDR1 comprises or consists of the amino acid sequence set forth in SEQ ID NO: 57; HCDR2 comprises or consists of the amino acid sequence set forth in SEQ ID NO: 58; HCDR3 comprises or consists of the amino acid sequence set forth in SEQ ID NO: 59; LCDR1 comprises or consists of the amino acid sequence set forth in SEQ ID NO: 62; LCDR2 comprises or consists of the amino acid sequence set forth in SEQ ID NO: 63; and / or LCDR3 comprises or consists of the amino acid sequence set forth in SEQ ID NO: 64; or
[0188] (iv) . HCDR1 comprises or consists of the amino acid sequence set forth in SEQ ID NO: 4; HCDR2 comprises or consists of the amino acid sequence set forth in SEQ ID NO: 67; HCDR3 comprises or consists of the amino acid sequence set forth in SEQ ID NO: 68; LCDR1 comprises or consists of the amino acid sequence set forth in SEQ ID NO: 10; LCDR2 comprises or consists of the amino acid sequence set forth in SEQ ID NO: 71; and / or LCDR3 comprises or consists of the amino acid sequence set forth in SEQ ID NO: 72.
[0189] In some embodiments of the present invention, the anti-DLL3 antibody or antigen-binding fragment thereof of the present invention comprises a VH and a VL, wherein
[0190] (i) . the VH comprises or consists of the amino acid sequence set forth in SEQ ID NO: 2 or an amino acid sequence having at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%or 99%identity thereto, and the VL comprises or consists of the amino acid sequence set forth in SEQ ID NO: 8 or an amino acid sequence having at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%or 99%identity thereto;
[0191] (ii) . the VH comprises or consists of the amino acid sequence set forth in SEQ ID NO: 45 or an amino acid sequence having at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%or 99%identity thereto and the VL comprises or consists of the amino acid sequence set forth in SEQ ID NO: 50 or an amino acid sequence having at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%or 99%identity thereto;
[0192] (iii) . the VH comprises or consists of the amino acid sequence set forth in SEQ ID NO: 55 or an amino acid sequence having at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%or 99%identity thereto, and the VL comprises or consists of the amino acid sequence set forth in SEQ ID NO: 60 or an amino acid sequence having at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%or 99%identity thereto; or
[0193] (iv) . the VH comprises or consists of the amino acid sequence set forth in SEQ ID NO: 65 or an amino acid sequence having at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%or 99%identity thereto, and the VL comprises or consists of the amino acid sequence set forth in SEQ ID NO: 69 or an amino acid sequence having at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%or 99%identity thereto.
[0194] In some embodiments of the present invention, the anti-DLL3 antibody or antigen-binding fragment thereof of the present invention comprises
[0195] (i) . three complementarity determining regions HCDR1, HCDR2 and HCDR3 contained in the VH set forth in SEQ ID NO: 2, and three complementarity determining regions LCDR1, LCDR2 and LCDR3 contained in the VL set forth in SEQ ID NO: 8;
[0196] (ii) . three complementarity determining regions HCDR1, HCDR2 and HCDR3 contained in the VH set forth in SEQ ID NO: 45, and three complementarity determining regions LCDR1, LCDR2 and LCDR3 contained in the VL set forth in SEQ ID NO: 50;
[0197] (iii) . three complementarity determining regions HCDR1, HCDR2 and HCDR3 contained in the VH set forth in SEQ ID NO: 55, and three complementarity determining regions LCDR1, LCDR2 and LCDR3 contained in the VL set forth in SEQ ID NO: 60; or
[0198] (iv) . three complementarity determining regions HCDR1, HCDR2 and HCDR3 contained in the VH set forth in SEQ ID NO: 65, and three complementarity determining regions LCDR1, LCDR2 and LCDR3 contained in the VL set forth in SEQ ID NO: 69;
[0199] for example, wherein the HCDR1, HCDR2, HCDR3, LCDR1, LCDR2, LCDR3 are determined according to any CDR definition scheme, e.g., as defined by Kabat, Chothia, Contact, AbM, IMGT, or a combination thereof respectively; for example, wherein the HCDR1 is determined according to Kabat &Chothia schemes, HCDR2 and HCDR3 are determined according to Kabat scheme, respectively, and the LCDR1, 2, and 3 are determined according to Kabat scheme, respectively.
[0200] In some embodiments of the present invention, the anti-DLL3 antibody or antigen-binding fragment thereof of the present invention comprises HCDR1, HCDR2, HCDR3, LCDR1, LCDR2, and LCDR3, wherein
[0201] (i) . HCDR1 comprises or consists of the amino acid sequence set forth in SEQ ID NO: 4; HCDR2 comprises or consists of the amino acid sequence set forth in SEQ ID NO: 5; HCDR3 comprises or consists of the amino acid sequence set forth in SEQ ID NO: 6; LCDR1 comprises or consists of the amino acid sequence set forth in SEQ ID NO: 10; LCDR2 comprises or consists of the amino acid sequence set forth in SEQ ID NO: 11; and LCDR3 comprises or consists of the amino acid sequence set forth in SEQ ID NO: 12;
[0202] (ii) . HCDR1 comprises or consists of the amino acid sequence set forth in SEQ ID NO: 47; HCDR2 comprises or consists of the amino acid sequence set forth in SEQ ID NO: 48; HCDR3 comprises or consists of the amino acid sequence set forth in SEQ ID NO: 49; LCDR1 comprises or consists of the amino acid sequence set forth in SEQ ID NO: 52; LCDR2 comprises or consists of the amino acid sequence set forth in SEQ ID NO: 53; and LCDR3 comprises or consists of the amino acid sequence set forth in SEQ ID NO: 54;
[0203] (iii) . HCDR1 comprises or consists of the amino acid sequence set forth in SEQ ID NO: 57; HCDR2 comprises or consists of the amino acid sequence set forth in SEQ ID NO: 58; HCDR3 comprises or consists of the amino acid sequence set forth in SEQ ID NO: 59; LCDR1 comprises or consists of the amino acid sequence set forth in SEQ ID NO: 62; LCDR2 comprises or consists of the amino acid sequence set forth in SEQ ID NO: 63; and LCDR3 comprises or consists of the amino acid sequence set forth in SEQ ID NO: 64; or
[0204] (iv) . HCDR1 comprises or consists of the amino acid sequence set forth in SEQ ID NO: 4; HCDR2 comprises or consists of the amino acid sequence set forth in SEQ ID NO: 67; HCDR3 comprises or consists of the amino acid sequence set forth in SEQ ID NO: 68; LCDR1 comprises or consists of the amino acid sequence set forth in SEQ ID NO: 10; LCDR2 comprises or consists of the amino acid sequence set forth in SEQ ID NO: 71; and LCDR3 comprises or consists of the amino acid sequence set forth in SEQ ID NO: 72.
[0205] In some embodiments of the present invention, the anti-DLL3 antibody or antigen-binding fragment thereof of the present invention comprises a VH and a VL, wherein
[0206] (i) . the VH comprises or consists of the amino acid sequence set forth in SEQ ID NO: 2, and the VL comprises or consists of the amino acid sequence set forth in SEQ ID NO: 8;
[0207] (ii) . the VH comprises or consists of the amino acid sequence set forth in SEQ ID NO: 45, and the VL comprises or consists of the amino acid sequence set forth in SEQ ID NO: 50;
[0208] (iii) . the VH comprises or consists of the amino acid sequence set forth in SEQ ID NO: 55, and the VL comprises or consists of the amino acid sequence set forth in SEQ ID NO: 60; or
[0209] (iv) . the VH comprises or consists of the amino acid sequence set forth in SEQ ID NO: 65, and the VL comprises or consists of the amino acid sequence set forth in SEQ ID NO: 69.
[0210] In an embodiment of the present invention, the amino acid changes described herein include amino acid substitutions, insertions or deletions. In a preferred embodiment, the amino acid changes described herein occur in region (s) outside a CDR (e.g., in the FR (s) ) . More preferably, the amino acid changes according to the invention occur in regions outside a heavy chain variable region and / or outside a light chain variable region. Preferably, the amino acid changes described herein are amino acid substitutions.
[0211] In some embodiments, the anti-DLL3 antibody or antigen-binding fragment thereof of the present invention is an antibody in the form of IgG1 or an antibody in the form of IgG2 or an antibody in the form of IgG3 or an antibody in the form of IgG4 or an antigen-binding fragment thereof, e.g., an antibody in the form of IgG1 or an antigen-binding fragment thereof.
[0212] In some embodiments, the anti-DLL3 antibody or antigen-binding fragment thereof of the present invention further comprises an antibody heavy chain constant region HC. In some embodiments, the anti-DLL3 antibody or antigen-binding fragment thereof of the present invention further comprises an antibody light chain constant region LC. In some embodiments, the anti-DLL3 antibody or antigen-binding fragment thereof of the present invention further comprises a heavy chain constant region HC and a light chain constant region LC. In some embodiments, the heavy chain constant region of the present invention comprises an Fc region.
[0213] In some embodiments, the heavy chain constant region of the anti-DLL3 antibody of the present invention is a constant region of (human) IgG1, IgG2, IgG3, or IgG4, for example a constant region of IgG1.
[0214] In some embodiments, the IgG1 heavy chain constant region suitable for the antibody molecule of the present invention
[0215] (i) comprises or consists of an amino acid sequence having at least 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%or 99%identity to the amino acid sequence of SEQ ID NO: 13;
[0216] (ii) comprises or consists of the amino acid sequence of SEQ ID NO: 13; or
[0217] (iii) comprises or consists of an amino acid sequence having one or more (preferably not more than 10 or 10, more preferably not more than 5, 4, 3, 2, 1) amino acid changes (preferably amino acid substitutions, more preferably amino acid conservative substitutions) compared to the amino acid sequence of SEQ ID NO: 13.
[0218] In some embodiments, the heavy chain constant region of the anti-DLL3 antibody of the present invention comprises an Fc region, e.g., a wild-type Fc region or a mutated Fc region. For example, the heavy chain constant region of the anti-DLL3 antibody of the present invention may comprise an Fc region modified in the property of the effector function of the Fc region (e.g., complement activation function of the Fc region) or an Fc region with modifications that alter binding affinity to one or more Fc receptors.
[0219] In some embodiments, the light chain constant region of the anti-DLL3 antibody of the present invention is a (human) Kappa or Lambda light chain constant region, e.g., a Kappa light chain constant region.
[0220] In some embodiments, the light chain constant region
[0221] (i) comprises or consists of an amino acid sequence having at least 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%or 99%identity to the amino acid sequence of SEQ ID NO: 14 or 15;
[0222] (ii) comprises or consists of the amino acid sequence of SEQ ID NO: 14 or 15; or
[0223] (iii) comprises or consists of an amino acid sequence having one or more (preferably no more than 10 or 10, more preferably no more than 5, 4, 3, 2, 1) amino acid changes (preferably amino acid substitutions, more preferably amino acid conservative substitutions) compared to the amino acid sequence of SEQ ID NO: 14 or 15.
[0224] In some embodiments, the anti-DLL3 antibody or antigen-binding fragment thereof of the present invention comprises an antibody heavy chain. In some embodiments, the anti-DLL3 antibody or antigen-binding fragment thereof of the present invention comprises an antibody light chain. In some embodiments, the anti-DLL3 antibody or antigen-binding fragment thereof of the present invention comprises a heavy chain and a light chain. In some embodiments, the anti-DLL3 antibody or antigen-binding fragment thereof of the present invention comprises or consist of two heavy chains and two light chains. In some embodiments, the heavy chain comprises or consists of the heavy chain variable region described herein and the heavy chain constant region described herein. In some embodiments, the light chain comprises or consists of the light chain variable region described herein and the light chain constant region described herein.
[0225] In some embodiments, said heavy chain HC of the anti-DLL3 antibody of the present invention
[0226] (i) comprises or consists of an amino acid sequence having at least 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%or 99%identity to the amino acid sequence of SEQ ID NO: 3, 46, 56 or 66; or
[0227] (ii) comprises or consists of the amino acid sequence of SEQ ID NO: 3, 46, 56 or 66; or
[0228] (iii) comprises or consists of an amino acid sequence comprising one or more (preferably not more than 10, more preferably not more than 5, 4, 3, 2, 1) amino acid changes (preferably amino acid substitutions, more preferably amino acid conservative substitutions) compared to the amino acid sequence of SEQ ID NO: 3, 46, 56 or 66, preferably said amino acid change (s) does not occur in the CDR regions, or does not occur in the VH regions.
[0229] In some embodiments, said heavy chain LC of the anti-DLL3 antibody of the present invention
[0230] (i) comprises or consists of an amino acid sequence having at least 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%or 99%identity to the amino acid sequence of SEQ ID NO: 9, 51, 61 or 70; or
[0231] (ii) comprises or consists of an amino acid sequence of SEQ ID NO: 9, 51, 61 or 70; or
[0232] (iii) comprises or consists of an amino acid sequence comprising 1 or more (preferably not more than 10, more preferably not more than 5, 4, 3, 2, 1) amino acid changes (preferably amino acid substitutions, more preferably amino acid conservative substitutions) compared to the amino acid sequence of SEQ ID NO: 9, 51, 61 or 70, preferably said amino acid change (s) does not occur in the CDR regions, or does not occur in the VL regions.
[0233] In some embodiments of the present invention, the anti-DLL3 antibody or antigen-binding fragment thereof of the present invention comprises an HC and an LC, wherein
[0234] (i) . the HC comprises or consists of the amino acid sequence set forth in SEQ ID NO: 3 or an amino acid sequence having at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%or 99%identity thereto, and / or the LC comprises or consists of the amino acid sequence set forth in SEQ ID NO: 9 or an amino acid sequence having at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%or 99%identity thereto;
[0235] (ii) . the HC comprises or consists of the amino acid sequence set forth in SEQ ID NO: 46 or an amino acid sequence having at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%or 99%identity thereto, and / or the LC comprises or consists of the amino acid sequence set forth in SEQ ID NO: 51 or an amino acid sequence having at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%or 99%identity thereto;
[0236] (iii) . the HC comprises or consists of the amino acid sequence set forth in SEQ ID NO: 56 or an amino acid sequence having at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%or 99%identity thereto, and / or the LC comprises or consists of the amino acid sequence set forth in SEQ ID NO: 61 or an amino acid sequence having at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%or 99%identity thereto; or
[0237] (iv) . the HC comprises or consists of the amino acid sequence set forth in SEQ ID NO: 66 or an amino acid sequence having at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%or 99%identity thereto, and / or the LC comprises or consists of the amino acid sequence set forth in SEQ ID NO: 70 or an amino acid sequence having at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%or 99%identity thereto.
[0238] In some embodiments of the present invention, the anti-DLL3 antibody or antigen-binding fragment thereof of the present invention comprises an HC and an LC, wherein
[0239] (i) . the HC comprises or consists of the amino acid sequence set forth in SEQ ID NO: 3 and the LC comprises or consists of the amino acid sequence set forth in SEQ ID NO: 9;
[0240] (ii) . the HC comprises or consists of the amino acid sequence set forth in SEQ ID NO: 46 and the LC comprises or consists of the amino acid sequence set forth in SEQ ID NO: 51;
[0241] (iii) . the HC comprises or consists of the amino acid sequence set forth in SEQ ID NO: 56 and the LC comprises or consists of the amino acid sequence set forth in SEQ ID NO: 61; or
[0242] (iv) . the HC comprises or consists of the amino acid sequence set forth in SEQ ID NO: 66 and the LC comprises or consists of the amino acid sequence set forth in SEQ ID NO: 70.
[0243] In some embodiments, the anti-DLL3 antibody or antigen-binding fragment thereof has one or more of the following properties:
[0244] (i) showing the same or similar binding affinity and / or specificity as the antibody of the present invention for DLL3;
[0245] (ii) inhibiting (e.g., competitively inhibiting) the binding of the antibody of the present invention to DLL3;
[0246] (iii) binding to the same or overlapping epitope as the antibody of the present invention;
[0247] (iv) competing for binding to DLL3 with the antibody of the present invention;
[0248] (v) having one or more of the biological properties of the antibody of the present invention.
[0249] In some embodiments, the anti-DLL3 antibody is a monoclonal antibody.
[0250] In some embodiments, the anti-DLL3 antibody is a full-length antibody.
[0251] In an embodiment, the anti-DLL3 antibodies of the present invention also encompass antibody fragments (e.g., antigen-binding fragments) thereof, preferably antibody fragments selected from the group consisting of: a Fab, a Fab', a Fab'-SH, an Fv, a single-chain antibody (e.g., scFv) , a (Fab') 2, a single-domain antibody (e.g. VHH) , a dAb (domain antibody) , a heavy-chain antibody or a linear antibody.
[0252] In an embodiment, the anti-DLL3 antibody of the present invention can also be a bispecific or multispecific antibody. In some embodiments, the multispecific antibody is capable of specifically binding to DLL3 and one or more other antigens.
[0253] It should be understood by those of skill in the art that any combination of any of the technical features of any of the domains defined herein, e.g., VH, VL, CDR, heavy chain and / or light chain, is within the contemplation of the present invention, unless the context clearly indicates to the contrary. Moreover, it will be understood by those skilled in the art that the antibody of the present invention (including any form of antibody) may comprise any of such combinations of such features unless the context clearly dictates to the contrary.
[0254] II-2. Polynucleotides, vectors and host cells
[0255] In an aspect, the invention provides a nucleic acid encoding any of the above anti-DLL3 antibodies or antigen-binding fragments thereof.
[0256] As will be understood by those skilled in the art, each amino acid sequence of an antibody or polypeptide can be encoded by a variety of nucleic acid sequences because of codon degeneracy.
[0257] In some embodiments, the nucleic acid of the present invention comprises a nucleic acid selected from the group consisting of those set forth in any one of SEQ ID NOs 1 or 7, or a nucleic acid having at least 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99%identity to a nucleic acid sequence selected from the group consisting of those set forth in any one of SEQ ID NOs 1 or 7.
[0258] In some embodiments, the nucleic acid of the present invention comprises a nucleic acid selected from the group consisting of those set forth in any one of SEQ ID NOs 73 or 74, or a nucleic acid having at least 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99%identity to a nucleic acid sequence selected from the group consisting of those set forth in any one of SEQ ID NOs 73 or 74.
[0259] In some embodiments, the nucleic acid of the present invention comprises a nucleic acid selected from the group consisting of those set forth in any one of SEQ ID NOs 75 or 76, or a nucleic acid having at least 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99%identity to a nucleic acid sequence selected from the group consisting of those set forth in any one of SEQ ID NOs 75 or 76.
[0260] In some embodiments, the nucleic acid of the present invention comprises a nucleic acid selected from the group consisting of those set forth in any one of SEQ ID NOs 77 or 78, or a nucleic acid having at least 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99%identity to a nucleic acid sequence selected from the group consisting of those set forth in any one of SEQ ID NOs 77 or 78.
[0261] In some embodiments, the nucleic acid of the present invention comprises a nucleic acid encoding an amino acid sequence selected from the group consisting of those set forth in any one of SEQ ID NOs 2, 3, 8, 9, 45, 46, 50, 51, 55, 56, 60, 61, 65, 66, 69 or 70, or a nucleic acid encoding an amino acid sequence having at least 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%or 99%identity to an amino acid sequence selected from the group consisting of those set forth in any one of SEQ ID NOs 2, 3, 8, 9, 45, 46, 50, 51, 55, 56, 60, 61, 65, 66, 69 or 70.
[0262] The nucleic acid sequences encoding the molecules of the present invention can be produced using methods well known in the art, for example by de novo solid phase DNA synthesis, or by PCR amplification.
[0263] In an aspect, the invention also provides a vector comprising the nucleic acid of the present invention. In an embodiment, the vector is an expression vector, such as a prokaryotic expression vector or a eukaryotic expression vector. The vector includes, but is not limited to, a virus, a plasmid, a cosmid, a λ phage, or a yeast artificial chromosome (YAC) . In a preferred embodiment, the expression vector is a pCDNA, such as a pCDNA3.1.
[0264] In an aspect, the invention also provides a host cell comprising said nucleic acid or said vector. In an embodiment, the host cell is eukaryotic. In another embodiment, the host cell is selected from the group consisting of a yeast cell, a mammalian cell (e.g., a CHO cell or a 293 cell, e.g., (a HEK 293 or a 293Fcell or a 293FT cell or a Expi293 cell) .
[0265] Suitable host cells include prokaryotic microorganisms such as E. coli, eukaryotic microorganisms such as filamentous fungi or yeast, or various eukaryotic cells such as Chinese hamster ovary Cells (CHO) , insect cells, and the like. Mammalian cell lines suitable for suspension culture may be used. Examples of useful mammalian host cell lines include SV40 transformed monkey kidney CV1 line (COS-7) ; human embryonic kidney lines (HEK 293 or 293Fcells or 293FT cells or Expi293 cells) , baby hamster kidney cells (BHK) , monkey kidney cells (CV1) , Vero cells (VERO-76) , human cervical cancer cells (HELA) , canine kidney cells (MDCK) , Bufarro rat liver cells (BRL 3A) , human lung cells (W138) , human liver cells (Hep G2) , CHO cells, NSO cells, myeloma cell lines such as YO, NS0, P3X63 and Sp2 / 0, and the like. Mammalian host cell lines suitable for antibody production are known in the art. In a preferred embodiment, the host cell is a CHO or a HEK293 cell or a 293Fcell or a 293FT cell or a Expi293 cell.
[0266] II-3. Production and purification of antibody molecules
[0267] In yet another aspect, the invention provides a method for producing the anti-DLL3 antibody or antigen-binding fragment thereof of the present invention, the method comprising: culturing a host cell comprising the nucleic acid encoding a polypeptide chain of said molecule under conditions suitable for expression of the polypeptide chain; optionally further comprising assembling the polypeptide chains to produce said anti-DLL3 antibody or antigen-binding fragment thereof under conditions suitable for assembly of said polypeptide chains into said molecule.
[0268] For ease of production and purification, the anti-DLL3 antibody or antigen-binding fragment thereof can be fused at the N-or C-terminus (e.g., C-terminus) to a secretory signal peptide, and / or a tag peptide that facilitates purification, such as a hexahistidine tag or biotin tag.
[0269] For recombinant production, a polynucleotide encoding the polypeptide chain of the anti-DLL3 antibody or antigen-binding fragments thereof of the present invention may be inserted into one or more vectors for further cloning and / or expression in host cells. Methods known to those skilled in the art can be used to construct a expression vector. Once the expression vector comprising one or more polynucleotides of the present invention has been prepared for expression, the expression vector can be transfected or introduced into a suitable host cell. Various techniques can be used for this purpose, for example, protoplast fusion, calcium phosphate precipitation, electroporation, retroviral transduction, viral transfection, biolistics, liposome-based transfection, or other conventional techniques.
[0270] Molecules prepared as described herein can be purified by known techniques in the prior art such as high performance liquid chromatography, ion exchange chromatography, gel electrophoresis, affinity chromatography (e.g., ProteinA affinity chromatography) , size exclusion chromatography, and the like. The actual conditions used to purify a particular protein also depend on factors such as net charge, hydrophobicity, hydrophilicity, and the like, and will be apparent to those skilled in the art.
[0271] The purity of the anti-DLL3 antibody or antigen-binding fragment thereof of the present invention can be determined by any of a variety of well-known analytical methods, including size exclusion chromatography, gel electrophoresis, high performance liquid chromatography, and the like. The physical / chemical properties and / or biological activities of the antibody molecules provided herein can be identified, screened or characterized by a variety of assays known in the art.
[0272] II-4. Assay methods
[0273] The anti-DLL3 antibodies or antigen-binding fragments thereof provided herein can be identified, screened, or characterized for their physical / chemical properties and / or biological activity by a variety of assays known in the art. The examples illustrate assays to determine the properties of the anti-DLL3 antibodies or antigen-binding fragments thereof or bispecific antibodies of the present invention, such as bio-layer interferometry technique (BLI) , and the like.
[0274] III. Immunoconjugates
[0275] III-1. Antibody-drug conjugates
[0276] In an aspect, the invention provides an immunoconjugate comprising the molecule of the present invention (e.g., the anti-DLL3 antibody or antigen-binding fragment thereof) and one or more other active ingredients (e.g., an active ingredient from a drug or therapeutic agent for treating a disease of the present invention, e.g., a small molecule that enhances the therapeutic effect of the molecule of the present invention) .
[0277] In some embodiments, the immunoconjugate is an antibody-drug-conjugate (ADC) .
[0278] The present invention provides an antibody-drug conjugate having formula (I) : Ab- (L-D) p (I)
[0279] or a pharmaceutically acceptable salt or solvate thereof,
[0280] wherein:
[0281] Ab is an antibody or fragment thereof, for example an antigen-binding fragment, that binds to DLL3 (e.g., human DLL3) ;
[0282] L is a linker;
[0283] D is a drug, preferably an anti-tumor compound; and
[0284] p is an integer selected from 1 to 16, for example an integer selected from 1 to 10, 1 to 9, 2 to 8, 4 to 10, 3 to 7, 4 to 6 or 2 to 6, for example 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11 or 12.
[0285] It should be understood that p refers to the number of -L-P attached to the Ab in the antibody-drug conjugate molecule.
[0286] In some embodiments, the Ab suitable for the ADC molecule of the present invention may comprise or consist of the anti-DLL3 antibody or antigen-binding fragment thereof of the present invention, provided that it is capable of specifically binding to DLL3, including, but not limited to, for example, a full-length antibody, a half-antibody, a Fab, a Fab', a Fab'-SH, an Fv, a single chain antibody (e.g., scFv) , (Fab') 2 , a single domain antibody (e.g., VHH) , a domain antibody (dAB) , a heavy chain antibody, or a linear antibody, and the like that specifically binds to DLL3.
[0287] In some embodiments, the Ab is derived from the anti-DLL3 antibody or antigen-binding fragment thereof described herein. In some embodiments, the Ab that specifically binds to DLL3 comprises 1, 2, 3, 4, 5, or 6 CDRs of the anti-DLL3 antibody described herein. In some embodiments, the Ab comprises 1, 2, or 3 heavy chain variable region CDRs of the anti-DLL3 antibodies described herein, i.e., HCDR1, HCDR2, and HCDR3. In some embodiments, the Ab comprises 1, 2, or 3 light chain variable region CDRs of the anti-DLL3 antibodies described herein, i.e., LCDR1, LCDR2, and LCDR3. In some embodiments, the Ab comprises 3 heavy chain variable region CDRs and 3 light chain variable region CDRs of the anti-DLL3 antibody described herein. In some embodiments, the Ab comprises the heavy chain variable region of the anti-DLL3 antibody described herein. In some embodiments, the Ab comprises the light chain variable region of the anti-DLL3 antibody described herein. In some embodiments, the Ab comprises the heavy chain variable region and the light chain variable region of the anti-DLL3 antibody described herein. In some embodiments, the Ab comprises the heavy chain of the anti-DLL3 antibody described herein. In some embodiments, the Ab comprises a light chain of the anti-DLL3 antibody described herein. In some embodiments, the Ab comprises the heavy and light chains of the anti-DLL3 antibody described herein. In some embodiments, the Ab comprises or consists of 2 heavy chains and 2 light chains of the anti-DLL3 antibody described herein. In some embodiments, the Ab is a full length antibody.
[0288] In some embodiments, D in formula (I) of the present invention may be any anti-tumor compound, without any particular limitation, as long as it has an anti-tumor effect and has a substituent, a partial structure, which can be linked to a linker structure. For example, the anti-tumor compound may be a pharmaceutically active compound that acts on a tumor. In the case of an anti-tumor compound, it is preferable that a part or the whole of the linker is cleaved off in a tumor cell to release the antitumor compound, thereby exhibiting an anti-tumor effect. When the linker is cleaved off at the linking part to the drug, the antitumor compound is released in an unmodified structure and can exhibits its original anti-tumor effect.
[0289] In some embodiments, the anti-tumor compound may be, for example, a cytotoxic agent or chemotherapeutic agent, for example camptothecins, e.g., exatecan (topoisomerase I inhibitor, Exatecan) , Dxd (anovel topoisomerase I inhibitor, an Exatecan derivative) , auristatins, e.g., monomethyl auristatin E (MMAE) , MMAF, or maytansinoids, e.g., small molecule microtubule inhibitor, DM1.
[0290] In some embodiments, D has a structure of formula -Q-L2-L1-D1,
[0291] wherein Q is -O-, -S-, or -NR7-;
[0292] L1 is absent or - (C1-C10 alkylene) -;
[0293] L2 is absent, *- (C1-C10 alkylene) -C (O) N (R5) -or *- (C1-C10 alkylene) -N (R5) C (O) -; wherein *represents said end is covalently linked to Q; and R5 is H or C1-C6 alkyl,
[0294] wherein D1 has a structure represented by formula (D-1) :
[0295] wherein R1 and R6 are independently selected from H, C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, C1-C6 haloalkyl, C2-C6 haloalkenyl and C2-C6 haloalkynyl; or R1 and R6 together with the carbon they are attached to form a 5-to 9-membered ring, for example 5-to 8-membered ring (e.g., 5-membered ring, 6-membered ring, 7-membered ring, 8-membered ring) ;
[0296] R2 is selected from H, halogen, C1-C6 alkyl, C1-C6 haloalkyl, -OR4 and -SR4; R3 is selected from H, halogen, CN, C1-C6 alkyl, C1-C6 haloalkyl and -OR4; or R2 and R3 together form -O (CH2) nO-or -O (CF2) nO-, wherein n is 1 or 2;
[0297] R4 is selected from H or C1-C4 alkyl; and
[0298] R7 is selected from H or C1-C6 alkyl.
[0299] It should be understood that the bond with wavy line crossing the phenyl ring in formula (D-1) refers to formula (D-1) is linked to -Q-L2-L1-at any feasible position. For example, in some embodiments, formula (D-1) can be linked to -Q-L2-L1-at the ring carbon atom corresponding to R1, R2, R3 or R6 or at any other feasible position. For example, formula (D-1) can be linked to -Q-L2-L1-at the ring carbon atom corresponding to R1, in which case the corresponding R1 group no longer exists.
[0300] In some embodiments, D1 has a structure represented by formula (D-1a) , (D-1b) or (D-1c) :
[0301] wherein, n1 and n2 are independently selected from 0, 1, 2 and 3, and n1+n2≤5, preferably ≤4,
[0302] the rest of the symbols (for example R1, R2, R3, R6) are as defined above.
[0303] It should be understood that the wavy line represents the position linking to -Q-L2-L1-.
[0304] In some embodiments, Q is -O-or -S-;
[0305] L1 is absent or - (C1-C10 alkylene) -;
[0306] L2 is absent, *- (C1-C10 alkylene) -C (O) N (R5) -or *- (C1-C10 alkylene) -N (R5) C (O) -; wherein *represents said end is covalently linked to Q; and R5 is H or C1-C6 alkyl,
[0307] wherein D1 has a structure represented by formula (D-1a) :
[0308] wherein R1 is selected from H, C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, C1-C6 haloalkyl, C2-C6 haloalkenyl and C2-C6 haloalkynyl;
[0309] R2 is selected from H, halogen, C1-C6 alkyl, C1-C6 haloalkyl, -OR4 and -SR4; R3 is selected from H, halogen, CN, C1-C6 alkyl, C1-C6 haloalkyl and -OR4; or R2 and R3 together form -O (CH2) nO-or -O (CF2) nO-, wherein n is 1 or 2;
[0310] R4 is selected from H or C1-C4 alkyl.
[0311] In some embodiments, R1 and R6 are H, R2 is C1-C6 alkyl or C1-C6 alkyloxy, R3 is halogen, preferably -F.
[0312] In some embodiments, R1 is H, R2 is C1-C6 alkyl or C1-C6 alkyloxy, R3 is halogen, preferably -F.
[0313] In some embodiments, D1 has a structure represented by formula (D-2) :
[0314] wherein each symbol (for example R1, R2, R3 and R6) is as defined above.
[0315] In some embodiments, D1 has a structure represented by formula (D-2a) , (D-2b) or (D-2c) :
[0316] wherein, each symbol (for example R1, R2, R3, R6, n1 and n2) is as defined above.
[0317] In some embodiments, n1 is 2, n2 is 0. In some embodiments, D1 has a structure represented by formula (D-2a) :
[0318] wherein R1, R2 and R3 are as defined above.
[0319] In some embodiments, D1 has a structure represented by formula (D-3) :
[0320] In some embodiments, D1 has a structure represented by formula (D-4a) , formula (D-4b) or formula (D-4c) :
[0321] wherein each symbol is as defined herein.
[0322] In some embodiments, D1 has a structure represented by formula (D-4a) :
[0323] In some embodiments, D1 has a structure represented by formula (D-4a)
[0324] In some embodiments, -L2-L1-is - (C1-C6 alkylene) -, *- (C1-C6 alkylene) -C (O) N (R5) - (C1-C6 alkylene) -or *- (C1-C6 alkylene) -N (R5) C (O) - (C1-C6 alkylene) -, wherein *represents said end is covalently linked to Q;
[0325] R5 is H or C1-C6 alkyl.
[0326] In some embodiments, -Q-is -O-or -S-.
[0327] In some embodiments, -L2-L1-is - (C1-C6 alkylene) -.
[0328] In some embodiments, -Q-L2-L1-is -OCH2-CH2-CH2-CH2-. It should be understood that the left end of this group is linked to L.
[0329] In some embodiments, D1 has a structure represented by formula (D-4c)
[0330] and
[0331] -Q-L2-L1-is -NR7-or -O-CH2-C (O) N (R5) -,
[0332] wherein R2, R3, R5 and R7 are as defined above.
[0333] It should be understood that the right end of the above -Q-L2-L1-is linked to D1.
[0334] In some embodiments, -Q-L2-L1-D1 is selected from
[0335] In some embodiments, -L-has the following structure: -Z-E-X-,
[0336] wherein Z is linked to Ab, X is linked to Q;
[0337] Z is -Z1-Z2-,
[0338] wherein Z1 is selected from : the end with wavy line at the left side is linked to Ab, the end with wavy line at the right side is linked to Z2,
[0339] Z2 is selected from wherein the end with wavy line at the left side is linked to Ab, the end with wavy line at the right side (carbonyl end) is linked to E,
[0340] wherein ma1 and ma2 are independently an integer selected from 0-20, for example 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15 or 16;
[0341] m is an integer selected from 1 to 10, for example 1, 2, 3, 4, 5, 6, 7 or 8,
[0342] preferably, Z is selected from wherein each symbol (for example m, ma1 and ma2) is as defined above,
[0343] more preferably is wherein m is an integer of 1 to 10, for example 1, 2, 3, 4, 5, 6, 7 or 8, preferably 5; the carbonyl at the right side is covalently linked to E;
[0344] E is a peptide residue comprising 2 to 10 amino acids, wherein the peptide residue is optionally substituted with one or more (for example 2, 3 or 4) groups selected from: C1-6 alkyl and polyol groups, wherein the N-terminus of the peptide residue is covalently linked to Z;
[0345] X is selected from absent, -NH-CH2-,
[0346] wherein each Ra1 is independently selected from C1-6 alkyl-, C1-6 alkyloxy-, haloC1-6 alkyl-, halogen, nitro, cyano, pentose, hexose, penturonic acid, hexuronic acid, disaccharide and trisaccharide; and
[0347] t is 0, 1, 2, 3 or 4;
[0348] the left end of said X group is linked to E, and the right end of said X group is linked to D.
[0349] It should be understood that without particularly illustration and conflicts with the context, the carbonyl at the right side of Z represented herein is covalently linked to E, the left end of X represented herein is linked to E, the left end of X is linked to D.
[0350] In some embodiments,
[0351] Z is selected from ma2 is an integer independently selected from 1 to 20, for example 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15 or 16; and
[0352] m is an integer selected from 1 to 10, for example 1, 2, 3, 4, 5, 6, 7 or 8.
[0353] In some embodiments, Z is selected from:
[0354] In some embodiments, E is a peptide residue consisting of 2 to 10 amino acids.
[0355] In some embodiments, -L-has the following structure: -Z-E-NH-CH2-, wherein Z and E are as defined above.
[0356] In some embodiments, E is a peptide residue comprising 2, 3 or 4 amino acids.
[0357] In some embodiments, E is a peptide residue consisting of 2, 3 or 4 amino acids.
[0358] In some embodiments, the amino acid is selected from, for example glycine, alanine, valine, glutamine, glutamic acid, phenylalanine, leucine, tyrosine, lysine, citrulline, serine, tryptophan, aspartic acid, asparagine, isoleucine, arginine and proline, and wherein the glutamine or glutamic acid is optionally substituted with one polyol group and optionally substituted with one C1-6 alkyl.
[0359] In some embodiments, the amino acid is selected from glycine, alanine, valine, glutamine, glutamic acid, phenylalanine and leucine, and wherein the glutamine or glutamic acid is optionally substituted with one polyol group and optionally substituted with one C1-6 alkyl.
[0360] In some embodiments, E is: -Gln-Val-Ala-, -Gly-Val-Ala-, -Gln-Phe-Ala-, -Gly-Phe-Ala-, -Gly-Gly-Phe-Gly-, -Val-Ala-, -Val-Cit-, -Ala-Ala-, -Ala-Cit-, -Ala-Lys-, -Ala-Val-, -Asn-Cit-, -Asp-Cit-, -Asn-Lys-, -Asp-Val-, -Cit-Ala-, -Cit-Asn-, -Cit-Asp-, -Cit-Cit-, -Cit-Lys-, -Cit-Ser-, -Cit-Val-, -Glu-Val-, -Glu-Gly-, -Ile-Cit-, -Ile-Pro-, -Ile-Val-, -Leu-Cit-, -Lys-Cit-, -Phe-Arg-, -Phe-Cit-, -Phe-Lys-, -Pro-Lys-, -Ser-Cit-, -Trp-Cit-, -Ala-Val-, -Val-Asp-, -Cit-Val-, -Val-Glu-, -Val-Lys-, -Gly-Gly-Gly-, -Gly-Gly-Arg-, -Phe-Lys-Gly-, -Leu-Lys-Gly-, -Leu-Leu-Gly-, -Glu-Val-Cit-, -Cit-Ala-Glu-, -Val-Lys-Gly-, -Val-Lys-Ala-, -Val-Gly-Gly-, -Val-Cit-Gly-, -Val-Gln-Gly-, -Val-Glu-Gly-, -Val-Lys-Gly-, -Val-Lys-Leu-, -Ala-Ala-Ala-, -Asn-Ala-Ala-, -Gly-Gly-Gly-Gly-, -Gly-Gly-Leu-Gly-, -Gly-Phe-Leu-Gly-, -Gly-Val-Lys-Gly-, -A1a-Leu-A1a-Leu-, -Gly-Phe-Leu-Gly-, -Ala-Leu-Ala-Leu-, -Gly-Phe-Gly-Gly-, and -Val-Lys-Gly-Gly, wherein Gln and / or Glu are optionally substituted with one polyol group and optionally substituted with one C1-6 alkyl.
[0361] In some embodiments, the polyol group is preferably
[0362] In some embodiments, the substituted glutamine (Gln) or glutamic acid (Glu) has a structure represented by the following formula:
[0363] wherein R6 is H or C1-C6 alkyl;
[0364] preferably
[0365] wherein R6 is H or C1-C6 alkyl.
[0366] In some embodiments, the substituted Gln or Glu has a structure represented by formula (G-1a) , formula (G-1a) or formula (G-1a) as described above.
[0367] In some embodiments, E is -Val-Ala-, -Gln-Val-Ala-, -Gly-Val-Ala-, -Gln-Phe-Ala-, -Gly-Phe-Ala-, -Gly-Gly-Phe-Gly-, or -Val-Cit- wherein R6 is H or C1-C6 alkyl, wherein said E group is covalently linked to Z through the N-terminus at the left side.
[0368] In some embodiments, X is selected from -NH-CH2-, wherein Ra1 is as defined herein.
[0369] In some embodiments, X is selected from -NH-CH2-, wherein Ra1 is as defined herein.
[0370] In some embodiments, each Ra1 is independently selected from pentose, hexose, penturonic acid and hexuronic acid;
[0371] In some embodiments, each Ra1 is independently selected from
[0372] In some embodiments, each Ra1 is independently selected from xylose, arabinose, glucose, galactose, mannose and fructose, xyluronic acid, arabinuronic acid, glucuronic acid, galacturonic acid and mannuronic acid.
[0373] In some embodiments, Ra1 is selected from
[0374] In some embodiments, X is selected from
[0375] -NH-CH2-,
[0376] In some embodiments, -Z-E-X-is selected from the following structures:
[0377] It should be understood that the left side of the above structure is linked to Ab moiety.
[0378] In some embodiments, the payload (e.g., drug) of the immunoconjugate of the present invention is attached to the modified antibody or antibody fragment through the sulfhydryl group of the free cysteine of the antibody or antigen binding fragment thereof (optionally via a linker) . In some embodiments, the payload (e.g., drug) of the immunoconjugate of the present invention is linked to the sulfhydryl group of the cysteine through a cleavable or non-cleavable linker.
[0379] In some embodiments, Ab is linked to L via the sulfur atom at the sulfhydryl group of Ab (for example, the sulfhydryl group produced by the reduction of a disulfide bond) , at this time, the antibody-drug conjugate of formula (I) may be represented by the following formula: Ab’ - (S-L-D) p (I’ )
[0380] wherein Ab’ is as defined above for Ab, L, D and p are as defined above.
[0381] In some embodiments, the antibody-drug conjugate has an average DAR of 5 to 11, 6 to 10, 7 to 9 or 7.5 to 8.5.
[0382] In some embodiments, the antibody-drug conjugate is selected from
[0383] wherein Ab is an antibody or fragment thereof defined herein, for example, the antibody as prepared in examples, e.g., the antibody 23A1; q is as defined above for p.
[0384] In some embodiments, the antibody-drug conjugate has an average DAR of 5 to 11, 6 to 10, 7 to 9 or 7.5 to 8.5.
[0385] In some embodiments, the antibody-drug conjugate may be represented by the following formula: Ab’ - (S-L-D) p (I’ )
[0386] wherein Ab’ is an antibody comprising HCDR1, HCDR2, HCDR3, LCDR1, LCDR2, and LCDR3, wherein the HCDR1 consists of the amino acid sequence set forth in SEQ ID NO: 4; the HCDR2 consists of the amino acid sequence set forth in SEQ ID NO: 5; the HCDR3 consists of the amino acid sequence set forth in SEQ ID NO: 6; the LCDR1 consists of the amino acid sequence set forth in SEQ ID NO: 10; the LCDR2 consists of the amino acid sequence set forth in SEQ ID NO: 11; and the LCDR3 consists of the amino acid sequence set forth in SEQ ID NO: 12; or Ab’ is an antibody comprising a heavy chain variable region VH and a light chain variable region VL, wherein the VH consists of the amino acid sequence set forth in SEQ ID NO: 2, and the VL consists of the amino acid sequence set forth in SEQ ID NO: 8;
[0387] D has a structure of formula -Q-L2-L1-D1, -Q-is -O-or -S-; -L2-L1-is - (C1-C6 alkylene) -; D1 has a structure represented by formula (D-3) :
[0388] -L-has the following structure: -Z-E-X-,
[0389] Z is selected from m is an integer selected from 1 to 10, for example 1, 2, 3, 4, 5, 6, 7 or 8;
[0390] E is -Val-Ala-, -Gln-Val-Ala-, -Gly-Val-Ala-, -Gln-Phe-Ala-, -Gly-Phe-Ala-, -Gly-Gly-Phe-Gly-, or -Val-Cit-, wherein R6 is H or C1-C6 alkyl, wherein said E group is covalently linked to Z through the N-terminus at the left side.
[0391] X is selected from -NH-CH2-;
[0392] and p is for example preferably an integer of 4 to 8.
[0393] In some embodiments, the antibody-drug conjugate is compound 23A1-NT3 of following structure:
[0394] wherein Ab is the antibody 23A1; q is preferably an integer of 4 to 8, most preferably 8.
[0395] In some embodiments, the antibody 23A1 comprises HCDR1, HCDR2, HCDR3, LCDR1, LCDR2, and LCDR3, wherein the HCDR1 consists of the amino acid sequence set forth in SEQ ID NO: 4; the HCDR2 consists of the amino acid sequence set forth in SEQ ID NO: 5; the HCDR3 consists of the amino acid sequence set forth in SEQ ID NO: 6; the LCDR1 consists of the amino acid sequence set forth in SEQ ID NO: 10; the LCDR2 consists of the amino acid sequence set forth in SEQ ID NO: 11; and the LCDR3 consists of the amino acid sequence set forth in SEQ ID NO: 12; or Ab’ is an antibody comprising a heavy chain variable region VH and a light chain variable region VL.
[0396] In some embodiments, the antibody 23A1 comprises a heavy chain variable region VH and a light chain variable region VL, wherein the VH consists of the amino acid sequence set forth in SEQ ID NO: 2, and / or the VL consists of the amino acid sequence set forth in SEQ ID NO: 8.
[0397] In some embodiments, the antibody 23A1 comprises a heavy chain constant region and a light chain constant region, wherein the heavy chain constant region consists of the amino acid sequence set forth in SEQ ID NO: 13, and / or the light chain constant region consists of the amino acid sequence set forth in SEQ ID NO: 14 or 15.
[0398] In some embodiments, the antibody 23A1 comprises a heavy chain and a light chain, wherein the heavy chain consists of the amino acid sequence set forth in SEQ ID NO: 3, and / or the light chain consists of the amino acid sequence set forth in SEQ ID NO: 9.
[0399] It should be understood that the S atom linked to Ab in the above ADC comes from the antibody Ab. Ab opens disulfide bonds (e.g. interchain disulfide bonds) under the action of a reducing agent such as TCEP to give a sulfhydryl (-SH) , which is then connected to the maleimide moiety of the linker.
[0400] III-2. Preparation of ADC molecules of the present invention
[0401] In another aspect, the present invention provides a method of using the antibodies of the present invention to prepare ADCs. The "ADC" in the present invention is defined as an antibody coupled to an active substance (D) having biological and / or pharmaceutical activity via a linker (L) . The method comprises coupling an antibody (Ab) of the present invention with one or more active substances D via one or more linkers (L) as defined herein. Preferably, the linker-active substance is coupled with the antibody in site-specific manner.
[0402] In some embodiments, the method comprises the steps of:
[0403] (a) adding the antibody Ab into a buffer solution, adding a reducing agent, and then incubating;
[0404] (b) adding a linker-payload to the reaction solution of step (a) for coupling to obtain a crude product; and
[0405] (c) optionally purifying the crude product to obtain the antibody drug conjugate of the present invention;
[0406] wherein Ab is as defined above.
[0407] It should be understood that the linker-payload is reacted with the Ab to provide -L-D moiety in the compound of formula I, and when -L-D is clearly defined, the structure of the linker-payload can be determined.
[0408] In some embodiments, the buffer solution of step a) is a PBS buffer, preferably at a pH of 5.0 to 9.0, for example 6.0 to 8.0.
[0409] In some embodiments, the reducing agent of step a) is TCEP.
[0410] In some embodiments, the linker-payload has the following structures: Z’ -E-NH-CH2-Q-L2-L1-D1, wherein E, Q, L2, L1, D1 are as defined above, Z’ is as defined above for Z, except that the divalent maleimide group in Z is replaced with
[0411] In some embodiments, the steps are performed under the specific reaction conditions disclosed in the examples.
[0412] In some embodiments, the preparation method of the compound 23A1-NT3 comprises the steps of:
[0413] (a) adding the antibody 23A1 into a buffer solution, adding a reducing agent, and then incubating;
[0414] (b) adding a linker-payload NT3 to the reaction solution of step (a) for coupling to obtain a crude product; and
[0415] (c) optionally purifying the crude product to obtain the antibody drug conjugate of 23A1-NT3.
[0416] It should be noted that the embodiments obtained by varying 100%, 80%, 60%, 40%, 20%, or 10%of ranges or specific values for the specific reaction conditions disclosed in the examples are also contemplated in the present invention.
[0417] IV. Pharmaceutical composition
[0418] In some embodiments, the present invention provides a composition comprising the molecule of the present invention (e.g., the anti-DLL3 antibody or antigen-binding fragment thereof or immunoconjugate thereof, e.g., the ADC molecule, of the present invention) , or the pharmaceutically acceptable salt thereof, preferably the composition is a pharmaceutical composition, e.g., a pharmaceutical formulation. In an embodiment, the composition further comprises a pharmaceutical excipient. In an embodiment, a composition, e.g., a pharmaceutical composition, comprises a combination of the molecule of the present invention (e.g., the anti-DLL3 antibody or antigen-binding fragment thereof or immunoconjugate thereof, e.g., the ADC molecule, of the present invention) , and one or more other therapeutic agents.
[0419] The invention also includes compositions (e.g., pharmaceutical compositions) comprising the molecule of the present invention (e.g., the anti-DLL3 antibody or antigen-binding fragment thereof or immunoconjugate thereof, e.g., the ADC molecule, of the present invention) or the pharmaceutically acceptable salt thereof. These compositions may also comprise suitable pharmaceutical excipients such as pharmaceutical carriers, pharmaceutical excipients, including buffers, as are known in the art.
[0420] As used herein, the “pharmaceutical carrier” includes any and all solvents, dispersion media, isotonic agents and absorption delaying agents, and the like that are physiologically compatible.
[0421] For use and application of pharmaceutical excipients, see also “Handbook of Pharmaceutical Excipients” , 8th edition, R. C. Rowe, P. J. Seskey and S. C. Owen, Pharmaceutical Press, London, Chicago.
[0422] The compositions of the present invention may be in a variety of forms. These forms include, for example, liquid, semi-solid, and solid dosage forms, such as liquid solutions (e.g., injectable solutions and infusion solutions) , powders or suspensions, liposomes, and suppositories. The preferred form depends on the intended mode of administration and therapeutic use.
[0423] A medicament comprising the molecule of the present invention (e.g., the anti-DLL3 antibody or antigen-binding fragment thereof, or immunoconjugate thereof, e.g., the ADC molecule, of the present invention) may be prepared by mixing the molecule of the present invention (e.g., the anti-DLL3 antibody or antigen-binding fragment thereof, or immunoconjugate thereof, e.g., ADC molecule, of the present invention) in the desired purity with one or more optional pharmaceutical excipients, preferably in the form of a lyophilized formulation or an aqueous solution.
[0424] Pharmaceutical compositions, e.g., formulations, of the present invention may also contain more than one active ingredients which may be required for the particular indication being treated, preferably those having complementary activities that do not adversely affect each other. For example, it may be desirable to also provide other therapeutic agents, including any active agent against the tumor, such as a chemotherapeutic agent, an angiogenesis inhibitor, a cytokine, a cytotoxic agent, an additional antibody, a small molecule drug, or an immunomodulatory agent (e.g., immune checkpoint inhibitors or agonists) , and the like. The active ingredients are suitably present in combination in an amount effective for the intended use.
[0425] Sustained release formulations can be prepared. Suitable examples of sustained release formulations include semipermeable matrices of solid hydrophobic polymers containing the antibody, which matrices are in the form of shaped articles, e.g., films, or microcapsules.
[0426] In some embodiments, the molecule of the present invention comprised in the composition is the antibody drug conjugate of 23A1-NT3.
[0427] VII. Pharmaceutical combination and kit
[0428] In some embodiments, the present invention also provides a pharmaceutical combination or pharmaceutical combination product comprising the molecule of the present invention (e.g., the anti-DLL3 antibody or antigen-binding fragment thereof or immunoconjugate thereof, e.g., the ADC molecule, of the present invention) , and one or more other therapeutic agents.
[0429] It is a further object of the present invention to provide a kit of parts comprising the pharmaceutical combination of the present invention, preferably in the form of pharmaceutical dosage units. Dosage units may thus be provided according to a dosing regimen or interval of drug administration.
[0430] In an embodiment, a kit of parts according to the present invention comprises in the same package:
[0431] -a first container containing a pharmaceutical composition comprising the molecule of the present invention (e.g., the anti-DLL3 antibody or antigen-binding fragment thereof or immunoconjugate thereof, e.g., the ADC molecule, of the present invention) ;
[0432] -a second container containing a pharmaceutical composition comprising a further therapeutic agent.
[0433] In some embodiments, the molecule of the present invention comprised in the pharmaceutical combination or kit is the antibody drug conjugate of 23A1-NT3.
[0434] VIII. Use and method
[0435] One aspect of the present invention provides a method of preventing or treating a disease in a subject comprising administering to the subject an effective amount of the molecule of the present invention (e.g., the anti-DLL3 antibody or antigen-binding fragment thereof or immunoconjugate thereof, e.g., the ADC molecule, of the present invention) , the pharmaceutical composition, the pharmaceutical combination, or the kit. In some embodiments, the disease is, for example, a tumor such as a cancer.
[0436] In some embodiments, the present invention relates to the molecule of the present invention (e.g., the anti-DLL3 antibody or antigen-binding fragment thereof or immunoconjugate thereof, e.g., the ADC molecule, of the present invention) for use in therapy, e.g., for treating a tumor, e.g., a cancer.
[0437] In some embodiments, the present invention relates to a method of treating diseases, such as tumors, e.g., cancers, using the molecule of the present invention (e.g., the anti-DLL3 antibody or antigen-binding fragment thereof, or immunoconjugate thereof, e.g., the ADC molecule, of the present invention) , or use of the molecule of the present invention for such treatment, or use of the molecule of the present invention in the manufacture of a medicament for such treatment.
[0438] In some embodiments, the tumor is a solid tumor or a hematological tumor and a metastatic lesion. In an embodiment, examples of solid tumors include malignant tumors. The cancer may be in an early, intermediate or advanced stage or metastatic cancer. In some embodiments, the tumor is a tumor with immune escape.
[0439] In some embodiments, the tumor is a DLL3 positive tumor or cancer. In some embodiments, the tumor is associated with aberrant expression or aberrant activity of DLL3.
[0440] In some embodiments, a DLL3 positive tumor or cancer refers to aberrant expression or activity of DLL3 in a subject having the tumor cancer. In some embodiments, the subject (particularly an adult subject) has DLL3 expression therein. In some embodiments, the subject (particularly an adult subject) has moderate to high expression of DLL3. In some embodiments, DLL3 is present (e.g., at an elevated level, e.g., an elevated nucleic acid or protein level or activity) in the subject (e.g., as compared to a healthy subject) . In some embodiments, the subject has DLL3 (e.g., at an elevated level, e.g., an elevated nucleic acid or protein level or activity) in a biological sample (e.g., a tumor cell or tumor tissue) (e.g., as compared to a biological sample from a healthy subject (e.g., a corresponding tissue or cell in a healthy subject) , or as compared to DLL3 in an adjacent healthy tissue or cell of the subject) .
[0441] In some embodiments, DLL3 positive tumors refer to aberrant expression of DLL3 in tumor cells. In some embodiments, aberrant expression of DLL3 refers to expression of DLL3 on the cell membrane of the tumor cell. In some embodiments, aberrant expression of DLL3 refers to moderate or high expression of DLL3 on the cell membrane of the tumor cell. In some embodiments, aberrant expression of DLL3 refers to expression of DLL3 on a tumor cell that is higher than expression of DLL3 in a control cell (e.g., a healthy cell of a corresponding tissue of a healthy subject, or a healthy cell in proximity to a tumor cell) .
[0442] In a particular embodiment, the molecule of the present invention, e.g., any antibody or antigen-binding fragment thereof or immunoconjugate such as the ADC molecule, is capable of killing tumor cells, and / or inhibiting tumor cell proliferation, e.g., tumor cells that express or aberrantly express DLL3, e.g., lung cancer cells, e.g., small cell lung cancer cells.
[0443] In a particular embodiment, the tumor is small cell lung cancer (SCLC) , such as advanced small cell lung cancer.
[0444] In a particular embodiment, the tumor is a chemotherapy-resistant tumor.
[0445] In a particular embodiment, the tumor is a neuroendocrine tumor, including large cell neuroendocrine lung cancer (LCNEC) , neuroendocrine prostate cancer (NEPC) , and other extrapulmonary neuroendocrine cancers.
[0446] In some embodiments, the tumor is a tumor that has or has experienced immune escape, e.g., a tumor that has been treated with immunotherapy.
[0447] In some embodiments, the tumor is a cancer, e.g., lung cancer, e.g., small cell lung cancer.
[0448] In some embodiments, the tumor is a tumor that has been treated with other treatments, such as chemotherapy and / or radiotherapy.
[0449] In some embodiments, the chemotherapy is a chemotherapy regimen for a small cell lung cancer, including but not limited to a combination of carboplatin and etoposide.
[0450] Depending on its therapeutic use, the antibody or antigen-binding fragment thereof or immunoconjugate thereof, e.g., the ADC molecule or the pharmaceutical composition, of the present invention may also be administered in combination with one or more other therapies, e.g., therapeutic modalities and / or other therapeutic agents, for uses described herein, e.g., for the prevention and / or treatment of the related diseases or disorders mentioned herein.
[0451] In some embodiments, when the molecule of the present invention (e.g., the anti-DLL3 antibody or antigen-binding fragment thereof or immunoconjugate thereof, etc. ) is used to treat a tumor, the treatment regimen comprises surgery; radiotherapy, localized irradiation, focused irradiation, or the like.
[0452] In other aspects, the invention provides the use of the molecule of the present invention (e.g., the anti-DLL3 antibody or antigen-binding fragment thereof or immunoconjugate thereof, etc. ) or the composition or the combination product comprising the same, in the manufacture or preparation of a medicament for use as described herein, e.g., for the prevention or treatment of a related disease or disorder mentioned herein.
[0453] In other aspects, the invention also provides the molecule of the present invention (e.g., the anti-DLL3 antibody or antigen-binding fragment thereof or immunoconjugate thereof, etc. ) or the composition or medicament or formulation or combination product comprising the same, for use in therapy, e.g., for treating a related disease or disorder mentioned herein.
[0454] The subject may be a mammal, e.g., a primate, preferably a higher primate, e.g., a human (e.g., a subject having or at risk of having a disease as described herein) . In an embodiment, the subject has or is at risk of having a disease described herein (e.g., cancer) . In some embodiments, the subject receives or has received other treatment, such as chemotherapy treatment and / or radiotherapy. In some embodiments, the subject has previously received or is receiving immunotherapy.
[0455] The combination therapies of the present invention encompass both combined administration (e.g., two or more therapeutic agents contained in the same formulation or separate formulations) , and separate administration, in which case administration of the molecule of the present invention (e.g., the anti-DLL3 antibody or antigen-binding fragment thereof or immunoconjugate thereof, etc. ) or the compositions or medicaments or formulations comprising the same, can occur prior to, concurrently with, and / or after administration of the other therapeutic agents and / or drugs.
[0456] The pharmaceutical composition is administrated according to known route of administration, e.g., orally, by intravenous injection, intraperitoneally, intracerebrally (intraparenchymal) , intracerebroventricularly, intramuscularly, intraocularly, intraarterially, intraportally or intralesionally; by a sustained release system or by an implanted device. In certain embodiments, the composition may be administered by bolus injection or by continuous infusion or by an implanted device.
[0457] The composition may also be administered topically via an implant membrane, sponge, or another suitable material onto which the desired molecules are absorbed or encapsulated. In certain embodiments, when an implant device is used, the device may be implanted into any suitable tissue or organ and the desired molecules may be delivered via diffusion, timed-release bolus, or continuous administration.
[0458] In some embodiments, the molecule of the present invention in the use or method is the antibody drug conjugate of 23A1-NT3.
[0459] IX. Other therapeutic agents
[0460] In some embodiments, when the molecule of the present invention (e.g., the anti-DLL3 antibody or antigen-binding fragment thereof or immunoconjugate thereof, e.g., the ADC molecule, of the present invention) is used to treat a tumor, another therapeutic agent that can be combined with the molecule of the present invention, or can be administered in combination with the molecule of the present invention encompass various therapeutic agents for treating tumors, e.g., a chemotherapeutic agent, an angiogenesis inhibitor, a cytokine, a cytotoxic agent, another antibody, a small molecule drug, or an immunomodulatory agent (e.g., a immune checkpoint inhibitor or an agonist) .
[0461] In some particular embodiments, the other therapeutic agent (s) that can be combined with the molecule of the present invention is a chemotherapeutic agent selected from carboplatin and / or etoposide. In some particular embodiments, the chemotherapeutic agents that may be combined with the molecule of the present invention is carboplatin in combination with etoposide.
[0462] In some particular embodiments, the other therapeutic agent (s) that can be combined with the molecule of the present invention is Topotecan, cyclophosphamide, and / or etoposide (TCE) .
[0463] In some specific embodiments, the other therapeutic agent (s) that can be combined with the molecules of the present invention are another antibody which is a bispecific antibody that specifically binds to DLL3 and CD3.
[0464] In some embodiments, the bispecific antibody that specifically binds to DLL3 and CD3 comprises a first antigen-binding region and a second antigen-binding region, wherein the first antigen-binding region specifically binds to DLL3 and the second antigen-binding region specifically binds to CD3.
[0465] The components of the bispecific antibody are described in detail below. It should be understood by those skilled in the art that any combination of any of the features of these components is within the contemplation of the present invention unless the context clearly indicates to the contrary. Also, it will be understood by those skilled in the art that bispecific antibody (including any form of antibody) of the present invention may comprise any of such combination of features unless the context clearly indicates to the contrary.
[0466] The first antigen binding region that specifically binds to DLL3
[0467] The first antigen-binding region suitable for the bispecific antibody may comprise or consist of an anti-DLL3 full length antibody or antigen-binding fragment thereof, provided that it is capable of specifically binding to DLL3. In some embodiments, the first antigen-binding region is derived from an anti-DLL3 antibody or antigen-binding fragment thereof, for example, is an anti-DLL3 Fab. In some embodiments, the first antigen-binding region suitable for the bispecific antibody may comprise or consist of an anti-DLL3 antibody or antigen-binding fragment thereof , provided that it is capable of specifically binding to DLL3, including, but not limited to, for example, a full length antibody, a half antibody, a Fab, a Fab', a Fab'-SH, an Fv, a single chain antibody (e.g., scFv) , a (Fab') 2 , a single domain antibody (e.g., a VHH) , a domain antibody (dAB) , a heavy chain antibody, or a linear antibody, and the like, that specifically binds to DLL3.
[0468] In some embodiments, the anti-DLL3 antibody from which the first antigen-binding region suitable for the bispecific antibody is derived is different from the anti-DLL3 antibody defined in Section II-1 of the present invention. In some embodiments, the first antigen-binding region suitable for the bispecific antibody comprises a CDR (e.g., 1, 2, or 3 HCDRs, or 1, 2, or 3 LCDRs) , or comprises a VH and / or VL that is different from the CDR or VH or VL of the anti-DLL3 antibody defined in Section II-1 of the present invention. In some embodiments, the DLL3 epitope to which the first antigen-binding region suitable for the bispecific antibody binds is different from the DLL3 epitope to which the anti-DLL3 antibody defined in Section II-1 of the present invention binds.
[0469] In some embodiments, the first antigen-binding region that specifically binds to DLL3 comprises 3 complementarity determining regions from a heavy chain variable region (HCDRs) : HCDR1, HCDR2 and HCDR3, wherein said HCDR1, HCDR2 and HCDR3 are HCDR1, HCDR2 and HCDR3 of the heavy chain variable region set forth in SEQ ID NO: 16. In some embodiments, the first antigen-binding region that specifically binds to DLL3 comprises 3 complementarity determining regions from the light chain variable region (LCDRs) : LCDR1, LCDR2, and LCDR3, wherein said LCDR1, LCDR2, and LCDR3 are LCDR1, LCDR2, and LCDR3 of the light chain variable region set forth in SEQ ID NO: 20. In some embodiments, in said first antigen-binding region that specifically binds to DLL3, the HCDR1 comprises or consists of the amino acid sequence set forth in SEQ ID NO: 17, the HCDR2 comprises or consists of the amino acid sequence set forth in SEQ ID NO: 18, the HCDR3 comprises or consists of the amino acid sequence set forth in SEQ ID NO: 19, the LCDR1 comprises or consists of the amino acid sequence set forth in SEQ ID NO: 21, the LCDR2 comprises or consists of the amino acid sequence set forth in SEQ ID NO: 22, and / or the LCDR3 comprises or consists of the amino acid sequence set forth in SEQ ID NO: 23.
[0470] In some embodiments, the HCDR1, HCDR2, HCDR3, LCDR1, LCDR2, LCDR3 of the first antigen-binding region are determined according to any CDR definition scheme, e.g., as determined by Kabat, Chothia, Contact, AbM, IMGT, or a combination thereof respectively; for example, wherein the HCDR1 is determined according to Kabat &Chothia schemes, the HCDR2, HCDR3, LCDR1, LCDR2, and LCDR3 are determined according to Kabat scheme respectively.
[0471] In some embodiments, the first antigen-binding region that specifically binds to DLL3 comprises a VH, wherein the VH comprises
[0472] (a) 3 complementarity determining regions from a heavy chain variable region (HCDRs) : HCDR1, HCDR2 and HCDR3, wherein the HCDR1 comprises or consists of the amino acid sequence set forth in SEQ ID NO: 17, the HCDR2 comprises or consists of the amino acid sequence set forth in SEQ ID NO: 18, and the HCDR3 comprises or consists of the amino acid sequence set forth in SEQ ID NO: 19; or
[0473] (b) the amino acid sequence set forth in SEQ ID NO: 16, or consists of the amino acid sequence set forth in SEQ ID NO: 16.
[0474] In some embodiments, the first antigen-binding region that specifically binds to DLL3 comprises a VL, wherein the VL comprises
[0475] (a) 3 complementarity determining regions from the light chain variable region (LCDRs) : LCDR1, LCDR2 and LCDR3, wherein the LCDR1 comprises or consists of the amino acid sequence set forth in SEQ ID NO: 21, the LCDR2 comprises or consists of the amino acid sequence set forth in SEQ ID NO: 22, and the LCDR3 comprises or consists of the amino acid sequence set forth in SEQ ID NO: 23; or
[0476] (b) the amino acid sequence set forth in SEQ ID NO: 20, or consists of the amino acid sequence set forth in SEQ ID NO: 20.
[0477] In some embodiments, the first antigen-binding region that specifically binds to DLL3 comprises 3 complementarity determining regions from a heavy chain variable region (HCDRs) : HCDR1, HCDR2 and HCDR3 and 3 complementarity determining regions from a light chain variable region (LCDRs) : LCDR1, LCDR2 and LCDR3, wherein HCDR1 comprises or consists of the amino acid sequence set forth in SEQ ID NO: 17; the HCDR2 comprises or consists of the amino acid sequence set forth in SEQ ID NO: 18, the HCDR3 comprises or consists of the amino acid sequence set forth in SEQ ID NO: 19, the LCDR1 comprises or consists of the amino acid sequence set forth in SEQ ID NO: 21, the LCDR2 comprises or consists of the amino acid sequence set forth in SEQ ID NO: 22, and the LCDR3 comprises or consists of the amino acid sequence set forth in SEQ ID NO: 23.
[0478] In some embodiments, the first antigen-binding region that specifically binds to DLL3 comprises a VH and a VL, wherein the VH comprises or consists of the sequence set forth in SEQ ID NO: 16; and / or the VL comprises or consists of the sequence set forth in SEQ ID NO: 20.
[0479] In some embodiments, the first antigen-binding region that specifically binds to DLL3 is a Fab fragment. In some embodiments, the Fab fragment is derived from the anti-DLL3 antibody and comprises the heavy chain variable region VH and the light chain variable region VL of the anti-DLL3 antibody. In some embodiments, the Fab that is the first antigen-binding region comprises the VH or the VL of the first antigen-binding region described herein, or comprises the VH and the VL of the first antigen-binding region described herein. In some embodiments, the heavy chain of the Fab that specifically binds to DLL3 as the first antigen-binding region comprises or consists of a VH and a CH1, wherein said VH is the VH of the first antigen-binding region described herein. In some embodiments, the light chain of the Fab that specifically binds to DLL3 as the first antigen-binding region comprises or consists of a VL and a CL, wherein said VL is the VL of the first antigen-binding region described herein. In some embodiments, the first antigen-binding region comprises a CH1 from an IgG1, and / or a Kappa light chain constant region.
[0480] In some embodiments, the heavy chain of the Fab that specifically binds to DLL3
[0481] (i) comprises or consists of an amino acid sequence having at least 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%or 99%identity to the amino acid sequence of SEQ ID NO: 39;
[0482] (ii) comprises or consists of the amino acid sequence of SEQ ID NO: 39; or
[0483] (iii) comprises or consists of an amino acid sequence having one or more (preferably no more than 10 or 10, more preferably no more than 5, 4, 3, 2, 1) amino acid changes (preferably amino acid substitutions, more preferably amino acid conservative substitutions) compared to the amino acid sequence of SEQ ID NO: 39.
[0484] In some embodiments, the light chain of the Fab that specifically binds to DLL3
[0485] (i) comprises or consists of an amino acid sequence having at least 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%or 99%identity to the amino acid sequence set forth in SEQ ID NO: 27;
[0486] (ii) comprises or consists of the amino acid sequence of SEQ ID NO: 27; or
[0487] (iii) comprises or consists of an amino acid sequence having one or more (preferably no more than 10 or 10, more preferably no more than 5, 4, 3, 2, 1) amino acid changes (preferably amino acid substitutions, more preferably amino acid conservative substitutions) compared to the amino acid sequence of SEQ ID NO: 27.
[0488] In some embodiments, a Fab that specifically binds to DLL3 comprises a Fab heavy chain and a Fab light chain, wherein the Fab heavy chain comprises or consists of an amino acid sequence having at least 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99%identity to the amino acid sequence set forth in SEQ ID NO: 39, and the Fab light chain comprises or consists of an amino acid sequence having at least 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99%identical to the amino acid sequence set forth in SEQ ID NO: 27.
[0489] In some embodiments, the heavy chain of the Fab that specifically binds to DLL3 comprises or consists of the amino acid sequence set forth in SEQ ID NO: 39 and the light chain of the Fab comprises or consists of the amino acid sequence set forth in SEQ ID NO: 27.
[0490] The second antigen-binding region that specifically binds to CD3
[0491] The second antigen-binding region suitable for the bispecific antibody may comprise or consist of an anti-CD3 full length antibody or antigen-binding fragment thereof, provided that it is capable of specifically binding to CD3. In some embodiments, the second antigen-binding region is derived from an anti-CD3 antibody or antigen-binding fragment thereof, for example, is an anti-CD3 Fab. In some embodiments, the second antigen-binding region suitable for the bispecific antibody of the present invention may comprise or consist of an anti-CD3 antibody or antigen-binding fragment thereof (the anti-CD3 antibody or antigen-binding fragment thereof as disclosed in WO2022068809A1, e.g., the HzSP34.24 antibody or antigen binding thereof) , provided that it is capable of specifically binding to CD3, including, but not limited to, for example, a full length antibody, a half antibody, a Fab, a Fab', a Fab'-SH, an Fv, a single chain antibody (e.g., scFv) , a (Fab') 2 , a single domain antibody (e.g., a VHH) , a domain antibody (dAB) , a heavy chain antibody, or a linear antibody, and the like, that specifically binds to CD3.
[0492] In some embodiments, the second antigen-binding region that specifically binds to CD3 comprises 3 complementarity determining regions from a heavy chain variable region (HCDRs) : HCDR1, HCDR2 and HCDR3, wherein said HCDR1, HCDR2 and HCDR3 are HCDR1, HCDR2 and HCDR3 of the heavy chain variable region set forth in SEQ ID NO: 28. In some embodiments, the second antigen-binding region that specifically binds to CD3 comprises 3 complementarity determining regions from the light chain variable region (LCDRs) : LCDR1, LCDR2, and LCDR3, wherein said LCDR1, LCDR2, and LCDR3 are LCDR1, LCDR2, and LCDR3 of the light chain variable region set forth in SEQ ID NO: 32. In some embodiments, in said second antigen-binding region that specifically binds to CD3, the HCDR1 comprises or consists of the amino acid sequence set forth in SEQ ID NO: 29, the HCDR2 comprises or consists of the amino acid sequence set forth in SEQ ID NO: 30, the HCDR3 comprises or consists of the amino acid sequence set forth in SEQ ID NO: 31, the LCDR1 comprises or consists of the amino acid sequence set forth in SEQ ID NO: 33, the LCDR2 comprises or consists of the amino acid sequence set forth in SEQ ID NO: 34, and / or the LCDR3 comprises or consists of the amino acid sequence set forth in SEQ ID NO: 35.
[0493] In some embodiments, the second antigen-binding region that specifically binds to CD3 comprises a VH, wherein the VH comprises
[0494] (a) 3 complementarity determining regions from a heavy chain variable region (HCDRs) : HCDR1, HCDR2 and HCDR3, wherein the HCDR1 comprises or consists of the amino acid sequence set forth in SEQ ID NO: 29, the HCDR2 comprises or consists of the amino acid sequence set forth in SEQ ID NO: 30, and the HCDR3 comprises or consists of the amino acid sequence set forth in SEQ ID NO: 31; or
[0495] (b) the amino acid sequence set forth in SEQ ID NO: 28, or consists of the amino acid sequence set forth in SEQ ID NO: 28.
[0496] In some embodiments, the second antigen-binding region that specifically binds to CD3 comprises a VL, wherein the VL comprises
[0497] (a) 3 complementarity determining regions from the light chain variable region (LCDRs) : LCDR1, LCDR2 and LCDR3, wherein the LCDR1 comprises or consists of the amino acid sequence set forth in SEQ ID NO: 33, the LCDR2 comprises or consists of the amino acid sequence set forth in SEQ ID NO: 34, and the LCDR3 comprises or consists of the amino acid sequence set forth in SEQ ID NO: 35; or
[0498] (b) the amino acid sequence set forth in SEQ ID NO: 32, or consists of the amino acid sequence set forth in SEQ ID NO: 32.
[0499] In some embodiments, the second antigen-binding region that specifically binds to CD3 comprises 3 complementarity determining regions from a heavy chain variable region (HCDRs) : HCDR1, HCDR2 and HCDR3 and 3 complementarity determining regions from a light chain variable region (LCDRs) : LCDR1, LCDR2 and LCDR3, wherein HCDR1 comprises or consists of the amino acid sequence set forth in SEQ ID NO: 29; the HCDR2 comprises or consists of the amino acid sequence set forth in SEQ ID NO: 30, the HCDR3 comprises or consists of the amino acid sequence set forth in SEQ ID NO: 31, the LCDR1 comprises or consists of the amino acid sequence set forth in SEQ ID NO: 33, the LCDR2 comprises or consists of the amino acid sequence set forth in SEQ ID NO: 34, and the LCDR3 comprises or consists of the amino acid sequence set forth in SEQ ID NO: 35.
[0500] In some embodiments, the second antigen-binding region that specifically binds to CD3 comprises a VH and a VL, wherein the VH comprises or consists of the sequence set forth in SEQ ID NO: 28; and / or the VL comprises or consists of the sequence set forth in SEQ ID NO: 32.
[0501] In some embodiments, the second antigen-binding region that specifically binds to CD3 is a Fab fragment. In some embodiments, the Fab fragment is derived from the anti-CD3 antibody and comprises the heavy chain variable region VH and the light chain variable region VL of the anti-CD3 antibody. In some embodiments, the Fab that is the second antigen-binding region comprises the VH or the VL of the second antigen-binding region described herein, or comprises the VH and the VL of the second antigen-binding region described herein. In some embodiments, the heavy chain of the Fab that specifically binds to CD3 as the second antigen-binding region comprises or consists of a VH and a CH1, wherein said VH is the VH of the second antigen-binding region described herein. In some embodiments, the light chain of the Fab that specifically binds to CD3 as the second antigen-binding region comprises or consists of a VL and a CL, wherein said VL is the VL of the second antigen-binding region described herein. In some embodiments, the second antigen-binding region comprises a CH1 from an IgG1, and / or a Lambda light chain constant region.
[0502] In some embodiments, the heavy chain of the Fab that specifically binds to CD3
[0503] (i) comprises or consists of an amino acid sequence having at least 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%or 99%identity to the amino acid sequence of SEQ ID NO: 40;
[0504] (ii) comprises or consists of the amino acid sequence of SEQ ID NO: 40; or
[0505] (iii) comprises or consists of an amino acid sequence having one or more (preferably no more than 10 or 10, more preferably no more than 5, 4, 3, 2, 1) amino acid changes (preferably amino acid substitutions, more preferably amino acid conservative substitutions) compared to the amino acid sequence of SEQ ID NO: 40.
[0506] In some embodiments, the light chain of the Fab that specifically binds to CD3
[0507] (i) comprises or consists of an amino acid sequence having at least 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%or 99%identity to the amino acid sequence set forth in SEQ ID NO: 38;
[0508] (ii) comprises or consists of the amino acid sequence of SEQ ID NO: 38; or
[0509] (iii) comprises or consists of an amino acid sequence having one or more (preferably no more than 10 or 10, more preferably no more than 5, 4, 3, 2, 1) amino acid changes (preferably amino acid substitutions, more preferably amino acid conservative substitutions) compared to the amino acid sequence of SEQ ID NO: 38.
[0510] In some embodiments, a Fab that specifically binds to CD3 comprises a Fab heavy chain and a Fab light chain, wherein the Fab heavy chain comprises or consists of an amino acid sequence having at least 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99%identity to the amino acid sequence set forth in SEQ ID NO: 40, and the Fab light chain comprises or consists of an amino acid sequence having at least 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99%identical to the amino acid sequence set forth in SEQ ID NO: 38.
[0511] In some embodiments, the heavy chain of the Fab that specifically binds to CD3 comprises or consists of the amino acid sequence set forth in SEQ ID NO: 40 and the light chain of the Fab comprises or consists of the amino acid sequence set forth in SEQ ID NO: 38.
[0512] Other domains
[0513] In some embodiments, the CH1 described herein, e.g. the CH1 comprised in the Fab is a CH1 from IgG1, IgG2, IgG3, or IgG4, preferably a CH1 from IgG1. In some embodiments, the CH1
[0514] (i) comprises or consists of an amino acid sequence having at least 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%or 99%identity to the amino acid sequence of SEQ ID NO: 25;
[0515] (ii) comprises or consists of the amino acid sequence of SEQ ID NO: 25; or
[0516] (iii) comprises or consists of an amino acid sequence having one or more (preferably no more than 10 or 10, more preferably no more than 5, 4, 3, 2, 1) amino acid changes (preferably amino acid substitutions, more preferably amino acid conservative substitutions) compared to the amino acid sequence of SEQ ID NO: 25.
[0517] In some embodiments, the CL described herein, e.g., the CL contained in the Fab is a Kappa light chain constant region or an Lambda light chain constant region. In some embodiments, CL is a Kappa light chain constant region. In some embodiments, the CL is as described above.
[0518] In some embodiments, the bispecific antibody further comprises an Fc region, wherein the Fc regions comprised therein may be the same or different. In some embodiments, the first Fc region and the second Fc region are different and are capable of dimerizing to form a heterodimeric Fc scaffold. In some embodiments, the Fc region is human IgG1, IgG2, IgG3, or IgG4 Fc. In some embodiments, the bispecific antibody is an IgG-like bispecific antibody comprising a dimeric Fc scaffold.
[0519] In some embodiments, the two Fc regions are different, wherein a mutation is introduced in the first and second Fc regions, promoting heterodimerization of the first and second Fc regions, based on Innobody technology (see, e.g., PCT / CN2021 / 143141 (which patent is incorporated herein in its entirety) . In some embodiments, the CH3 of one Fc region comprises the S364R and D399K mutations, and the CH3 of the other Fc region comprises the Y349T, K370S, and K409D mutations, wherein
[0520] a) one Fc region comprises or consists of the amino acid sequence set forth in SEQ ID NO: 24 and the other Fc region comprises or consists of the amino acid sequence set forth in SEQ ID NO: 36;
[0521] b) one Fc region comprises an amino acid sequence having at least 85%, 90%, 95%, 96%, 97%, 98%, 99%identity to the amino acid sequence set forth in SEQ ID NO: 24 and comprises the mutations S364R and D399K, whereas the other Fc region comprises an amino acid sequence having at least 85%, 90%, 95%, 96%, 97%, 98%, 99%identity to the amino acid sequence set forth in SEQ ID NO: 36 and comprises the mutations Y349T, K370S and K409D; or
[0522] c) one Fc region comprises an amino acid sequence having at least 85%, 90%, 95%, 96%, 97%, 98%, 99%identity to the amino acid sequence set forth in SEQ ID NO: 24 and comprises the mutations S364R and D399K and L234A / L235A, whereas the other Fc region comprises an amino acid sequence having at least 85%, 90%, 95%, 96%, 97%, 98%, 99%identity to the amino acid sequence set forth in SEQ ID NO: 36 and comprises the mutations Y349T, K370S and K409D and L234A / L235A.
[0523] Exemplary bispecific antibodies
[0524] In some embodiments, the bispecific antibody is an IgG-like antibody having the configuration shown in Fig. 18B.
[0525] In a particular embodiment, the bispecific antibody that specifically binds to DLL3 and CD3 comprises or consists of:
[0526] heavy chain 1: from N-terminus to C-terminus comprising or consisting of: the heavy chain variable region of a Fab that specifically binds to DLL3-heavy chain constant region CH1-first Fc region, wherein the heavy chain constant region CH1 is linked at its C-terminus to the N-terminus of the first Fc region, with or without a linker (e.g., hinge region) ;
[0527] light chain 1: from N-terminus to C-terminus comprising or consisting of: the light chain variable region of a Fab that specifically binds to DLL3-light chain constant region;
[0528] heavy chain 2: from N-terminus to C-terminus comprising or consisting of: the heavy chain variable region of a Fab that specifically binds to CD3-heavy chain constant region CH1-second Fc region, wherein the heavy chain constant region CH1 is linked at its C-terminus to the N-terminus of the second Fc region, with or without a linker (e.g., hinge region) ; and / or
[0529] light chain 2: from N-terminus to C-terminus comprising or consisting of: the light chain variable region of a Fab that specifically binds to CD3-light chain constant region.
[0530] Various domains, e.g., the Fab that specifically binds to DLL3 (e.g., Fab heavy chain variable region and Fab light chain variable region) , the Fab that specifically binds to CD3 (e.g., Fab heavy chain variable region and Fab light chain variable region) , the heavy chain constant region CH1, the Fc region, the light chain constant region, and the like, as described above, are each described herein.
[0531] In some embodiments, the domains are linked via a linker, or directly linked without a linker. In some embodiments, the domains are directly linked.
[0532] In some embodiments, the light chain constant region in light chain 1 is the same or different from the light chain constant region in light chain 2, e.g., the light chain constant region in light chain 1 is a Kappa light chain constant region and the light chain constant region in light chain 2 is a Lambda light chain constant region.
[0533] In some specific embodiments, a bispecific antibody that specifically binds to DLL3 and CD3 comprises or consists of heavy chain 1, heavy chain 2, light chain 1 and light chain 2, wherein
[0534] heavy chain 1 comprises or consists of the amino acid sequence set forth in SEQ ID NO: 26, or an amino acid sequence having at least 85%, 90%, 95%, 96%, 97%, 98%, 99%identity thereto;
[0535] light chain 1 comprises or consists of the amino acid sequence set forth in SEQ ID NO: 27, or an amino acid sequence having at least 85%, 90%, 95%, 96%, 97%, 98%, 99%identity thereto;
[0536] heavy chain 2 comprises or consists of the amino acid sequence set forth in SEQ ID NO: 37, or an amino acid sequence having at least 85%, 90%, 95%, 96%, 97%, 98%, 99%identity thereto; and / or
[0537] light chain 2 comprises or consists of the amino acid sequence set forth in SEQ ID NO: 38, or an amino acid sequence having at least 85%, 90%, 95%, 96%, 97%, 98%, 99%identity thereto.
[0538] These and other aspects and embodiments of the application are described in the drawings and detailed description and are illustrated in the following examples. Any or all of the features discussed above and throughout this disclosure may be combined in various embodiments of the present application. The following examples further illustrate the present invention. However, it is to be understood that the examples are described by way of illustration and not limitation, and that various modifications may be made by those skilled in the art.
[0539] Examples
[0540] Example 1. Preparation and screening for hybridomas generating anti-DLL3 antibody
[0541] 1. Immunization
[0542] Fully humanized transgenic mice (RenMab, available from Biocytogen) were immunized with human DLL3 extracellular domain protein (Kactusbio, Cat#DLL-HM103) , which was emulsified with Freund's complete adjuvant (Sigma, Cat#F5881) and two weeks later with Freund's incomplete adjuvant (Sigma, F5506) , three times via subcutaneous injection every two weeks (50 ug protein per mouse) .
[0543] 2. Cell fusion and high throughput screening
[0544] When the serum titer met the requirement, the spleen of a mouse was picked to prepare a B lymphocyte suspension, and the B lymphocyte suspension was mixed with SP2 / 0 myeloma cells (ATCC) in a ratio of 1: 2-1: 1 to perform electrofusion. The fused cells were transferred from the electrode dish into a 50 ml centrifuge tube, then diluted to 1-2 ×104 cells / ml by using a HAT-containing culture medium to obtain a cell suspension, which was added into each well of a 96-well plate at 100 μl. The screening medium was changed at day 7 after the fusion, and after culture for 10 days (or longer, depending on the cell growth state) , flow cytometry (FACS) detection was carried out to screen positive clones.
[0545] Hybridoma cells specifically expressing anti-DLL3 antibody were screened by flow cytometry (FACS) . A cell line to be over-expressed (GS-CHO human DLL3, DLL3 gene (Uniprot ID, Q9NYJ7) -is constructed into a pXC17.4 vector (Lonza) , which was linearized and then electro-transfected into CHO cells (Lonza) to obtain GS-CHO human DLL3 cells stably expressing DLL3) was counted, diluted to 1×10 6 cells / ml, and added to a U-shaped bottom 96-well plate with 100 μl / well. The cell culture medium was removed by centrifugation at 500g for 5 min. The hybridoma culture supernatant in 96-well plate was added to a U-plate and the cells were resuspended in 100 μl per well and allowed to stand on ice for 30 min. The supernatant was removed by centrifugation at 500g for 5min, and the cells were washed 1 time with PBS. PBS was removed at 500g for 5min, 100 μl of FITC-labeled secondary antibody against mouse Fab (Jackson Immunoresearch, Cat#115-545-006) (1: 500 diluted in PBS) was added to each well, and 100 μl of PE-labeled secondary antibody against human Fc (Biolegend, Cat#409304) was added as the positive control antibody. An incubation for 30 min on ice in the dark was performed. The supernatant was removed at 500g for 5min and the cells were washed 1 time with PBS. The cells were resuspended in 50 μl of 1×PBS and tested on a flow cytometer through FACS. Clones positive to the human DLL3 antigen were obtained though screening.
[0546] 3. Subcloning positive hybridoma cells
[0547] Subcloning using limiting dilution assay (LDA) was performed as follows: 200 μl of medium was added to each well in a 96-well plate, wherein the medium was based on the screening medium except that HAT was replaced with HT (Gibco, Cat#11067-030) , with the rest of the formula being the same. The cells in the positive wells screened by the above fusion were prepared into cell suspensions. 100 μl of the cell suspensions was respectively taken and added into each well in the 1st row, followed by uniformly mixing; then 100 μl of the cell suspensions from the 1st row was taken and added into each well in the 2nd row, followed by uniformly mixing, 100 μl of the cell suspensions was taken and added into the next row, followed by repeating the above steps, with the 96-well plate standing still for 30 min, and the cell suspensions were observed and an counted under a microscope. A corresponding volume of 100 cells was taken and added to 20 ml of medium, the mixture was then well mixed and plated at 200 μl per well. After one week, observation was performed under a microscope, and wells with single clone were identified and marked.
[0548] When the cell confluency in each well reached more than 50%, target positive wells were selected by detecting with the same high throughput screening method above, and then cells were cryopreserved after an expanded culture (finally 51 stable clone strains selected) .
[0549] 4. Preparation of recombinant antibodies
[0550] The 51 hybridoma candidate clones obtained above were subjected to an identification of the light and heavy chain gene sequences of the antibodies, and which were then constructed into fully human recombinant antibodies.
[0551] About 5×106 cells per fresh cultured cell strain were taken and RNA was extracted (Macherey-Nagel, Cat#740984.250) . The cDNA was obtained by reverse transcription using PrimeScript II 1st Strand cDNA Synthesis Kit (Takara) . An upstream primer was designed based on the base sequence of FR1 region located at the 5'end, and a downstream primer was designed based on the base sequence located at the antibody constant region or FR4 region, to amplify antibody light and heavy chain variable region gene fragments, which were ligated into a T-vector (Mighty TA-cloning Kit, Takara) . The single clones were picked up for sequencing and the sequencing results were analyzed and aligned using MEGA7 software. Through alignment, 47 pairs of candidate clone sequences were obtained according to sequence homology.
[0552] Based on affinities of the antibodies to Human DLL3, Rhesus DLL3, and sequence diversities, 28 candidate molecules were finally selected. The light chain and heavy chain variable region gene fragments of the candidate molecules were ligated into a pcDNA3.1 vector containing a heavy chain constant region or a light chain constant region (wherein the heavy chain constant region was selected from IgG1 wild type (SEQ ID NO: 13) and light chain constant region was selected from Kappa (SEQ ID NO: 15) ) by a homologous recombinase from Nanjing Vazyme Biotech Co., Ltd. ( Cat#C112-01) , respectively, to obtain an expression plasmid of light and heavy chains of antibodies. Then, the light chain plasmid and the heavy chain plasmid of the same antibody were mixed at a molar ratio of 1: 1, then transfected into 293Fcells with Polyethyleneimine (PEI) (Polysciences, Cat#23966) , and after incubation 5-7 days, when the cell viability was less than 60%, cell culture supernatants were collected and purified using Protein A affinity columns to obtain monoclonal antibodies.
[0553] 5. In vitro screening of recombinant antibodies
[0554] Affinity assay
[0555] The equilibrium dissociation constant (KD) of the antibodies of the present invention binding to human DLL3 and macaque DLL3 were determined using bio-layer interferometry (ForteBio) . ForteBio affinity assays were performed according to the current method (Estep, P, et al, High throughput solution Based measurement of antibody-antibody affinity and epitope binding. MAbs, 2013.5 (2) : pages 270-8) .
[0556] Briefly, the AHQ (Pall, 1506091) sensor was equilibrated off-line in assay buffer for 30 min, then tested on-line for 60 seconds to establish a baseline, and the purified antibodies obtained as described above were loaded on line onto an AHQ sensor (ForteBio) for ForteBio affinity measurements. The sensor with the loaded antibody was then exposed to antigen DLL3 (human DLL3 (DL3-H52H4, Acro biosystems) and macaque DLL3 (DLL-RM 103, Kactusbio) ) , before the sensor was transferred to assay buffer for dissociation rate measurements. KD values were analyzed using ForteBio analysis software. See tables 1-1 below for results:
[0557] Table 1-1 The results of the antibody affinity measurements were shown in this table:
[0558] 6. Detection of endocytosis effect:
[0559] Meanwhile, a flow cytometry method was adopted to detect the endocytosis effect of different candidate molecules. 1) The antibody to be tested was diluted to 40 nM with medium in a 96-well plate for a three-fold serial dilution across 9 points in total. 2) 100 μl ZenonTM pHrodoTM iFL Green Human IgG Labeling Reagent (Invitrogen, Z25611) was added to 5 mL of medium, the mixture was mixed well, and added to a 96-well plate at 25 ul / well. 25 μl of the antibody after a gradient dilution was added to a 96-well plate and incubated for 5 min at room temperature. 3) The cells were counted and SHP-77 cell density was adjusted to 2×106 / ml. The cells were added to the antibody / Labeling Reagent mixed solution at 50 μl / well, and incubated in an incubator at a 37℃ for 16 h. 4) After 16 h, the cells were washed twice and detected by flow cytometry (BD, FACSCELESTA) and concentration-dependent curves were fitted with GraphPad according to their MFI (Fig. 1) . Meanwhile, the MFI value of the antibody at the concentration of 1.1 nM was divided by the MFI value at the respective lowest concentration of the antibody, and the resulted endocytosis indexes were 2.05, 2.03, 2.11, and 2.01, respectively.
[0560] Example 2. Affinity assay of DLL3 monoclonal antibody
[0561] Further, the present invention measured the affinity (KD) of the antibody for binding to DLL3 using bio-layer interferometry (BLI) technique by the affinity properties of the expressed and purified pure protein. Half an hour before the start of the experiment, an appropriate number of AHC sensors (18-5060, Sartorius) were dipped in SD buffer (1×PBS, 0.1%BSA, 0.05%Tween-20) depending on the number of samples. The antibodies and human DLL3 (DLL-HM103, Kactusbio) , macaque DLL3 (DLL-RM103, Kactusbio) , human DLL1 (DL1-H52H8, Acro biosystems) , and human DLL4 (DL4-H5227, Acro biosystems) were diluted to 100 nM.
[0562] The SD buffer, the antibody solution, and the antigen were added to 96-well black polystyrene microwell plates (Greiner, 655209) , respectively. Detection was performed using Fortebio Octet Red96e, and the sensor position was chosen according to the sample position layout. The instrument set-up parameters were as follows: the operation steps were as follows: 120 s of equilibrating baseline, 100 s of loading immobilized antibody, 120 s of equilibrating baseline, 100 s of associating antigen and 120 s of dissociating antigen, with a rotating speed of 1000 rpm, and a temperature of 30℃. After the experiment was completed, KD values were analyzed using ForteBio Octet analysis software. The results were shown in Table 2-1 below.
[0563] Table 2-1. Affinity constants (equilibrium dissociation constant) for the exemplified antibodies with different species DLL3 and human DLL1, DLL4
[0564] Example 3. In vitro binding assays of DLL3 monoclonal antibody to DLL3 / DLL1 / DLL4-over-expressing cells
[0565] Preparation of cells:
[0566] CHO-hDLL3: the human DLL3 gene NCBI ID: 10683 was constructed into a pXC17.4 vector, which was then electro-transfected into CHO cells. CHO-hDLL3 was obtained by sorting positive single clones, and cultured and sub-cultured according to the routine operation.
[0567] CHO-hDLL1: the human DLL1 gene NCBI ID: 28514 was constructed into a pXC17.4 vector, which was then electro-transfected into CHO cells. CHO-hDLL1 was obtained by sorting positive cell population, and cultured and sub-cultured according to the routine operation.
[0568] 293T-hDLL4: the human DLL4 gene NCBI ID: 54567 was constructed into a pLenti-C-MYC-DDK-IRES-puro vector, 293T cells were used for packaging virus and then infected. 293T-hDLL4 was obtained by sorting positive cell population, and cultured and sub-cultured according to the routine operation.
[0569] CHO-DLL3, CHO-hDLL1, and CHO-hDLL4 cells were taken out and subjected to cell density adjustment, and plated at 1 × 105 cells / well in a 96-well plate. The supernatant was discarded after centrifugation at 500g for 3 min. The cells were added with 100 μl of the molecule to be detected with a final concentration of 300 nM, mixed, incubated at 4℃ for 30 min, followed by discarding the supernatant after centrifugation, washing with pre-cooled 1×PBS for 2 times, incubating with secondary antibody, adding with 100 μl of Goat Anti-Human IgG-PE (Southern Biotech, 2040-09; 1: 200 dilution) per well, incubating at 4℃ for 30 min, discarding the supernatant after centrifugation, and washing with pre-cooled FACS buffer twice. The plate was washed for the second time and the supernatant was discarded, the cells were resuspended with addition of FACS buffer at 100 μl / well, and tested on the machine. The experimental data was analyzed using GraphPad Prism software, resulting in Fig. 2.
[0570] In experiments of the assays as described above, exemplary antibodies 23A1, 12B2, and 38D4 specifically bound to DLL3-overexpressing CHO cells; while the results for binding to CHO-hDLL1 and 293T-hDLL4 showed that the exemplary antibodies did not bind to DLL3 homologous protein (DLL1 / DLL4) -overexpressing cell lines.
[0571] Example 4. Measurement of in vitro endocytosis rate of DLL3 monoclonal antibody in small cell lung cancer
[0572] Construction of DMS53-DLL3 cells: the full-length coding gene of human DLL3 (UniProt ID: Q9NYJ7) was cloned into a lentivirus vector pLenti-C-MYC-DDK-IRES-puro, 293T cells (ATCC) were used for packaging lentivirus, DMS53 (Nanjing Cobioer Biosciences Co., Ltd., CBP60172) cells were infected, and the cells DMS53-DLL3 for expressing DLL3 were obtained through pressure screening with puromycin (Gibco, A11138-02) .
[0573] DMS53-DLL3 and SHP-77 subjected to cell density adjustment and plated at 1×105 cells / well in a 96-well plate. The supernatant was discarded after centrifugation at 500g for 3min. The cells were mixed with 50 μl of molecule to be detected at a final concentration of 10 nM, followed by incubating at 4℃ for 30 min. The supernatant was discarded after centrifugation. The cell was washed with pre-cooled 1×PBS for 2 times, and resuspended with 4℃ complete culture medium, with at least 2 duplicates for each sample, followed by incubating at 37℃ for a period of time (time for endocytosis in each group was set to 0 h, 15 min, 30 min, 1 h, 2 h, 3 h, 4 h, 6 h or 8 h) to allow antigen to be endocytosed. Fig. 3 showed a schematic representation of the endocytosis rate assay.
[0574] According to the experimental design, corresponding cells were taken out from the incubator at different time points, respectively, and added into a 96-well plate on ice ready for use; after the cell collection at the last time point was completed, the supernatant was discarded after centrifugation, and the cells were washed 2 times with pre-cooled 1×PBS, 100 μl of Goat Anti-Human IgG-PE (Southern Biotech, 2040-09; 1: 200 dilution for use) was added to each well and incubated at 4℃ for 30 min. After completion of incubation, the supernatant was discarded after centrifugation, and the cells were washed twice with pre-cooled FACS buffer.
[0575] The plate was washed for the second time and the supernatant was discarded, the cells were resuspended with addition of FACS buffer at 100 μl / well, and tested on the machine. The experimental data were analyzed using GraphPad Prism software, resulting in Fig. 4 (SHP-77) and Fig. 5 (DMS53-DLL3) . As shown in Fig. 4 and Fig. 5, antibody 23A1 had a faster endocytosis rate on both cell lines, with approximately 50%endocytosis at 30 min.
[0576] Example 5. Synthesis of ADC molecules
[0577] Example 5.1 Synthesis of linker-payloads
[0578] Example 5.1.1 Synthesis of compound NT3
[0579] Compound NT3 was prepared according to the procedures disclosed in Example 4 of WO2021173773A1. The physico-chemical data, including 1H NMR and mass spectral data, were in consistent with those disclosed in WO2021173773A1.
[0580] Example 5.1.2 Synthesis of compound PL17
[0581] (2S, 3R, 4S, 5S, 6S) -2- (5-formyl-2-nitrophenoxy) -6- (methoxycarbonyl) tetrahydro-2H-pyran-3, 4, 5-triyl triacetate (1)
[0582] To a solution of methyl (2S, 3S, 4S, 5R, 6R) -3, 4, 5-triacetoxy-6-bromo-tetrahydro-2H-pyran-2-carboxylate (2.0 g, 5.0 mmol) in acetonitrile (50 mL) was added 3-hydroxy-4-nitrobenzaldehyde (825 mg, 4.93 mmol) . The mixture was cooled to 0 ℃ under stirring. Silver oxide (5.8 g, 25 mmol) was added to the reaction slowly. The mixture was stirred overnight at room temperature. The mixture was filtered and washed with ethyl acetate (100 ml) . The filtrate was concentrated under reduced pressure. The residue was purified by silica gel column chromatography (DCM / MeOH= 150: 1) to obtain compound 1 (1.65 g, yield 67%) , as a light-yellow gum.
[0583] LC-MS (ESI) : m / z 506.2 [M+Na] +.
[0584] (2S, 3R, 4S, 5S, 6S) -2- (2-amino-5- (hydroxymethyl) phenoxy) -6- (methoxycarbonyl) tetrahydro-2H-pyran-3, 4, 5-triyl triacetate (2)
[0585] To a solution of compound 1 (8.2 g, 23.16 mmol) in EtOAc (100 mL) was added 10%Pd / C (1.84 g) under N2 atmosphere at room temperature. The reaction mixture was stirred for 6 h under H2 atmosphere at room temperature. The mixture was filtered, and the filtrate was concentrated under reduced pressure. The residue was purified by silica gel column chromatography (DCM / MeOH=150: 1) to obtain compound 2 (5.89 g, yield 67%) , as an off-white solid.
[0586] LC-MS (ESI) : m / z 478.4 [M+Na] +.
[0587] (2S, 3R, 4S, 5S, 6S) -2- (2- ( (S) -2- ( (tert-butoxycarbonyl) amino) propanamido) -5- (hydroxymethyl) phenoxy) -6- (methoxycarbonyl) tetrahydro-2H-pyran-3, 4, 5-triyl triacetate (3)
[0588] To a solution of compound 2 (5.8 g, 12.73 mmol) and Boc-Ala-OH (3.6 g, 19.1 mmol) in DCM (100 mL) was added EEDQ (4.72 g, 19.1 mmol) . The mixture was stirred for 18 h at room temperature under N2. NaHCO3 aqueous solution (100 mL) was added. The resulting mixture was extracted with EtOAc (100 mL) . The organic layer was washed with brine, dried over Na2SO4 and concentrated under reduced pressure. The residue was purified by silica gel column chromatography (DCM / MeOH= 150: 1) to obtain compound 3 (5.4 g, yield 68%) , as a light-yellow solid.
[0589] LC-MS (ESI) : m / z 649.5 [M+Na] +.
[0590] (2S, 3R, 4S, 5S, 6S) -2- (2- ( (S) -2- ( (S) -2- ( (tert-butoxycarbonyl) amino) -3-methylbutanamido) propanamido) -5- (hydroxymethyl) phenoxy) -6- (methoxycarbonyl) tetrahydro-2H-pyran-3, 4, 5-triyl triacetate (5)
[0591] To a solution of compound 3 (5.3 g, 8.46 mmol) in DCM (40 mL) was added TFA (6.0 mL) at room temperature. The reaction mixture was stirred for 20 min at room temperature. The mixture was adjusted with DIPEA to pH = 7. To the resulting solution was added Boc-Val-OH (2.2 g, 10.15 mmol) , HATU (3.86 g, 10.15 mmol) and DIPEA (1.64 g, 12.69 mmol) . The reaction mixture was stirred at room temperature under N2 overnight. The organic layer was washed with 1 N HCl, water, NaHCO3 aqueous solution, water, brine, dried over Na2SO4 and concentrated under reduced pressure. The residue was purified by silica gel column chromatography (DCM / MeOH= 150: 1) to obtain compound 5 (4.5 g, yield 73%) , as an off-white solid.
[0592] LC-MS (ESI) : m / z 748.6 [M+Na] +.
[0593] (2S, 3R, 4S, 5S, 6S) -2- (2- ( (S) -2- ( (S) -2- ( (tert-butoxycarbonyl) amino) -3-methylbutanamido) propanamido) -5- ( ( ( (4-nitrophenoxy) carbonyl) oxy) methyl) phenoxy) -6- (methoxycarbonyl) tetrahydro-2H-pyran-3, 4, 5-triyl triacetate (6)
[0594] To a solution of compound 5 (3.5 g, 4.8 mmol) and 4-nitrophenyl chloroformate (3.89 g, 19.3 mmol) in DCM (50 mL) was added pyridine (1.53 g, 19.3 mmol) at room temperature. The mixture was stirred for 1.5 h at room temperature. The mixture was concentrated under reduced pressure. The residue was purified by silica gel column chromatography (DCM / MeOH= 150: 1) to obtain compound 6 (2.8 g, yield 65%) , as a light-yellow solid.
[0595] LC-MS (ESI) : m / z 913.5 [M+Na] +.
[0596] (2S, 3R, 4S, 5S, 6S) -2- (2- ( (S) -2- ( (S) -2- ( (tert-butoxycarbonyl) amino) -3-methylbutanamido) propanamido) -5- ( ( ( ( (1S, 9S) -9-ethyl-5-fluoro-9-hydroxy-4-methyl-10, 13-dioxo-2, 3, 9, 10, 13, 15-hexahydro-1H, 12H-benzo [de] pyrano [3', 4': 6, 7] indolizino [1, 2-b] quinolin-1-yl) carbamoyl) oxy) methyl) phenoxy) -6- (methoxycarbonyl) tetrahydro-2H-pyran-3, 4, 5-triyltriacetate (7)
[0597] To a solution of compound 6 (1.13 g, 1.27 mmol) and Exatecan mesylate (450 mg, 0.85 mmol) in DMF (9 mL) was added DIPEA (545 mg, 4.23 mmol) at room temperature. The mixture was stirred for 2 h at room temperature. The mixture was diluted with EtOAc (100 mL) and washed with brine, dried over Na2SO4 and concentrated under reduced pressure. The residue was purified by silica gel column chromatography (DCM / MeOH= 150: 1) to obtain compound 7 (815 mg, yield 54%) , as a light-yellow solid.
[0598] LC-MS (ESI) : m / z 1209.6 [M+Na] +.
[0599] (2S, 3S, 4S, 5R, 6S) -6- (2- ( (17S, 20S) -1- (2, 5-dioxo-2, 5-dihydro-1H-pyrrol-1-yl) -17-isopropyl-20-methyl-15, 18-dioxo-3, 6, 9, 12-tetraoxa-16, 19-diazahenicosan-21-amido) -5- ( ( ( ( (1S, 9S) -9-ethyl-5-fluoro-9-hydroxy-4-methyl-10, 13-dioxo-2, 3, 9, 10, 13, 15-hexahydro-1H, 12H-benzo [de] pyrano [3', 4': 6, 7] indolizino [1, 2-b] quinolin-1-yl) carbamoyl) oxy) methyl) phenoxy) -3, 4, 5-trihydroxy tetrahydro-2H-pyran-2-carboxylic acid (PL17)
[0600] To a solution of compound 7 (200 mg, 0.175 mmol) in THF / H2O (6 / 2 mL) was added LiOH. H2O (37 mg, 0.875 mmol) at 0℃. The mixture was stirred for 30 min at 0℃. AcOH (3.5 mL) was added. The resulting mixture was concentrated under reduced pressure, then lyophilized. The residue was added into DCM (6 mL) , then TFA (1.5 mL) was added at room temperature. The resulting mixture was stirred for 30 min at room temperature.
[0601] The mixture was adjusted with DIPEA to pH = 7, and diluted with DMF (3 mL) . To the resulting solution was added Mal-PEG4-NHS (77 mg, 0.175 mmol) and DIPEA (113 mg, 0.875 mmol) . The reaction mixture was stirred for 2h at room temperature under N2. The volatile was evaporated under reduced pressure. The remaining solution was purified by prep-HPLC to obtain compound PL17 (20 mg, yield 9%) , as a yellow solid.
[0602] LC-MS (ESI) : m / z 1296.7 [M+Na] +.
[0603] Example 5.1.3 Synthesis of compound PL1
[0604] Compound PL1 was prepared according to the procedures disclosed in Example 4 of WO2024208359A1. The physico-chemical data, including mass spectral data, were in consistent with those disclosed in WO2024208359A1.
[0605] Example 5.2 Synthesis of ADCs
[0606] A series of ADCs were designed and synthesized based on the antibody and linker-payload as prepared in the above examples, and the control ADCs were prepared.
[0607] Example 5.2.1 Synthesis of 23A1-ADC
[0608] Based on 23A1, ADC coupled with small molecular compounds NT3 was further designed and synthesized, which was named as 23A1-ADC.
[0609] wherein Ab is the antibody 23A1; q is for example an integer of 4 to 8, dominantly 8, the obtained 23A1-ADC had an average DAR of 7.73 as determined in the experiments described below.
[0610] The specific procedures were as follows:
[0611] preparation of 23A1-ADC (23A1-NT3)
[0612] (a) The antibody 23A1 prepared according to the method of Example 1 was dissolved in PBS buffer (thermofisher, 10010023) . Reducing agent solution (TCEP, Aldrich, Catalog Number 646547, dissolved in water) was added and the reaction mixture was reacted for 2-4 hours at room temperature, wherein
[0613] (i) the optimal concentration of 23A1 was 2 to 10 mg / mL,
[0614] (ii) the optimal molar ratio of TCEP / mAb was 10.0-20.0,
[0615] (iii) the optimal temperature for the reaction was 20-37 ℃,
[0616] (iv) the optimum pH for the reaction was between 6.0 and 8.0.
[0617] (b) An excess of linker-payload (also called linker-toxin sometimes) (NT3, dissolved in DMSO) was added, reacted with the reduced antibody in step (a) , and the reaction mixture was placed at room temperature for 1 to 2 hours, wherein
[0618] (i) the optimal molar ratio of NT3 / mAb was 10.0-16.0,
[0619] (ii) the optimal temperature for the reaction was 20-37 ℃,
[0620] and the ADC crude product was obtained.
[0621] (c) The crude ADC product was desalted via spin, purified by ultrafilteration or dialyzation to obtain the final ADC product 23A1-ADC.
[0622] (d) DAR value was calculated using RP-HPLC from the peak areas of the individual peaks at UV 280nm. The analysis conditions were described in the following table.
[0623] After calculation, the measured DAR of 23A1-NT3 was 7.73.
[0624] The purity of 23A1-ADC was obtained by SEC-HPLC based on the ratio of the peak areas of monomer peak, aggregate, oligomer at UV 280 nm. After calculation, the purity is 99.68%. The analysis conditions were described in the following table.
[0625] Example 5.2.2 Synthesis of Control IgG1-NT3 (IgG-ADC)
[0626] The preparation process was the same as that of the above 23A1-ADC, except that the monospecific antibody 23A1 was replaced by the control antibody IgG (heavy chain: SEQ ID NO: 41; light chain: SEQ ID NO: 42) . Using the same analytical method as 23A1-ADC, the measured DAR was determined as 7.71, and the purity was 98.99%.
[0627] Example 5.2.3 Synthesis of Rovalpituzumab-ADC
[0628] The preparation process was the same as that of the above 23A1-ADC, except that the monospecific antibody 23A1 was replaced by Rovalpituzumab (heavy chain: SEQ ID NO: 43; light chain: SEQ ID NO: 44) . Rovalpituzumab-ADC was obtained, the measured DAR was determined as 7.88, and the purity was 99.25%.
[0629] Example 5.2.4 Synthesis of other DLL3-NT3 ADCs
[0630] The preparation process was the same as that of the above 23A1-ADC, except that the antibodies 12B2, 18C5 and 38D4 were respectively used together with NT3 to prepare other DLL3-NT3 ADCs. 12B2-ADC, 18C5-ADC, and 38D4-ADC were obtained, the measured DARs were determined as 7.64, 7.74 and 7.74, respectively.
[0631] Example 5.2.5 Synthesis of 23A1-ADC-1
[0632] According to the method disclosed in WO2024208359A1 (method A in Example 12) , the antibody 23A1 and PL17 were used to synthesize 23A1-ADC-1.
[0633] wherein Ab is the antibody 23A1; q is for example an integer of 4 to 8, dominantly 8. Upon measuring, the average DAR of the obtained 23A1-ADC-1 was 7.81 and the purity was >99%.
[0634] Example 5.2.6 Synthesis of 23A1-ADC-2
[0635] According to the method disclosed in WO2024208359A1 (method A in Example 12) , the antibody 23A1 and PL1 were used to synthesize 23A1-ADC-2.
[0636] wherein Ab is the antibody 23A1; q is for example an integer of 4 to 8, dominantly 8. Upon measuring, the average DAR of the obtained 23A1-ADC-2 was 7.78 and the purity was >99%.
[0637] Example 6. Cell binding assay for 23A1-ADC molecule
[0638] In order to detect whether the binding property of the monoclonal antibody moiety of the 23A1-ADC molecule to the target cell was changed by the conjugation of the small molecule, the affinity of the 23A1-ADC to the target was detected by using a human small cell lung cancer cell line DMS53-DLL3 over-expressing DLL3 and using a flow cytometry technology, and the experimental method was the same as that in Example 3. As shown in Fig. 6, 23A1 mAb and 23A1-ADC had similar activity affinities to DMS53-hDLL3, indicating that the antibody binding depended on expression specificity of the target and that conjugation of small molecules (i.e., payload moieties) did not affect the antibody binding.
[0639] Example 7. In vitro killing assay of ADC molecule
[0640] Example 7.1 In vitro direct killing assay of 23A1-ADC molecule
[0641] When the ADC binds to the antigen on the surface of the cell membrane, the ADC-antigen complex enters the cell through endocytosis and kills the target cell. We therefore assessed the in vitro activity of the 23A1-ADC molecule using the Cell Titer-Glo (Promega, G9242) Assay Kit to determine the effect on DLL3-positive and DLL3-negative cells viability following endocytosis of the ADC drug on various cell lines expressing DLL3 as shown in Table 7-1.
[0642] After being digested with Trypsin, the adherent cells were subjected to density adjustment, and uniformly plated into a 96-well plate (Table 7-1) . The diluted samples 23A1-ADC molecule and control molecule IgG-ADC of specific concentrations were added (dilution was started at 100nM with a dilution factor of 3) , and incubated in an incubator at 37℃ for 6 days. After 6 days, 100 μl of Cell Titer Glo detection reagent was added to each well, incubated at room temperature for 30 min, and detected using a microplate reader. Relative cell viability rates were calculated (relative cell viability = tested wells / negative control wells ×100%) and curves were fitted with Graph Pad Prism 8.0.
[0643] As shown in Fig. 7 and Figs. 8A-8F, killing cell lines by ADC molecules was dependent on the expression level of cell surface DLL3. In DLL3-negative H460 cells (ATCC, HTB-177, DLL3-negative cells) , the 23A1-ADC molecule had no significant effect on cell viability; the 23A1-ADC molecule has a significant killing effect on the constructed DMS53-DLL3, as well as cell strains H82 (ATCC HTB-175) , DMS79 (ATCC CRL-2049) , SHP-77 (ATCC CRL-2195) and DMS53 (Nanjing Cobioer Biosciences Co., Ltd., CBP 60172) . This indicated that the 23A1-ADC molecule had a good specificity and effectiveness.
[0644] Table 7-1. Cell plating density and IC 50 for in vitro direct killing assay
[0645] Example 7.2 In vitro killing assay of DLL3-NT3 candidate molecule
[0646] After 4 strongly endocytic DLL3 monoclonal antibodies were conjugated to NT3 toxin (12B2-ADC, 18C5-ADC, 23A1-ADC and 38D4-ADC, see Example 5.2.4) , the killing ability in vitro was tested using the same experimental procedure as that in Example 7.1, with a time for drug treatment of 4 days.
[0647] As shown in Fig. 9, in the small cell lung cancer cell line DMS53 over-expressing DLL3, 4 candidate DLL3-NT3 all showed significant dose-dependent cytotoxic activity with a maximal killing to 90%, wherein 18C5-ADC was slightly weaker than the other 3 candidate ADCs.
[0648] Example 7.3 In vitro killing assay of ADCs obtained by coupling 23A1 to different toxins
[0649] The killing activities in vitro of 23A1 coupled to different toxins were evaluated using the same experimental procedure as that in Example 7.1, with a time for drug treatment of 6 days.
[0650] As shown in Fig. 10, killing cell lines by ADC molecules conjugated to different toxins was dependent on the expression level of cell surface DLL3. In DLL3-negative H460 cells, the killing effect of DLL3-ADC molecule was comparable to that of the negative control IgG-ADC; all DLL3-ADC molecules conjugated to different toxins had significant killing effects on the constructed cell line over-expressing DMS53-DLL3 and cell lines H82, DMS79, SHP-77 and DMS53, and the killing activity was approximately equivalent, wherein 23A1-ADC showed stronger activities in part of the cell lines.
[0651] Example 8. Bystander killing effect of 23A1-ADC molecule
[0652] During the synthesis of ADC drugs, small molecule compounds can be attached to antibodies via cleavable linkers, which were cleaved after endocytosis into the cell membrane, and the small molecules released to kill the target cells. After the target cell dies, the small molecule compounds were released from the target cell into the intercellular space, further killing a certain range of non-target cells. This effect was known as a bystander killing effect. Since the cells within a tumor can vary greatly in expression levels of the target (tumor heterogeneity) , the bystander killing effect was important for effectively killing tumor cells and inhibiting a tumor growth.
[0653] In the present invention, non-target cells MDA-MB-468-Luc (the full length coding gene of Luciferase (UniProt ID: V9VFW4) was constructed into a vector pcDNA3.1 to construct a plasmid, a transfection reagent 3000 (Invitrogen, L3000008) was used to transfer a constructed plasmid into MDA-MB-468 cells, and the transfected cells were subjected to pressure screening by Geneticin (Gibco, 10131-027) to obtain cells expressing the Luciferase MDA-MB-468-Luc) was mixed with target cell DMS53-DLL3 to detect the bystander killing effect of 23A1-ADC molecules. Steps were performed as follows: after digesting cells with Trypsin, adjusting the density, preparing a 96-well cell culture plate, adding MDA-MB-468-Luc 2000 / well and DMS53-DLL34000 / well, with a total volume of the cells of 50 μl, adding 50 μl of to-be-detected sample 23A1-ADC and IgG-ADC molecules into each well, with a final concentration of 10 nM, 5 nM, and 1 nM, respectively, and setting 3 duplicates for each sample. The cell culture plate was placed in a 37℃ incubator and cultured for 4 days. After 4 days, 100 μl of One-Glo (Promega, E6120) detection reagent was added to each well and incubated at room temperature for 5 min, luminescence was measured using a microplate reader, and a histogram was plotted using Graph Pad Prism 8.0. The results were shown in Fig. 11.
[0654] Example 9. Anti-tumor efficacy of 23A1-ADC molecule in H82 small cell lung cancer transplantation model
[0655] To evaluate the in vivo efficacy of the 23A1-ADC molecule, H82 cells (ATCC, HTB-175) to inoculate BALB / c Nude mice to determine the anti-tumor efficacy of the molecules of the present invention. Female mice of SPF grade (16-19 g, available from Beijing Vital River Laboratory Animal Technology Co., Ltd. ) were used for the experiments.
[0656] H82 cells were routinely sub-cultured for subsequent in vivo experiments. Cells were harvested by centrifugation and H82 cells were dispersed in PBS (1×) to prepare a cell suspension with a cell concentration of 2.5×107 cells / ml. A H82 tumor-bearing mouse model was established by subcutaneous inoculation of 0.2 ml of the cell suspension into the right abdominal region of BALB / c Nude mice on day 0. On day 24 after tumor cell inoculation, all mice were divided into 3 groups (5 mice per group) based on the tumor volume, and administration dosage and route were shown in Table 9-1. Mice were administered on the day of grouping, and monitored for the tumor volume and body weight twice weekly until day 42, as shown in Figs. 12A and 12B.
[0657] Relative tumor growth inhibition (TGI%) was calculated on day 42 after the inoculation, and the formula was as follows:
[0658] TGI%=100%× (control tumor volume-treatment tumor volume) / (control tumor volume-control tumor volume before administration) . The TGI calculation was based on 100%if it exceeds 100%.
[0659] Tumor volume determination: the maximum long axis (L) and maximum wide axis (W) of the tumor were measured using a vernier caliper, and the tumor volume was calculated as follows:
[0660] V=L×W2 / 2. Body weight was measured using an electronic balance.
[0661] Table 9-1. Experimental design table
[0662] The tumor inhibition rate results were shown in Table 9-2 and Fig. 12A: on the day 42 after the inoculation, the tumor inhibition rate of Rovalpitauzuma-ADC reached 94.83%after a single administration of 5 mg / kg, and the tumor inhibition rate of 23A1-ADC reached 100%after a single administration of 5 mg / kg. Meanwhile, the body weights of the mice were measured, and the results were shown in Fig. 12B, indicating that the body weights of the mice had no significant difference. Table 9-2. Tumor inhibition rate on day 42
[0663] Example 10. Anti-tumor efficacy of 23A1-ADC molecule in SHP-77 small cell lung cancer transplantation model
[0664] To evaluate the in vivo efficacy of the 23A1-ADC molecules at different doses, SHP-77 cells (ATCC CRL-2195) were used to inoculate BALB / c Nude mice to determine the anti-tumor efficacy of the molecules of the present invention. Female mice of SPF grade (16-19 g, available from Beijing Vital River Laboratory Animal Technology Co., Ltd. ) were used for the experiments.
[0665] SHP-77 cells were routinely sub-cultured for subsequent in vivo experiments. Cells were harvested by centrifugation and SHP-77 cells were dispersed in PBS (1×) to prepare a cell suspension with a cell concentration of 2.5×107 cells / ml. A SHP-77 tumor-bearing mouse model was established by subcutaneous inoculation of 0.2 ml of the cell suspension into the right abdominal region of BALB / c Nude mice on day 0. On day 11 after tumor cell inoculation all mice were randomized into 5 groups (6 mice per group) , and administration dosage and route were shown in Table 10-1. Mice were administered on day 11 after the inoculation, and monitored for the tumor volume and body weight twice weekly until day 32, as shown in Figs. 13A and 13B.
[0666] Relative tumor growth inhibition (TGI%) was calculated on day 32 after the inoculation, and the formula was as follows:
[0667] TGI%=100%× (control tumor volume-treatment tumor volume) / (control tumor volume-control tumor volume before administration) . The TGI calculation was based on 100%if it exceeds 100%.
[0668] Tumor volume determination: the maximum long axis (L) and maximum wide axis (W) of the tumor were measured using a vernier caliper, and the tumor volume was calculated as follows:
[0669] V=L×W2 / 2. Body weight was measured using an electronic balance.
[0670] Table 10-1. Experimental design table
[0671] The tumor inhibition rate results were shown in Table 10-2 and Fig. 13A: on day 32 after the inoculation, the tumor inhibition rate of 23A1-ADC reached 59.46%after a single administration of 2 mg / kg, and the tumor inhibition rate of 23A1-ADC reached 100%after a single administration of 6 mg / kg. Meanwhile, the body weights of the mice were measured, and the results were shown in Fig. 13B, indicating that the body weights of the mice had no significant difference.
[0672] Table 10-2. Tumor inhibition rate on day 32
[0673] Example 11. Anti-tumor efficacy of 23A1-ADC molecule in DMS79 small cell lung cancer transplantation model
[0674] To evaluate the in vivo efficacy of the 23A1-ADC molecule, DMS79 cells (ATCC CRL-2049) were used to inoculate NOG mice to determine the anti-tumor efficacy of the molecules of the present invention. Female mice of SPF grade (16-19 g, available from Beijing Vital River Laboratory Animal Technology Co., Ltd. ) were used for the experiments.
[0675] DMS79 cells were routinely sub-cultured for subsequent in vivo experiments. Cells were harvested by centrifugation and DMS79 cells were dispersed in PBS (1×) to prepare a cell suspension with a cell concentration of 2.5×107 cells / ml. A DMS79 tumor-bearing mouse model was established by subcutaneous inoculation of 0.2 ml of the cell suspension into the right abdominal region of the NOG mice on day 0. On day 15 after tumor cell inoculation, all mice were randomized into 3 groups (6 mice per group) , and administration dosage and route were shown in Table 11-1. Mice were administered on day 15 after the inoculation, and monitored for the tumor volume and body weight twice weekly until day 33, as shown in Figs. 14A and 14B.
[0676] Relative tumor growth inhibition (TGI%) was calculated on day 33 after the inoculation, and the formula was as follows:
[0677] TGI%=100%× (control tumor volume-treatment tumor volume) / (control tumor volume-control tumor volume before administration) . The TGI calculation was based on 100%if it exceeds 100%.
[0678] Tumor volume determination: the maximum long axis (L) and maximum wide axis (W) of the tumor were measured using a vernier caliper, and the tumor volume was calculated as follows:
[0679] V=L×W2 / 2. Body weight was measured using an electronic balance.
[0680] Table 11-1. Experimental design table
[0681] The tumor inhibition rate results were shown in Table 11-2 and Fig. 14A: on the day 33 after the inoculation, the tumor inhibition rate of the 23A1-ADC reached 100%after a single administration. Meanwhile, the body weights of the mice were measured, and the results were shown in Fig. 14B, indicating that the body weights of the mice had no significant difference.
[0682] Table 11-2. Tumor inhibition rate on day 33
[0683] Example 12. Comparison of the anti-tumor efficacy of 23A1-ADC molecule with existing small cell chemotherapy regimens in SHP-77small cell lung cancer transplantation model
[0684] To demonstrate whether the 23A1-ADC molecule has better in vivo efficacy than existing small cell chemotherapy regimens, SHP-77 cells were used to inoculate CB17-SCID mice to determine the anti-tumor efficacy of the molecules of the present invention. Female mice of SPF grade (16-19 g, available from Beijing Vital River Laboratory Animal Technology Co., Ltd. ) were used for the experiments.
[0685] SHP-77 cells were routinely sub-cultured for subsequent in vivo experiments. Cells were harvested by centrifugation and SHP-77 cells were dispersed in PBS (1×) to prepare a cell suspension with a cell concentration of 2.5×107 cells / ml. A mouse model of SHP-77 tumor-bearing mice was established by subcutaneous inoculation of 0.2 ml of the cell suspension into the right abdominal region of CB17-SCID mice on day 0. On day 14 after tumor cell inoculation all mice were randomized into 3 groups (6 mice per group) and administrated with h-IgG (Equitech-Bio SLH56-0001) , carboplatin in combination with etoposide (carboplatin + etoposide, 3+15 mpk) , and 23A1-ADC, respectively. The administration dosage and route were shown in Table 13-1. Mice were administrated on day 14 after the inoculation, and monitored for the tumor volume and body weight twice weekly until day 59, as shown in Figs. 15A and 15B.
[0686] Relative tumor growth inhibition (TGI%) was calculated on day 28 after the inoculation, and the formula was as follows:
[0687] TGI%=100%× (control tumor volume-treatment tumor volume) / (control tumor volume-control tumor volume before administration) . The TGI calculation was based on 100%if it exceeds 100%.
[0688] Tumor volume determination: the maximum long axis (L) and maximum wide axis (W) of the tumor were measured using a vernier caliper, and the tumor volume was calculated as follows:
[0689] V=L×W2 / 2. Body weight was measured using an electronic balance.
[0690] Table 12-1. Experimental design table
[0691] The results were shown in Table 12-2 and Fig. 15A. The chemotherapeutic combination therapy showed a weaker anti-tumor effect in this model and slightly delayed tumor growth. The 23A1-ADC had a strong efficacy compared to the chemotherapeutic therapy, with a significant reduction in tumor volume after 4 doses, and maintaining complete tumor regression on day 59 after the inoculation. And no significant decrease in terms of body weight in mice due to tumor volume load or drug toxicity was observed (see Fig. 15B) .
[0692] Table 12-2. Tumor inhibition rate on day 28
[0693] Example 13. Anti-tumor efficacy of 23A1-ADC molecule in chemotherapy-treated SHP-77 small cell lung cancer transplantation model
[0694] In order to explore whether the 23A1-ADC molecule was effective continuously in the posterior-line patients after chemotherapy treatment, an SHP-77 model was adopted to inoculate CB17-SCID mice. After progression in the multiple chemotherapy, the 23A1-ADC drug was administrated, and the size of the tumor was monitored to judge the efficacy. Female mice of SPF grade (16-19 g, available from Beijing Vital River Laboratory Animal Technology Co., Ltd. ) were used for the experiments.
[0695] SHP-77 cells were routinely sub-cultured for subsequent in vivo experiments. Cells were harvested by centrifugation and SHP-77 cells were dispersed in PBS (1×) to prepare a cell suspension with a cell concentration of 2.5×107 cells / ml. A mouse model of SHP-77 tumor-bearing mice was established by subcutaneous inoculation of 0.2 ml of the cell suspension into the right abdominal region of CB17-SCID mice on day 0. On day 14 after tumor cell inoculation, all mice were randomized into 3 groups (6 mice per group) : h-IgG group (Equitech-Bio SLH56-0001) ; group 1: carboplatin in combination with etoposide (3+15 mpk) ; and Group 2: carboplatin in combination with etoposide (3 +15 mpk, cycle 1) changed to 23A1-ADC (5 m pk, cycle 2) . Group 1 and Group 2 were administrated with chemotherapeutic drugs from day 14 to 21 after the inoculation. On day 24 after the inoculation, chemotherapy groups mice were divided into two groups, with group 1 continuing to be administrated with chemotherapy and group 2 being changed to 23A1-ADC, to mimic patients on first line chemotherapy in the clinic. The administration dosage and route were shown in Table 13-1, and mice were monitored for the tumor volume and body weight twice weekly on day 14 after the inoculation until day 66, as shown in Fig. 16.
[0696] Tumor volume determination: the maximum long axis (L) and maximum wide axis (W) of the tumor were measured using a vernier caliper, and the tumor volume was calculated as follows:
[0697] V=L×W2 / 2. Body weight was measured using an electronic balance.
[0698] Table. 13-1. Experimental design table
[0699] The results were shown in Fig. 16, where the tumor growth continued in the chemotherapy group of mice, whereas in the 23A1-ADC group of mice, 3 out of 4 mice showed tumor volume reduction until complete regression.
[0700] Example 14. Anti-tumor efficacy of 23A1-ADC molecule in combination with DLL3 / CD3 bispecific antibody in a small cell lung cancer model H82 humanized model
[0701] To evaluate whether the 23A1-ADC molecule in combination with DLL3 / CD3 bispecific antibody (D3-107 / CD3-C1) has superior in vivo efficacy, H82 cells were used to inoculate NOG mice to determine the anti-tumor efficacy of the molecules of the present invention. Female mice of SPF grade (16-19 g, available from Beijing Vital River Laboratory Animal Technology Co., Ltd. ) were used for the experiments
[0702] 1. Preparation of D3-107 / CD3-C1 bispecific antibody
[0703] The D3-107 / CD3-C1 molecule is a bispecific antibody specifically binding to DLL3 and CD3, with the structure shown in Fig. 17B, and the sequence shown in Table 14-1 and the Sequence Listing.
[0704] Table 14-1: The D3-107 / CD3-C1 bispecific antibody has specific sequences as follows
[0705] The bispecific antibody was prepared by respectively expressing and purifying two parent proteins and then performing in-vitro reduction, oxidation and recombination. The bispecific antibody preparation route was shown in Fig. 17A, and the structure was shown in Fig. 17B.
[0706] Plasmid construction: the sequence was synthesized from the GENEWIZ, Inc. and loaded into the vector of pcDNA3.1, and the coding gene sequence was shown in Table 14-1 above.
[0707] Expi293F cells (available from Gibco) were cultured in Expi293F medium (Gibco, REF#A14351-01) . The cell density was measured the day before transfection (with viability should be greater than 95%) , and adjusted to 3×106 cells / ml with fresh Expi293F medium for continuous culture. On the day of transfection, the cell density was adjusted to 3×106 cells / ml.
[0708] Steps were performed as follows: taking 1 / 10 transfection final volume of Opti-MEM medium (Gibco, REF#31985-070) as a transfection buffer, adding the DNA to be transfected at a ratio of 1 mg / L wherein the ratio of light and heavy chain plasmids was 1: 1, mixing well, adding PEIMax (Polysciences Inc. Cat#24765-1) at a mass ratio 1: 3 of DNA: PEI, mixing, incubating at room temperature for 20 min, pouring the mixture into Expi293Fcell suspension gently while shaking, and culturing the cells in a shaking table under the conditions of 8%CO2, 36.5℃ and 120 rpm.
[0709] After culturing for 16-18 h, the cell suspension was supplemented with 2% (volume ratio) of Feed (100 g / L Phytone Peptone + 100 g / L Difco Select Phytone) with a concentration of 200 g / L, a glucose solution with a final concentration of 5 g / L, and Valproic acid sodium salt (Merk, Cat#P4543-100G) with a final concentration of 2.2 mM , the mixture was mixed gently and cultured for 7 days at the temperature of 8%CO2, 36.5℃ and 120 rpm, and then the sample was collected. The cell broth was mixed with diatomite (Sartorius, Cat 1000037025) (40 g diatomite added to 1 L cell broth) and filtered using a 0.22 μm disposable vacuum filtration apparatus.
[0710] Purifying the target protein by affinity chromatography was performed as follows: selecting HiTrap MabSelect PrismA (GE Healthcare, Cat#17549853) affinity chromatography column for affinity capture, flowing 10-20 times of column volume of 0.1M NaOH through the pipeline and the affinity chromatography column before purification, then washing the pipeline and the column by using 10-20 times of column volume of distilled water, and equilibrating the filled column by using 5 times of column volume of 1×PBS (Gibco) ; passing the filtered cell broth through the column, and then washing the filled column by using 10 times of column volume of 1×PBS (phosphate buffer solution) to remove non-specific binding protein; rinsing the filler with 5 times of column volume of elution buffer (100 mM sodium citrate, pH 3.5) , collecting the eluate, adjusting pH to 6.0 with 2M Tris, sterilizing by filtering for further ion exchange chromatography.
[0711] In vitro reduction and oxidation were performed as follows: mixing the protein collection liquid obtained by affinity chromatography at a molar ratio of 1: 1, adding a proper amount of GSH, and adjusting the reaction pH to 8.0 by using 2M Tris, standing overnight at room temperature, and changing the solution of reactant to PBS and standing at 4℃ for later use.
[0712] Purifying bispecific antibody by ion exchange chromatography was performed as follows: selecting Mono S 5 / 50 GL (available from GE Healthcare) ion exchange chromatography column and placing in the AKTApure system (available from GE Healthcare) ; removing endotoxin for 2 h by using 0.5M NaOH from an AKTApure system equipped with a Mono S5 / 50 GL ion exchange chromatography column, and then washing the system and column with distilled water; equilibrating the column with 5-10 times of column volume of loading buffer (20 mM NaPO4, pH 6.6) until the conductance and pH stabilized; diluting the protein obtained by affinity chromatography by 10 times by using a loading buffer solution, and then loading; re-equilibrating using 5 times of column volume of loading buffer; performing linear elution with a gradient of 0-40%elution buffer (20 mM NaPO4, 1M NaCl, pH 6.6) for a total of 30 column volumes, and collecting samples based on UV absorbance.
[0713] The purity of the collected samples in each fraction tube was checked by Size Exclusion Chromatography (SEC) . Samples from fraction tubes with a purity greater than 95%were pooled according to SEC results.
[0714] The purified bispecific antibody solution was centrifuged at 4500 rpm for 30 min using a 15 ml ultrafiltration centrifuge tube, the protein was diluted with PBS and centrifuged further at 4500 rpm for 30 min, and this operation was repeated several times to replace the buffer. The antibodies after buffer exchange were pooled and the antibody concentration was determined. The composition and content of bispecific antibody DLL3 / CD3 were further characterized and quantified by capillary electrophoresis (CE-SDS) in combination with liquid chromatography-mass spectrometry (LC-MS) .
[0715] Negative control IgG1 was available from BioXCell BP0297.
[0716] 2. Affinity of the D3-107 / CD3-C1 bispecific antibody
[0717] The affinity (KD) of the bispecific antibody binding to DLL3 was determined using bio-layer interferometry technique (BLI) . Half an hour before the start of the experiment, an appropriate number of AHC sensors (18-5060, Sartorius) were dipped in SD buffer (1×PBS, 0.1%BSA, 0.05%Tween-20) depending on the number of samples. Bispecific antibody and human DLL3 (DL3-H52H4, Acro biosystems) were diluted to 100 nM.
[0718] The SD buffer, the antibody solution and human DLL3 were added to 96-well black polystyrene microwell plates (Greiner, 655209) , respectively. Detection was performed using Fortebio Octet Red96e, and the sensor position was chosen according to the sample position layout. The instrument set-up parameters were as follows: the operation steps were as follows: 120 s of equilibrating baseline, 100 s of loading immobilized antibody, 120 s of equilibrating baseline, 100 s of associating antigen and 120 s of dissociating antigen, with a rotating speed of 1000 rpm, and a temperature of 30℃. After the experiment was completed, KD values were analyzed using ForteBio Octet analysis software. The results were shown in Table 14-2 below.
[0719] Table 14-2. Analysis of KD values with ForteBio Octet analysis software
[0720] 3. Binding assay of the bispecific antibody D3-107 / CD3-C1 to small cell lung cancer and T cells
[0721] The binding ability of DLL3 / CD3 bispecific antibody to the DLL3 over-expressing cell line was tested by flow cytometry.
[0722] CHO-hDLL3 was cultured for subculture according to the routine protocol. The cells were counted after centrifugation and resuspension, adjusted to a cell density of 4×106 cell / mL, and poured into the loading wells, and seeded into 96-well plates at 50 μl per well using a multi-channel pipette. 50 μl of the antibody samples diluted in a gradient (starting from 300 nM, 3-fold dilution, 12 gradients in total) were added to 50 μl of cells per well and incubated in a refrigerator at 4℃ for 30 min. And then the following steps were performed: centrifuging at 400 g for 5 min, spinning the plate, adding 200 μl PBS to resuspend, resuspending after re-centrifugation, repeating 2 times; adding a PE anti-human IgG Fc recombinant antibody (1: 200) , incubating for 30 min at 4℃ in the dark, and washing the plate for 2 times with 200 μl PBS then spinning the plate; resuspending in 100 μl PBS and reading by a flow cytometer; calculating EC50 values by fitting the curve.
[0723] PBMC (Oricells, Cat#FPB005-C) were thawed following routine procedures. After thawing, the cells were counted after centrifugation and resuspension, adjusted to a cell density of 4×106 cell / ml, Human TruStain FcXTM (Biolegend, 422302) was added and mixed well, and blocked at 4℃ for 10 min. After blocking was complete, FITC anti-human CD4 Antibody (Biolegend, 300506) and APC anti-human CD8a Antibody (Biolegend, 301014) were added and mixed well. The mixture was poured into the loading wells and inoculated 50 μl per well in a 96-well plate with a multi-channel pipette. 50 μl of the antibody samples diluted in a gradient (starting from 300 nM, 3-fold dilution, 12 gradients in total) were added to 50 μl of cells per well and incubated in a refrigerator at 4℃ for 30 min. And then the following steps were performed: centrifuging 5 min at 400 g and spinning the plate, adding 200 μl PBS, spinning the plate at 400 g for 5 min, repeating 3 times; centrifuging at 400 g for 5 min, spinning the plate, adding 200 μl PBS to resuspend, resuspending after re-centrifugation, repeating 2 times; adding a PE anti-human IgG Fc recombinant antibody (1: 200) , incubating for 30 min at 4℃ in the dark, and washing the plate for 2 times with 200 μl PBS then spinning the plate; resuspending in 100 μl PBS and reading by a flow cytometer; calculating EC50 values by fitting the curve.
[0724] The results were shown in Fig. 18, from which it can be seen that the D3-107 / CD3-C1 bispecific antibody was able to concentration-dependently bind to human DLL3 and CD4 or CD3 on CD 8T cells.
[0725] 4. In vitro activation experiments of T cell killing small cell lung cancer by D3-107 / CD3-C1 bispecific antibody
[0726] The killing activity of the exemplified antibodies against tumor cells in vitro was evaluated by primary PBMC and small cell lung cancer co-culture systems. The killing ability of human CD8+ T cells against DLL3-positive tumor cells was evaluated by detecting the rate of PI positivity of tumor cells by addition of the exemplified antibody for 24 h under the condition of co-culture of human PBMC cells and DLL3-positive cells using the Propidium Iodide (PI) staining.
[0727] The PBMC were rapidly thawed at 37℃ from a liquid nitrogen tank, and added dropwise to a preheated 1640 medium (containing 0.1%DNase) containing 10%FBS to obtain 10 ml of a mixture, which was then centrifuged at 400 g for 5 min, resuspended with 10 ml 1640 medium containing 10%FBS, and added with 10 μl DNase, incubated in a 5%CO2 incubator overnight at 37℃ for cell adherence.
[0728] DLL3-positive cells (SHP-77 (ATCC CRL-2195) , DMS-79 (ATCC CRL-2049) , and H82 (ATCC HTB-175) ) were respectively used as target cells, the cells were centrifuged at 400g for 5 min, to remove the supernatant, and washed twice with 30 ml of PBS, and then the supernatant was removed after centrifugation. The cells were labeled with CellTrace Far Red Cell staining solution (THERMO FIHER, C34564) and incubated at 37℃ for 20 min in an incubator in the dark. After the incubation, 1640 complete medium was added, the supernatant was removed after centrifugation at 400g for 5 min. After resuspension with the complete medium, the cells were transferred to a CO2 incubator and cultured for overnight.
[0729] The target cell was adjusted to a density of 2 × 10E5 / ml and the PBMC cell was adjusted to a density of 4 × 10E6 / ml, 50 μl of antibody (starting concentration at 10 n M, 3-fold dilution, 10 gradients in total) , 50 μl of target cells and 50 μl of PBMC cells were added, mixed well and cultured in a CO2 incubator. And the 96-well plate was taken out after killing for 24 h, 100 μl of PI detection solution was added into each well, mixed with the cells well, and a detection was performed by flow cytometry.
[0730] Detailed results were shown in Fig. 19, wherein D3-107 / CD3-C1 was able to effectively kill DLL3-positive tumor cells, showing a remarkable dose effect.
[0731] 5. Verification of drug efficacy
[0732] The PBMC cells were thawed in pre-warmed RPMI-1640 medium with 0.1%DNase and then dispersed with PBS to prepare a cell suspension with a cell concentration of 20×106 / mL. Mice were intravenously injected with the PBMC cell suspension, 0.2 mL / mouse, i.e., at an inoculum amount was 4 ×106 cells / mouse.
[0733] H82 cells were routinely sub-cultured for subsequent in vivo experiments. 6 days after PBMC cell inoculation, H82 cells were dispersed in PBS and Matrigel with a 1: 1 ratio to prepare a cell suspension with a cell concentration of 1.25 × 107 cells / mL. The right dorsal side of the NOG mice was shaved and subcutaneously injected with the suspension of H82 cells at 0.2 mL / mouse, i.e., at an inoculum amount of 2.5 × 106 cells / mouse. All mice were randomized into 4 groups (7 mice per group) on day 4 post the tumor cell inoculation, and administered with hIgG, 23A1-ADC, DLL3 / CD3, and the combination drug, respectively. The administration dosage and route were shown in Table 14-3, and mice were administered on day 4 after the inoculation and monitored for the tumor volume and body weight twice weekly until day 36 after the inoculation, as shown in Fig. 20.
[0734] Relative tumor growth inhibition (TGI%) was calculated on day 26 after the inoculation, and the formula was as follows:
[0735] TGI%=100%× (control tumor volume-treatment tumor volume) / (control tumor volume-control tumor volume before administration) . The TGI calculation was based on 100%if it exceeds 100%.
[0736] Tumor volume determination: the maximum long axis (L) and maximum wide axis (W) of the tumor were measured using a vernier caliper, and the tumor volume was calculated as follows:
[0737] V=L×W2 / 2. Body weight was measured using an electronic balance.
[0738] Table 14-3. Experimental design table
[0739] The results were shown in Table 14-4 and Fig. 20, in which 23A1-ADC single drug group and D3-107 / CD3-C1 single drug group both had comparable anti-tumor effects. In comparison, in the combination drug group, the efficacy was significantly enhanced, the tumor volume was significantly reduced, the tumor inhibition rate reached 100%from day 15 after the inoculation, and most mice still maintained complete tumor regression on day 36 after the inoculation.
[0740] Table 14-4. Tumor inhibition rate on day 26
[0741] Example 15. PK study of 23A1-ADC molecule in mice
[0742] The stability of the 23A1-ADC molecule in vivo was observed by PK experiments in mice. BALB / c mice were administered with 10 mpk of 23A1-ADC via tail vein injection, and mouse serum samples were taken at 5 min, 0.5 h, 2 h, 6 h, 24 h, 48 h, 72 h, 168 h, 336 h, and 504 h for detection with ELISA. The ELISA used two methods for detection: Method 1, plates were coated with biotin-labelled DLL3 antigen (Acrobiosystem, DL3-H82E4) , followed by addition of the serum to be tested, then detection with a secondary antibody against human Fc (BETHYL, A80-104P) and finally subjected to color development with TMB; Method 2, plates were coated with anti-payload (18E7C9) antibody (Innoventbio, LOT#20220424) , followed by addition of the serum to be tested, then addition of the biotin-labeled DLL3 antigen (Acrobiosystem, DL3-H82E4) , followed by addition of secondary antibody with streptavidin (BIOLEGEND, 405210) , and finally subjected to color development with TMB. The PK detection results were shown in Fig. 22, and the main pharmacokinetic parameters obtained by the two methods were basically close to each other, indicating that the 23A1-ADC was relatively stable in mice, with an overall clearance rate in BALB / c mice, the half-life period reached 241-249 h, and the clearance rate was 0.32-0.34 ml / kg / h. The PK details were shown in Table 15-1.
[0743] Table 15-1. PK parameters for 23A1-ADC
[0744] Note: TAB in Table 15-1 represents total antibodies, including toxin-conjugated ADC and toxin-shed naked antibodies; ADC was an antibody conjugated to a toxin.
[0745] Example 16. Anti-tumor efficacy of DLL3-ADC molecules in SHP-77 small cell lung cancer transplantation model
[0746] To evaluate the in vivo efficacy of different DLL3-ADC molecules, BALB / c Nude mice were inoculated with SHP-77 cells to determine the anti-tumor efficacy of the ADC molecules. Female mice of SPF grade (16-19 g, available from Beijing Vital River Laboratory Animal Technology Co., Ltd. ) were used for the experiments.
[0747] SHP-77 cells were routinely sub-cultured for subsequent in vivo experiments. Cells were harvested by centrifugation and SHP-77 cells were dispersed in PBS (1×) to prepare a cell suspension with a cell concentration of 2.5×107 cells / ml. A SHP-77 tumor-bearing mouse model was established by subcutaneous inoculation of 0.2 ml of the cell suspension into the right abdominal region of BALB / c Nude mice on day 0. On day 9 after tumor cell inoculation, all mice were randomized into 10 groups (7 mice per group) , the administration dosage and route were shown in Table 16-1, and mice were administered on day 9 after the inoculation and monitored for the tumor volume and body weight twice weekly until day 27, as shown in Figs. 22A, 22B and 22C.
[0748] Relative tumor growth inhibition (TGI%) was calculated on day 27 after the inoculation, and the formula was as follows:
[0749] TGI%=100%× (control tumor volume-treatment tumor volume) / (control tumor volume-control tumor volume before administration) .
[0750] Tumor volume determination: the maximum long axis (L) and maximum wide axis (W) of the tumor were measured using a vernier caliper, and the tumor volume was calculated as follows:
[0751] V=L×W2 / 2. Body weight was measured using an electronic balance.
[0752] Table 16-1. Experimental design table
[0753] The tumor inhibition results were shown in Table 16-2 and Figs. 22A and 22B: on day 27 after the inoculation, at the dose of 5 mpk, the tumor inhibition rates of 23A1-ADC, 38D4-ADC, and 12B2-ADC were all >100%, which was greater than the tumor inhibition rate of the positive control Rovalpituzumab-ADC, 71%; at the dose of 1 mpk, the 23A1-ADC has the strongest tumor inhibition activity, and the tumor inhibition rate reached 65%. Meanwhile, the body weights of the mice were detected, and the results were shown in Fig. 22C, wherein the body weights of the mice had no significant change.
[0754] Table 16-2. Tumor Inhibition on Day 27
[0755] .
[0756] Example 17. Anti-tumor efficacy of DLL3-ADC molecules in DMS79 small cell lung cancer transplantation model
[0757] In order to evaluate the in vivo efficacy of the ADC molecules obtained by coupling 23A1 monoclonal antibody with different toxins, DMS79 cells were used to inoculate NOG mice to determine the anti-tumor efficacy of the molecule of the present invention. Female mice of SPF grade (16-19 g, available from Beijing Vital River Laboratory Animal Technology Co., Ltd. ) were used for the experiments.
[0758] DMS79 cells were routinely sub-cultured for subsequent in vivo experiments. The cells were harvested by centrifugation and DMS79 cells were dispersed in PBS (1×) to prepare a cell suspension with a cell concentration of 2.5×107 cells / ml. A DMS79 tumor-bearing mouse model was established by subcutaneous inoculation of 0.2 ml of the cell suspension into the right abdominal region of the NOG mice on day 0. On day 15 after tumor cell inoculation, all mice were randomized into 7 groups, administration dosage and route were shown in Table 17-1, and mice were monitored for the tumor volume and body weight twice weekly after dosing until day 33. Tumor volume measurements and tumor inhibition rate calculations were the same as that in Example 11.
[0759] Table 17-1 Experimental design table
[0760] The tumor inhibition rate results were shown in Table 17-2 and Fig. 23A: on day 33 after the inoculation, at the dose of 5 mpk, the tumor inhibition rates of 23A1-ADC, 23A1-ADC-2, and 23A1-ADC-1 all reached 100 %, showing the strong tumor inhibition effect. The mouse body weight results were shown in Fig. 23B, showing no effect.
[0761] Table 17-2. Tumor inhibition on day 33
[0762] Sequence information:
Claims
1.An anti-DLL3 antibody or antigen-binding fragment thereof comprising 3 CDRs of a heavy chain variable region VH: HCDR1, HCDR2 and HCDR3, and 3 CDRs of a light chain variable region VL: LCDR1, LCDR2 and LCDR3, wherein(i) the HCDR1, the HCDR2 and the HCDR3 are three complementarity determining regions HCDR1, HCDR2 and HCDR3 contained in the VH set forth in SEQ ID NO: 2, and the LCDR1, the LCDR2 and the LCDR3 are three complementarity determining regions LCDR1, LCDR2 and LCDR3 contained in a VL set forth in SEQ ID NO: 8;(ii) the HCDR1, the HCDR2 and the HCDR3 are three complementarity determining regions HCDR1, HCDR2 and HCDR3 contained in the VH set forth in SEQ ID NO: 45, and the LCDR1, the LCDR2 and the LCDR3 are three complementarity determining regions LCDR1, LCDR2 and LCDR3 contained in a VL set forth in the SEQ ID NO: 50;(iii) the HCDR1, the HCDR2 and the HCDR3 are three complementarity determining regions HCDR1, HCDR2 and HCDR3 contained in the VH set forth in SEQ ID NO: 55, and the LCDR1, the LCDR2 and the LCDR3 are three complementarity determining regions LCDR1, LCDR2 and LCDR3 contained in the VL set forth in SEQ ID NO: 60; or(iv) the HCDR1, the HCDR2 and the HCDR3 are three complementarity determining regions HCDR1, HCDR2 and HCDR3 contained in the VH set forth in SEQ ID NO: 65, and the LCDR1, the LCDR2 and the LCDR3 are three complementarity determining regions LCDR1, LCDR2 and LCDR3 contained in the VL set forth in SEQ ID NO: 69.2.An anti-DLL3 antibody or antigen-binding fragment thereof comprising HCDR1, HCDR2, HCDR3, LCDR1, LCDR2, and LCDR3, wherein(i) the HCDR1 comprises or consists of the amino acid sequence set forth in SEQ ID NO: 4; the HCDR2 comprises or consists of the amino acid sequence set forth in SEQ ID NO: 5; the HCDR3 comprises or consists of the amino acid sequence set forth in SEQ ID NO: 6; the LCDR1 comprises or consists of the amino acid sequence set forth in SEQ ID NO: 10; the LCDR2 comprises or consists of the amino acid sequence set forth in SEQ ID NO: 11; and the LCDR3 comprises or consists of the amino acid sequence set forth in SEQ ID NO: 12;(ii) the HCDR1 comprises or consists of the amino acid sequence set forth in SEQ ID NO: 47; the HCDR2 comprises or consists of the amino acid sequence set forth in SEQ ID NO: 48; the HCDR3 comprises or consists of the amino acid sequence set forth in SEQ ID NO: 49; the LCDR1 comprises or consists of the amino acid sequence set forth in SEQ ID NO: 52; the LCDR2 comprises or consists of the amino acid sequence set forth in SEQ ID NO: 53; and the LCDR3 comprises or consists of the amino acid sequence set forth in SEQ ID NO: 54;(iii) the HCDR1 comprises or consists of the amino acid sequence set forth in SEQ ID NO: 57; the HCDR2 comprises or consists of the amino acid sequence set forth in SEQ ID NO: 58; the HCDR3 comprises or consists of the amino acid sequence set forth in SEQ ID NO: 59; the LCDR1 comprises or consists of the amino acid sequence set forth in SEQ ID NO: 62; the LCDR2 comprises or consists of the amino acid sequence set forth in SEQ ID NO: 63; and the LCDR3 comprises or consists of the amino acid sequence set forth in SEQ ID NO: 64; or(iv) the HCDR1 comprises or consists of the amino acid sequence set forth in SEQ ID NO: 4; the HCDR2 comprises or consists of the amino acid sequence set forth in SEQ ID NO: 67; the HCDR3 comprises or consists of the amino acid sequence set forth in SEQ ID NO: 68; the LCDR1 comprises or consists of the amino acid sequence set forth in SEQ ID NO: 10; the LCDR2 comprises or consists of the amino acid sequence set forth in SEQ ID NO: 71; and the LCDR3 comprises or consists of the amino acid sequence set forth in SEQ ID NO: 72.3.The antibody or antigen-binding fragment thereof of claim 1 or 2, comprising a heavy chain variable region VH, wherein the heavy chain variable region(i) comprises or consists of an amino acid sequence having at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%or 99%identity to the amino acid sequence set forth in SEQ ID NO: 2, 45, 55 or 65, or(ii) comprises or consists of the amino acid sequence set forth in SEQ ID NO: 2, 45, 55 or 65; orcomprising a light chain variable region VL, wherein the light chain variable region(i) comprises or consists of an amino acid sequence having at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%or 99%identity to the amino acid sequence set forth in SEQ ID NO: 8, 50, 60 or 69, or(ii) comprises or consists of the amino acid sequence set forth in SEQ ID NO: 8, 50, 60 or 69.4.The antibody or antigen-binding fragment thereof of claim 3, comprising a heavy chain variable region VH and a light chain variable region VL, wherein(i) . the VH comprises or consists of the amino acid sequence set forth in SEQ ID NO: 2 or an amino acid sequence having at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%or 99%identity thereto, and the VL comprises or consists of the amino acid sequence set forth in SEQ ID NO: 8 or an amino acid sequence having at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%or 99%identity thereto;(ii) . the VH comprises or consists of the amino acid sequence set forth in SEQ ID NO: 45 or an amino acid sequence having at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%or 99%identity thereto and the VL comprises or consists of the amino acid sequence set forth in SEQ ID NO: 50 or an amino acid sequence having at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%or 99%identity thereto;(iii) . the VH comprises or consists of the amino acid sequence set forth in SEQ ID NO: 55 or an amino acid sequence having at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%or 99%identity thereto, and the VL comprises or consists of the amino acid sequence set forth in SEQ ID NO: 60 or an amino acid sequence having at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%or 99%identity thereto; or(iv) . the VH comprises or consists of the amino acid sequence set forth in SEQ ID NO: 65 or an amino acid sequence having at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%or 99%identity thereto, and the VL comprises or consists of the amino acid sequence set forth in SEQ ID NO: 69 or an amino acid sequence having at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%or 99%identity thereto.5.An anti-DLL3 antibody or antigen-binding fragment thereof comprising a heavy chain variable region VH and a light chain variable region VL, wherein(i) . the VH comprises or consists of the amino acid sequence set forth in SEQ ID NO: 2 or an amino acid sequence having at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%or 99%identity thereto, and the VL comprises or consists of the amino acid sequence set forth in SEQ ID NO: 8 or an amino acid sequence having at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%or 99%identity thereto;(ii) . the VH comprises or consists of the amino acid sequence set forth in SEQ ID NO: 45 or an amino acid sequence having at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%or 99%identity thereto and the VL comprises or consists of the amino acid sequence set forth in SEQ ID NO: 50 or an amino acid sequence having at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%or 99%identity thereto;(iii) . the VH comprises or consists of the amino acid sequence set forth in SEQ ID NO: 55 or an amino acid sequence having at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%or 99%identity thereto, and the VL comprises or consists of the amino acid sequence set forth in SEQ ID NO: 60 or an amino acid sequence having at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%or 99%identity thereto; or(iv) . the VH comprises or consists of the amino acid sequence set forth in SEQ ID NO: 65 or an amino acid sequence having at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%or 99%identity thereto, and the VL comprises or consists of the amino acid sequence set forth in SEQ ID NO: 69 or an amino acid sequence having at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%or 99%identity thereto.6.An anti-DLL3 antibody or antigen-binding fragment thereof comprising a heavy chain variable region VH and a light chain variable region VL, wherein(i) . the VH comprises or consists of the amino acid sequence set forth in SEQ ID NO: 2, and the VL comprises or consists of the amino acid sequence set forth in SEQ ID NO: 8;(ii) . the VH comprises or consists of the amino acid sequence set forth in SEQ ID NO: 45, and the VL comprises or consists of the amino acid sequence set forth in SEQ ID NO: 50;(iii) . the VH comprises or consists of the amino acid sequence set forth in SEQ ID NO: 55, and the VL comprises or consists of the amino acid sequence set forth in SEQ ID NO: 60; or(iv) . the VH comprises or consists of the amino acid sequence set forth in SEQ ID NO: 65, and the VL comprises or consists of the amino acid sequence set forth in SEQ ID NO: 69.7.The antibody or antigen-binding fragment thereof of any one of claims 1-6, further comprising a heavy chain constant region HC, wherein, e.g., the heavy chain constant region HC of the antibody is a heavy chain constant region of IgG1, IgG2, IgG3, or IgG4, preferably a heavy chain constant region of human IgG1.8.The antibody or antigen-binding fragment thereof of claim 7, the heavy chain constant region(i) comprises or consists of an amino acid sequence having at least 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%or 99%identity to an amino acid sequence selected from SEQ ID NO: 13, or(ii) comprises or consists of the amino acid sequence set forth in SEQ ID NO: 13.9.The antibody or antigen-binding fragment thereof of any one of claims 1-8, further comprising a light chain constant region, wherein, e.g., the light chain constant region is a Lambda or Kappa light chain constant region.10.The antibody or antigen-binding fragment thereof of claim 9, wherein the light chain constant region(i) comprises or consists of an amino acid sequence having at least 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%or 99%identity to the amino acid sequence set forth in SEQ ID NO: 14 or 15; or(ii) comprises or consists of the amino acid sequence set forth in SEQ ID NO: 14 or 15.11.The antibody or antigen-binding fragment thereof of any one of claims 1-10, wherein the antibody or antigen-binding fragment thereof comprises a heavy chain HC, which(i) comprises or consists of an amino acid sequence having at least 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%or 99%identity to the amino acid sequence set forth in SEQ ID NO: 3, 46, 56 or 66, or(ii) comprises or consists of the amino acid sequence set forth in SEQ ID NO: 3, 46, 56 or 66; orthe antibody or antigen-binding fragment thereof comprises a light chain LC, which(i) comprises or consists of an amino acid sequence having at least 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%or 99%identity to the amino acid sequence set forth in SEQ ID NO: 9, 51, 61 or 70; or(ii) comprises or consists of the amino acid sequence set forth in SEQ ID NO: 9, 51, 61 or 70.12.The antibody or antigen-binding fragment thereof of claim 11, wherein the antibody or antigen-binding fragment thereof comprises an HC and an LC, wherein(i) . the HC comprises or consists of the amino acid sequence set forth in SEQ ID NO: 3 or an amino acid sequence having at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%or 99%identity thereto, and the LC comprises or consists of the amino acid sequence set forth in SEQ ID NO: 9 or an amino acid sequence having at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%or 99%identity thereto;(ii) . the HC comprises or consists of the amino acid sequence set forth in SEQ ID NO: 46 or an amino acid sequence having at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%or 99%identity thereto, and the LC comprises or consists of the amino acid sequence set forth in SEQ ID NO: 51 or an amino acid sequence having at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%or 99%identity thereto;(iii) . the HC comprises or consists of the amino acid sequence set forth in SEQ ID NO: 56 or an amino acid sequence having at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%or 99%identity thereto, and the LC comprises or consists of the amino acid sequence set forth in SEQ ID NO: 61 or an amino acid sequence having at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%or 99%identity thereto; or(iv) . the HC comprises or consists of the amino acid sequence set forth in SEQ ID NO: 66 or an amino acid sequence having at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%or 99%identity thereto, and the LC comprises or consists of the amino acid sequence set forth in SEQ ID NO: 70 or an amino acid sequence having at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%or 99%identity thereto.13.An anti-DLL3 antibody or antigen-binding fragment thereof comprising a heavy chain variable region VH and a light chain variable region VL, wherein the antibody or antigen-binding fragment thereof comprises an HC and an LC, wherein(i) . the HC comprises or consists of the amino acid sequence set forth in SEQ ID NO: 3 or an amino acid sequence having at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%or 99%identity thereto, and the LC comprises or consists of the amino acid sequence set forth in SEQ ID NO: 9 or an amino acid sequence having at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%or 99%identity thereto;(ii) . the HC comprises or consists of the amino acid sequence set forth in SEQ ID NO: 46 or an amino acid sequence having at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%or 99%identity thereto, and the LC comprises or consists of the amino acid sequence set forth in SEQ ID NO: 51 or an amino acid sequence having at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%or 99%identity thereto;(iii) . the HC comprises or consists of the amino acid sequence set forth in SEQ ID NO: 56 or an amino acid sequence having at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%or 99%identity thereto, and the LC comprises or consists of the amino acid sequence set forth in SEQ ID NO: 61 or an amino acid sequence having at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%or 99%identity thereto; or(iv) . the HC comprises or consists of the amino acid sequence set forth in SEQ ID NO: 66 or an amino acid sequence having at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%or 99%identity thereto, and the LC comprises or consists of the amino acid sequence set forth in SEQ ID NO: 70 or an amino acid sequence having at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%or 99%identity thereto.14.An anti-DLL3 antibody or antigen-binding fragment thereof, wherein the antibody or antigen-binding fragment thereof comprises a HC and a LC, wherein(i) . the HC comprises or consists of the amino acid sequence set forth in SEQ ID NO: 3 and the LC comprises or consists of the amino acid sequence set forth in SEQ ID NO: 9;(ii) . the HC comprises or consists of the amino acid sequence set forth in SEQ ID NO: 46 and the LC comprises or consists of the amino acid sequence set forth in SEQ ID NO: 51;(iii) . the HC comprises or consists of the amino acid sequence set forth in SEQ ID NO: 56 and the LC comprises or consists of the amino acid sequence set forth in SEQ ID NO: 61; or(iv) . the HC comprises or consists of the amino acid sequence set forth in SEQ ID NO: 66 and the LC comprises or consists of the amino acid sequence set forth in SEQ ID NO: 70.15.The antibody or antigen-binding fragment thereof of any one of claims 1-14, wherein the antibody is a humanized antibody or a chimeric antibody or a human antibody.16.The antibody or antigen-binding fragment thereof of any one of claims 1-15, wherein the antibody is a monoclonal antibody.17.The antibody or antigen-binding fragment thereof of any one of claims 1-16, wherein the antigen-binding fragment is an antibody fragment selected from the group consisting of: a Fab, a Fab', a Fab'-SH, an Fv, a single-chain antibody (e.g. an scFv) , a (Fab') 2, a single-domain antibody (e.g. a VHH) , a domain antibody (dAb) or a linear antibody.18.A nucleic acid molecule encoding an antibody or antigen-binding fragment thereof of any one of claims 1-17.19.A vector comprising the nucleic acid molecule of claim 18; preferably, the vector is an expression vector.20.A host cell comprising the nucleic acid molecule of claim 18 or the vector of claim 19.21.A method for producing the antibody or antigen-binding fragment thereof of any one of claims 1-17, the method comprising: culturing a host cell comprising the nucleic acid encoding a polypeptide chain of said antibody or antigen-binding fragment thereof under conditions suitable for expression of the polypeptide chain; optionally further comprising assembling the polypeptide chains to produce said antibody or antigen-binding fragment thereof under conditions suitable for assembly of said polypeptide chains into said antibody or antigen-binding fragment thereof.22.An immunoconjugate comprising the antibody or antigen-binding fragment of any one of claims 1-17, preferably the immunoconjugate is an antibody-drug conjugate.23.An antibody-drug conjugate having a structure represented by formula (I) : Ab- (L-D) p (I)or a pharmaceutically acceptable salt or solvate thereof,wherein:L is a linker;D is a drug, preferably an anti-tumor compound; andp is an integer selected from 1 to 16, for example 2, 3, 4, 5, 6, 7, 8, 9 or 10,wherein Ab in formula (I) is the antibody or antigen-binding fragment thereof according to any one of claims 1-17.24.The antibody-drug conjugate, or the pharmaceutically acceptable salt or solvate thereof according to claim 23, wherein the anti-tumor compound is a cytotoxic agent, for example camptothecins, auristatins or maytansinoids.25.The antibody-drug conjugate, or the pharmaceutically acceptable salt or solvate thereof according to any one of claims 23-24, wherein D has a structure of formula -Q-L2-L1-D1,wherein Q is -O-, -S-or -NR7-;L1 is absent or - (C1-C10 alkylene) -;L2 is absent, *- (C1-C10 alkylene) -C (O) N (R5) -or *- (C1-C10 alkylene) -N (R5) C (O) -; wherein *represents said end is covalently linked to Q; and R5 is H or C1-C6 alkyl,wherein D1 has a structure represented by formula (D-1) :wherein R1 and R6 are independently selected from H, C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, C1-C6 haloalkyl, C2-C6 haloalkenyl and C2-C6 haloalkynyl; or R1 and R6 together with the carbon they are attached to form a 5-to 9-membered ring, for example, 5-to 8-membered ring;R2 is selected from H, halogen, C1-C6 alkyl, C1-C6 haloalkyl, -OR4 and -SR4; R3 is selected from H, halogen, CN, C1-C6 alkyl, C1-C6 haloalkyl and -OR4; or R2 and R3 together form -O (CH2) nO-or -O (CF2) nO-, wherein n is 1 or 2;R4 is selected from H or C1-C4 alkyl; andR7 is selected from H or C1-C6 alkyl;preferably, D1 has a structure represented by formula (D-2) :wherein R1, R2, R3 and R6 are as defined above.26.The antibody-drug conjugate, or the pharmaceutically acceptable salt or solvate thereof according to claim 25, wherein R1 and R6 are H, R2 is C1-C6 alkyl or C1-C6 alkyloxy, R3 is halogen, preferably -F.27.The antibody-drug conjugate, or the pharmaceutically acceptable salt or solvate thereof according to claim 25 or 26, wherein D1 has a structure represented by formula (D-2a) , (D-2b) or (D-2c) : wherein, R1, R2, R3, and R6 are as defined in claim 25 or 26; n1 and n2 are independently selected from 0, 1, 2 and 3, and n1+n2≤5.28.The antibody-drug conjugate, or the pharmaceutically acceptable salt or solvate thereof according to claim 25, whereinD1 has a structure represented by formula (D-4a) or formula (D-4b) :29.The antibody-drug conjugate, or the pharmaceutically acceptable salt or solvate thereof according to any one of claims 23-28, wherein-Q-is -O-or -S-;-L2-L1-is - (C1-C6 alkylene) -, *- (C1-C6 alkylene) -C (O) N (R5) - (C1-C6 alkylene) -or *- (C1-C6 alkylene) -N (R5) C (O) - (C1-C6 alkylene) -, wherein *represents said end is covalently linked to Q;R5 is H or C1-C6 alkyl;preferably, -L2-L1-is - (C1-C6 alkylene) -.30.The antibody-drug conjugate, or the pharmaceutically acceptable salt or solvate thereof according to any one of claims 23-27, wherein D1 has a structure represented by formula (D-4c) and -Q-L2-L1-is -NR7-or -O-CH2-C (O) N (R5) -,wherein R2, R3, R5 and R7 are as defined in any one of claims 23-27.31.The antibody-drug conjugate, or the pharmaceutically acceptable salt or solvate thereof according to any one of claims 23-28, wherein -Q-L2-L1-D1 is selected from 32.The antibody-drug conjugate, or the pharmaceutically acceptable salt or solvate thereof according to any one of claims 23-31, wherein -L-has the following structure: -Z-E-X-wherein Z is linked to Ab, X is linked to Q;Z is -Z1-Z2-,wherein Z1 is selected from: the end with wavy line at the left side is linked to Ab, the end with wavy line at the right side is linked to Z2,Z2 is selected fromwherein the end with wavy line at the left side is linked to Ab, the end with wavy line at the right side is linked to E,wherein ma1 and ma2 are independently an integer selected from 0 to 20, for example 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15 or 16;m is an integer selected from 1 to 10, for example 1, 2, 3, 4, 5, 6, 7 or 8,preferably, Z is selected fromwherein m, ma1 and ma2 are as defined above,preferably, Z is selected fromma2 is an integer independently selected from 1 to 20; and m is an integer selected from 1 to 10;the carbonyl at the right side of Z is covalently linked to E;E is a peptide residue comprising 2 to 10 amino acids, wherein the peptide residue is optionally substituted with one or more groups selected from C1-6 alkyl and polyol groups, wherein the N-terminus of the peptide residue is covalently linked to Z,preferably, the amino acid is selected from glycine, alanine, valine, glutamine, glutamic acid, phenylalanine, leucine, tyrosine, lysine, citrulline, serine, tryptophan, aspartic acid, asparagine, isoleucine, arginine and proline, and wherein the glutamine or glutamic acid is optionally substituted with one polyol group and optionally substituted with one C1-6 alkyl;X is selected from absent, -NH-CH2-, wherein each Ra1 is independently selected from C1-6 alkyl-, C1-6 alkyloxy-, haloC1-6 alkyl-, halogen, nitro, cyano, pentose, hexose, penturonic acid, hexuronic acid, disaccharide and trisaccharide; andt is 0, 1, 2, 3 or 4;the left end of X is linked to E, the left end of X is linked to D.33.The antibody-drug conjugate, or the pharmaceutically acceptable salt or solvate thereof according to claim 32,wherein E is a peptide residue consisting of 2, 3 or 4 amino acids, the amino acid is selected from glycine, alanine, valine, glutamine, glutamic acid, phenylalanine and leucine, and wherein the glutamine or glutamic acid is optionally substituted with one polyol group and optionally substituted with one C1-6 alkyl.34.The antibody-drug conjugate, or the pharmaceutically acceptable salt or solvate thereof according to claim 32 or 33,wherein E is: -Gln-Val-Ala-, -Gly-Val-Ala-, -Gln-Phe-Ala-, -Gly-Phe-Ala-, -Gly-Gly-Phe-Gly-, -Val-Ala-, -Val-Cit-, -Ala-Ala-, -Ala-Cit-, -Ala-Lys-, -Ala-Val-, -Asn-Cit-, -Asp-Cit-, -Asn-Lys-, -Asp-Val-, -Cit-Ala-, -Cit-Asn-, -Cit-Asp-, -Cit-Cit-, -Cit-Lys-, -Cit-Ser-, -Cit-Val-, -Glu-Val-, -Glu-Gly-, -Ile-Cit-, -Ile-Pro-, -Ile-Val-, -Leu-Cit-, -Lys-Cit-, -Phe-Arg-, -Phe-Cit-, -Phe-Lys-, -Pro-Lys-, -Ser-Cit-, -Trp-Cit-, -Ala-Val-, -Val-Asp-, -Cit-Val-, -Val-Glu-, -Val-Lys-, -Gly-Gly-Gly-, -Gly-Gly-Arg-, -Phe-Lys-Gly-, -Leu-Lys-Gly-, -Leu-Leu-Gly-, -Glu-Val-Cit-, -Cit-Ala-Glu-, -Val-Lys-Gly-, -Val-Lys-Ala-, -Val-Gly-Gly-, -Val-Cit-Gly-, -Val-Gln-Gly-, -Val-Glu-Gly-, -Val-Lys-Gly-, -Val-Lys-Leu-, -Ala-Ala-Ala-, -Asn-Ala-Ala-, -Gly-Gly-Gly-Gly-, -Gly-Gly-Leu-Gly-, -Gly-Phe-Leu-Gly-, -Gly-Val-Lys-Gly-, -A1a-Leu-A1a-Leu-, -Gly-Phe-Leu-Gly-, -Ala-Leu-Ala-Leu-, -Gly-Phe-Gly-Gly-, and -Val-Lys-Gly-Gly, wherein Gln and / or Glu is optionally substituted with one polyol group and optionally substituted with one C1-6 alkyl.35.The antibody-drug conjugate, or the pharmaceutically acceptable salt or solvate thereof according to any one of claims 32-34, wherein the substituted glutamine, Gln, or glutamic acid, Gly has a structure represented by the following formula:wherein R6 is H or C1-C6 alkyl;preferably iswherein R6 is H or C1-C6 alkyl.36.The antibody-drug conjugate, or the pharmaceutically acceptable salt or solvate thereof according to claim 34,wherein, E is -Val-Ala-, -Gln-Val-Ala-, -Gly-Val-Ala-, -Gln-Phe-Ala-, -Gly-Phe-Ala-, -Gly-Gly-Phe-Gly-, -Val-Cit-orwherein R6 is H or C1-C6 alkyl, wherein said E group is covalently linked to Z through the N-terminus at the left side.37.The antibody-drug conjugate, or the pharmaceutically acceptable salt or solvate thereof according to claim 36,Wherein X is selected from -NH-CH2-, wherein Ra1 is as defined in claim 28;preferably, X is selected from -NH-CH2-, wherein Ra1 is as defined in claim 32.38.The antibody-drug conjugate, or the pharmaceutically acceptable salt or solvate thereof according to claim 37,wherein each Ra1 is independently selected from pentose, hexose, penturonic acid and hexuronic acid; preferably, each Ra1 is independently selected from xylose, arabinose, glucose, galactose, mannose and fructose, xyluronic acid, arabinuronic acid, glucuronic acid, galacturonic acid and mannuronic acid;preferably, each Ra1 is independently selected frommore preferably, Ra1 is selected from39.The antibody-drug conjugate, or the pharmaceutically acceptable salt or solvate thereof according to claim 37,wherein, X is selected from-NH-CH2-, 40.The antibody-drug conjugate, or the pharmaceutically acceptable salt or solvate thereof according to claim 36,wherein -Z-E-X-is selected from the following structuresthe left side of the above structure is linked to Ab moiety.41.The antibody-drug conjugate, or the pharmaceutically acceptable salt or solvate thereof according to any one of claims 23-40, wherein the antibody-drug conjugate of formula (I) has the following structure: Ab’- (S-L-D) p (I’)wherein Ab’ is as defined in claim 19 for Ab, L, D and p are as defined in any one of claims 23-40.42.The antibody-drug conjugate, or the pharmaceutically acceptable salt or solvate thereof according to any one of claims 23-41, having an average DAR of 5 to 11, for example 7.5 to 8.5.43.The antibody-drug conjugate, or the pharmaceutically acceptable salt or solvate thereof according to claim 23, wherein the antibody-drug conjugate is selected from wherein Ab is the antibody or antigen-binding fragment thereof according to any one of claims 1-14;q is as defined for p in claim 23,preferably, the antibody-drug conjugate, or the pharmaceutically acceptable salt or solvate thereof has an average DAR of 5 to 11 or 7.5 to 8.5.44.A preparation method of antibody-drug conjugate, or the pharmaceutically acceptable salt or solvate thereof according to any one of claims 23-43 comprising the steps of:(a) adding the antibody or antigen-binding fragment thereof of any one of claims 1-17 into a buffer solution, adding a reducing agent, and then incubating;(b) adding a linker-drug to the reaction solution of step (a) for coupling to obtain a crude product; and(c) optionally purifying the crude product to obtain the antibody drug conjugate.45.A pharmaceutical composition comprising the antibody or antigen-binding fragment thereof of any one of claims 1-17, the immunoconjugate of claim 22, or the antibody-drug conjugate or a pharmaceutically acceptable salt or solvate thereof of any one of claims 23-43, and optionally one or more other therapeutic agents, such as a chemotherapeutic agent, an angiogenesis inhibitor, a cytokine, a cytotoxic agent, another antibody, a small molecule drug, or an immunomodulatory agent, and optionally a pharmaceutical adjuvant.46.A pharmaceutical combination comprising the antibody or antigen-binding fragment thereof of any one of claims 1-17, the immunoconjugate of claim 22, or the antibody-drug conjugate or a pharmaceutically acceptable salt or solvate thereof of any one of claims 23-43, such as a chemotherapeutic agent, an angiogenesis inhibitor, a cytokine, a cytotoxic agent, another antibody, a small molecule drug, or an immunomodulatory agent.47.A method of preventing or treating a tumor, such as a cancer, in a subject, wherein the method comprises administering to the subject an effective amount of the antibody or antigen-binding fragment thereof of any one of claims 1-17, the immunoconjugate of claim 22, or the antibody-drug conjugate or a pharmaceutically acceptable salt or solvate thereof of any one of claims 23-43, or the pharmaceutical composition of claim 45, or the pharmaceutical combination of claim 46.48.The method of claim 47, wherein the tumor is a DLL3 positive tumor, such as a DLL3 positive cancer, preferably the cancer has an elevated level (e.g. nucleic acid or protein level) of DLL3, e.g., as compared to a healthy subject or to a healthy tissue adjacent to a cancer tissue of a patient.49.The method of claim 48, wherein the cancer is selected from a lung cancer, such as a small cell lung cancer, such as advanced small cell lung cancer.50.The method of claim 47, wherein the tumor is selected from chemoresistant tumor.51.The method of claim 47, wherein the tumor is selected from neuroendocrine carcinomas, including large cell neuroendocrine lung cancer (lung LCNEC) , neuroendocrine prostate cancer (NEPC) and other extra-pulmonary neuroendocrine carcinomas.52.The method of any one of claims 47-49, wherein the method further comprises administering to the patient one or more therapies, such as a therapeutic modality and / or other therapeutic agent, preferably the therapeutic modality includes a radiotherapy or a surgery, or the other therapeutic agent includes a chemotherapeutic agent, an angiogenesis inhibitor, a cytokine, a cytotoxic agent, another antibody, a small molecule drug, or an immunomodulatory agent.53.The pharmaceutical composition of claim 45, the pharmaceutical combination of claim 46 or the method of claim 52, wherein the other therapeutic agent is a chemotherapeutic agent selected from carboplatin or etoposide, or carboplatin in combination with etoposide.54.The pharmaceutical composition of claim 45, the pharmaceutical combination of claim 46 or the method of claim 52, wherein the other therapeutic agent is Topotecan, cyclophosphamide, or etoposide (TCE) .55.The pharmaceutical composition of claim 45, the pharmaceutical combination of claim 46 or the method of claim 45, wherein the other therapeutic agent is a bispecific antibody that specifically binds to DLL3 and CD3.56.The pharmaceutical composition, the pharmaceutical combination or the method of claim 55, wherein the bispecific antibody comprises a first antigen-binding region and a second antigen-binding region,wherein the first antigen-binding region specifically binds to DLL3 and the second antigen-binding region specifically binds to CD3, wherein the first antigen-binding region comprises 3 complementarity determining regions from a heavy chain variable region (HCDRs) : HCDR1, HCDR2 and HCDR3, and 3 complementarity determining regions from a light chain variable region (LCDRs) : LCDR1, LCDR2 and LCDR3, wherein the HCDR1 comprises or consists of the amino acid sequence set forth in SEQ ID NO: 17, the HCDR2 comprises or consists of the amino acid sequence set forth in SEQ ID NO: 18, the HCDR3 comprises or consists of the amino acid sequence set forth in SEQ ID NO: 19, the LCDR1 comprises or consists of the amino acid sequence set forth in SEQ ID NO: 21, the LCDR2 comprises or consists of the amino acid sequence set forth in SEQ ID NO: 22, and the LCDR3 comprises or consists of the amino acid sequence set forth in SEQ ID NO: 23.57.The pharmaceutical composition, the pharmaceutical combination or the method of claim 55 or claim 56, wherein the first antigen-binding region comprises a VH and a VL, wherein the VH comprises or consists of the sequence set forth in SEQ ID NO: 16; and the VL comprises or consists of the sequence set forth in SEQ ID NO: 20.58.The pharmaceutical composition, the pharmaceutical combination or the method of claim 56 or claim 57, wherein the second antigen-binding region comprises 3 complementarity determining regions from a heavy chain variable region (HCDRs) : HCDR1, HCDR2 and HCDR3, and 3 complementarity determining regions from a light chain variable region (LCDRs) : LCDR1, LCDR2 and LCDR3, wherein the HCDR1 comprises or consists of the amino acid sequence set forth in SEQ ID NO: 29; the HCDR2 comprises or consists of the amino acid sequence set forth in SEQ ID NO: 30, the HCDR3 comprises or consists of the amino acid sequence set forth in SEQ ID NO: 31, the LCDR1 comprises or consists of the amino acid sequence set forth in SEQ ID NO: 33, the LCDR2 comprises or consists of the amino acid sequence set forth in SEQ ID NO: 34, and the LCDR3 comprises or consists of the amino acid sequence set forth in SEQ ID NO: 35.59.The pharmaceutical composition, the pharmaceutical combination or the method of any one of claims 56-58, wherein the second antigen-binding region comprises a VH and a VL, wherein the VH comprises or consists of the sequence set forth in SEQ ID NO: 28; and the VL comprises or consists of the sequence set forth in SEQ ID NO: 32.60.The pharmaceutical composition, the pharmaceutical combination or the method of any one of claims 56-59, wherein the first antigen-binding region is a Fab fragment and / or the second antigen-binding region is a Fab fragment.61.The pharmaceutical composition, the pharmaceutical combination or the method of claim 60, wherein the Fab as the first or second antigen-binding region comprises a CH1, wherein the CH1 is a CH1 from IgG1, IgG2, IgG3 or IgG4, preferably is a CH1 from IgG1, e.g. the CH1(i) comprises or consists of an amino acid sequence having at least 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%or 99%identity to an amino acid sequence of SEQ ID NO: 25; or(ii) comprises or consists of the amino acid sequence of SEQ ID NO: 25.62.The pharmaceutical composition, the pharmaceutical combination or the method of claim 60, wherein the Fab as the first antigen-binding region or the second antigen-binding region comprises a light chain constant region, wherein the light chain constant region is a Kappa light chain constant region or a Lambda light chain constant region as defined in claim 9 or claim 10, optionally the first antigen-binding region and the second antigen-binding region comprise the same or different light chain constant regions, e.g., the first antigen-binding region comprises the Kappa light chain constant region and the second antigen-binding region comprises the Lambda light chain constant region.63.The pharmaceutical composition, the pharmaceutical combination or the method of any one of claims 55-62, wherein the bispecific antibody comprises a first Fab as the first antigen-binding region that specifically binds to DLL3 and a second Fab as the second antigen-binding region that specifically binds to CD3, wherein the bispecific antibody comprisesheavy chain 1: from N-terminus to C-terminus comprising or consisting of: the first Fab heavy chain variable region-the heavy chain constant region CH1-a first Fc region, wherein the heavy chain constant region CH1 is linked at its C-terminus to the N-terminus of the first Fc region with or without a linker (e.g., a hinge region) ;light chain 1: from N-terminus to C-terminus comprising or consisting of: the first Fab light chain variable region-the light chain constant region;heavy chain 2: from N-terminus to C-terminus comprising or consisting of: the second Fab heavy chain variable region-the heavy chain constant region CH1-a second Fc region, wherein the heavy chain constant region CH1 is linked at its C-terminus to the N-terminus of the second Fc region with or without a linker (e.g., a hinge region) ;light chain 2: from N-terminus to C-terminus comprising or consisting of: the second Fab the light chain variable region-the light chain constant region.64.The pharmaceutical composition, the pharmaceutical combination or the method of claim 63, wherein the Fc region is a human IgG1, IgG2, IgG3, or IgG4 Fc,e.g., a mutation is introduced in the first and second Fc regions based on the Innobody technique, promoting heterodimerization of the first and second Fc regions,e.g., wherein a CH3 of one Fc region comprises mutations S364R and D399K and a CH3 of the other Fc region comprises mutations Y349T, K370S and K409D, optionally the first and / or the second Fc region comprises mutations L234A / L235A.65.A pharmaceutical composition, the pharmaceutical combination or the method of claim 63 or claim 64, whereinthe heavy chain 1 comprises or consists of the amino acid sequence set forth in SEQ ID NO: 26, or an amino acid sequence having at least 85%, 90%, 95%, 96%, 97%, 98%, 99%identity thereto;the light chain 1 comprises or consists of the amino acid sequence set forth in SEQ ID NO: 27, or an amino acid sequence having at least 85%, 90%, 95%, 96%, 97%, 98%, 99%identity thereto;the heavy chain 2 comprises or consists of the amino acid sequence set forth in SEQ ID NO: 37, or an amino acid sequence having at least 85%, 90%, 95%, 96%, 97%, 98%, 99%identity thereto; and / orthe light chain 2 comprises or consists of the amino acid sequence set forth in SEQ ID NO: 38, or an amino acid sequence having at least 85%, 90%, 95%, 96%, 97%, 98%, 99%identity thereto.66.An antibody or antigen-binding fragment thereof of any one of claims 1-17, an immunoconjugate of claim 22, an antibody-drug conjugate or a pharmaceutically acceptable salt or solvate thereof of any one of claims 23-43, a pharmaceutical composition of any one of claims 45 and 53-65, or a pharmaceutical combination of any one of claims 46 and 53-65, for use in the prevention or treatment of a tumor, preferably a cancer, in a subject.67.Use of an antibody or antigen-binding fragment thereof of any one of claims 1-17, an immunoconjugate of claim 22, an antibody-drug conjugate or a pharmaceutically acceptable salt or solvate thereof of any one of claims 23-43, a pharmaceutical composition of any one of claims 45 and 53-65, or a pharmaceutical combination of any one of claims 46 and 53-65, in the manufacture of a medicament for the prevention or treatment of a tumor, preferably a cancer, in a subject.
